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Abstract 
Effective surveillance of foot-and-mouth disease (FMD) is of the utmost importance in 
order to understand the disease risks and implement effective control strategies. 
Epidemiological data obtained for FMD is mostly obtained through recognition and 
reporting of clinical cases by farmers which has several limitations. For example, 
under-reporting of disease is common, due to deficiencies in veterinary infrastructure, 
the effort involved for sample collection, or the repercussions of control measures for 
farmers. Diagnostic sample types, usually vesicular epithelium and fluid, are invasive 
and labour intensive to obtain, and can only be collected from acutely infected animals. 
Therefore, animals with sub-clinical FMD infection (particularly those in vaccinated 
herds) may not be identified but may still contribute to disease transmission. It is likely, 
therefore, that the true prevalence of FMD is not accurately known in parts of the world 
where the disease is endemic. Consequently, the requirement exists for a simple 
approach for FMD surveillance that does not rely on farmer reporting. Milk is a non-
invasive sample type routinely collected from dairy farms and has been utilised for the 
surveillance of a number of other diseases. Despite numerous publications suggesting 
the potential of milk as a valuable sample type for foot-and-mouth disease (FMD) 
surveillance, empirical studies have mainly focused on the risk of transmission via 
milk, or the detection of FMD virus (FMDV) in milk from individual animals. This thesis 
aimed to expand on previous studies to determine the utility of milk and its limitations 
for the surveillance of FMD at the individual and herd level, using data collected from 
experimental and field studies. A highly sensitive and specific high-throughput RNA 
extraction and real-time rRT-PCR was optimised and utilised for FMDV RNA genome 
identification throughout the project. Using this method, it was demonstrated that 
FMDV RNA genome could be detected up to 28 days post infection using milk samples 
collected from individual cows. Further analysis using serotyping or lineage-specific 
rRT-PCR assays and VP1 sequencing of milk samples collected from individual cows in 
northern Tanzania highlighted the use of milk as a suitable alternative to more invasive 
sample types such as epithelium. Additionally, storage and shipment condition 
simulations performed demonstrated good stability of FMDV RNA genome within milk 
samples.  Following these experiments, the potential use of pooled milk for herd–level 
FMD surveillance was investigated. Two proof-of-concept pilot studies were 
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performed comparing the rRT-PCR results of pooled milk samples collected from both 
a large-scale dairy farm in Saudi Arabia and milk pooling facilities supplied by 
smallholder dairy farms in Kenya, with farmer reports of clinical disease. Results 
supported laboratory limit of detection studies, demonstrating that FMDV could be 
detected from milk pools of up 10,000 litres, even when there were low numbers of 
clinical cases. Furthermore, both studies suggested the detection of subclinical 
infection in milk samples, where disease was not reported. Data from pilot studies 
performed in this thesis therefore support the use of milk as a simple, non-invasive 
approach for herd-level FMD surveillance. Further field studies are required to 
determine the full utility of this method before it may be implemented for 
targeted/risk-based surveillance alongside existing surveillance systems to facilitate 
improved knowledge of FMD epidemiology, or for use in FMD contingency plans.  
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CHAPTER 1 
 
Introduction:  
A review of diagnostic approaches for the 
surveillance of foot-and-mouth disease  
 
1.1 Summary 
A significant challenge for the world’s expanding population is sustainable food 
production. In order to manage this in the long term, animal health and welfare are key 
priorities. Infectious diseases have a considerable impact on global animal production 
and human poverty, and threats to food security are further increased by the 
international trade of animals and their products. Foot-and-mouth disease (FMD) is a 
contagious viral livestock disease of great economic importance with high costs for 
prevention and control. In order to quantify disease burden, inform control efforts and 
reduce disease impacts, effective surveillance is essential. However, in many regions 
where the disease is endemic, several limitations of current surveillance systems exist. 
Surveillance is often dependent upon the recognition and reporting of clinical cases by 
farmers, occasionally supplemented by targeted case finding or serological surveys. 
The capacity for undertaking outbreak investigation and collecting clinical specimens 
in countries with limited resources is also often restricted. Additionally, as clinical 
samples are usually only collected from acutely infected animals, subclinical infection 
may not be represented. This chapter explores these limitations in more detail, and 
highlights the potential use of milk as a cost-effective, non-invasive alternative for FMD 
surveillance, with the aim of reducing the bias observed when relying on sample 
vesicular epithelium or blood, and consequently aiming to improve the understanding 
of the epidemiology of FMD in a region.   
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1.2 Foot-and mouth disease 
1.2.1 Overview of disease 
Foot-and-mouth disease (FMD) is a highly contagious, transboundary disease of 
cloven-hooved mammals. Clinical signs include high body temperature, excessive 
salivation, and the formation of vesicles on the feet, in and around the mouth and nose 
(Kitching, 2002; Alexandersen et al., 2003; Jamal and Belsham, 2013). Although the 
disease has a low mortality rate, outbreaks of the disease in endemic regions are 
frequent, generally involving the infection of large numbers of animals, and therefore 
have a high impact (Onono et al., 2013). Additionally, the consequences of an outbreak 
in a normally disease-free country can be high, due to the rapid spread of infection 
through a naïve population. Consequently, FMD has an estimated annual global impact 
of US $11 billion (90% range: US $6.5 – 21 billion) (Knight-Jones and Rushton, 2013). 
 
1.2.2 Causative virus 
The disease is caused by FMD virus (FMDV), a single stranded positive sense RNA virus, 
that belongs to the genus Aphthovirus within the family Picornaviridae (Grubman and 
Baxt, 2004). The virus particle is 25-30nm in diameter, containing a single copy of the 
FMDV genome approximately 8400 nucleotides (nt) in length, surrounded by a 
icosahedral shaped protein capsid composed of 60 capsomers (Acharya et al., 1989). 
Each capsomer consists of four structural virus proteins (VP). VP1, VP2 and VP3 which 
are exposed on the surface of the virus, are encoded by the genes 1D, 1B and 1C 
respectively. VP4 is located internally and is encoded by the 1A gene. The non-
structural proteins (NPs) are encoded by the 2A, 2B, 2C, 3A, 3B, 3CPro, 3Dpol and Lpro 
genes which control replication and maturation of the FMDV virus (Figure 1.1) 
(Domingo et al., 2003; Sangula et al., 2010; Jamal and Belsham, 2013; Kamel et al., 
2019).  
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Figure 1.1 The structure of the FMD virus genome. Adapted from Jamal and Belsham 
(2013). 
  
1.2.3 Geographical distribution of FMD 
There are seven immunologically distinct serotypes of FMDV; O, A, C, Asia 1, and 
Southern African Territories (SAT) 1, 2 and 3 (Robson et al., 1977). The serotypes are 
not evenly distributed spatially, and there is a tendency for genetically related viruses 
within a serotype to appear in the same geographical area, for reasons such as animal 
movement and trade patterns. Globally, the distribution of FMDV is divided into seven 
geographic pools, based on nucleotide sequence analyses (World Organisation for 
Animal Health (OIE), 2019)(Figure 1.2). Pools 1, 2 and 3 include serotypes O, A, and 
Asia 1 and cover East and Southeast Asia, South Asia, and West Asia respectively; Pool 
4 includes serotypes O, A, SAT 1, 2 (and 3) in East Africa; Pool 5 is restricted to West 
Africa (serotypes O, A, SAT 1 and 2); Pool 6 includes serotypes SAT 1, 2 and 3 in 
Southern Africa; and pool 7 in South America (O and A) (Paton et al. 2009). Serotype C 
is not included in any of the pools since it has not been identified since 2004 (Sangula 
et al., 2011).  
Within each serotype, different topotypes exist in the respective areas, which are 
geographically distinct groups of FMDV isolates. For example in pool 4 (East Africa), at 
least 5 of the 7 serotypes are known to be in circulation. Within pool 4, serotype O 
comprises four different eastern African (EA) topotypes including EA-1, EA-2, EA-3 and 
EA-4, and serotype A includes lineages G-VII and G-I from the AFRICA topotype (Brito 
et al., 2015). Notably, the latter was identified in Tanzania in 2014, but had not been 
detected for over 30 years previously (Kasanga et al., 2015). SAT 1 includes topotype 
IX and I (NWZ), and SAT 2 topotypes IV, XIII, and VII, with some of these topotypes 
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being detected for the first time in the past ten years (Legesse et al., 2013; Brito et al., 
2015). In the Middle East (pool 3) at least 3 of the 7 serotypes circulate, and again, 
several different topotypes also exist within these serotypes. These include but are not 
limited to: for serotype O: the PanAsia, PanAsia-2 and Ind-2001d lineages of the ME-SA 
topotype; for serotype A: the Iran-05, and Iran-96 lineages of the ASIA topotype and; 
for serotype ASIA 1: the Sindh-08 lineage of the ASIA topotype (Knowles and Samuel, 
2003; Knowles et al., 2016). 
Additionally, incursions of new serotypes and/or topotypes that are not normally 
found in that region frequently occur. Examples of such incursions include the 2015 
emergence of the A/ASIA/G-VII lineage (which is endemic in Indian sub-continent) into 
Saudi Arabia, Iran, Armenia, Israel, and Turkey (Bachanek-Bankowska et al., 2018), and 
the expansion of the distribution of the O/ME-SA/Ind-2001 lineage into the Middle 
East and North Africa since 2013 (Valdazo-González et al., 2014; Knowles et al., 2015). 
Additionally, the role of wildlife in maintaining circulation of different FMDV serotypes 
is unclear. For example, African buffalo (Syncerus caffer) are known to be maintenance 
hosts for serotypes SAT 1, SAT 2 and SAT 3 in East Africa, and may contribute to 
increasing the level of antigenic diversity, with the potential to trigger new outbreaks 
in livestock (Vosloo et al., 1996; Casey et al., 2013). Outbreaks are reported through 
observation of clinical animals and diagnosis either in country or by international 
reference laboratories. However, there is a need to obtain a more thorough 
understanding of the exact serotypes/topotypes circulating in a region, to better 
understand the complex epidemiology of FMDV to improve effective control of FMDV 
outbreaks in endemic areas (Picado et al., 2011; Kasanga et al., 2012; Kasanga et al., 
2015). 
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Figure 1.2 The geographical distribution of FMDV into the seven virus pools based on 
nucleotide sequence analyses, 2019. Colour coding displays the OIE FMD classification 
status of each country. (The extent of countries and zones without an official OIE status 
is not fully shown)(World Organisation for Animal Health (OIE), 2019). Courtesy of Dr 
Antonello Di Nardo (The Pirbright Institute, UK). 
 
1.2.4 Impact of FMD 
FMD has a large global impact of approximately US $11 billion (90% range: US $6.5 – 
21 billion). The consequences of outbreaks in FMD free countries and zones can result 
in losses of over US $1.5 billion per year (Reid et al., 2001; Knight-Jones and Rushton, 
2013; Hall et al., 2013). However, FMD has the most dramatic impact in endemic 
countries where approximately three-quarters of the world’s livestock population 
reside. These are often low and middle income countries that lack the resources and 
infrastructure to eliminate the disease, and therefore also pose a significant threat to 
disease-free countries (Knight-Jones and Rushton, 2013; Knight-Jones et al., 2016).  
 
1.2.4.1 Direct losses 
FMD costs are a result of direct losses and indirect losses. The direct impacts of FMD 
are not typically due to animal mortality which is generally low, but due to production 
losses. These may include, but are not limited to, the suppression of fertility and 
livestock growth rates, the utility of draught animals due to lameness, delay in the sale 
of livestock or their products, and a reduction in milk yield (discussed further in section 
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1.5.4), which affects consumption for both calves and humans (Rufael et al., 2008; 
Knight-Jones and Rushton, 2013; Young et al., 2013; Ansari-Lari et al., 2017; Chaters et 
al., 2018).  
 
1.2.4.2 Indirect losses 
Indirect losses are due to the reaction to disease and include additional costs, forgone 
earnings and wider consequences. Additional costs may include control measures such 
as vaccination and culling, movement and trade restrictions, surveillance and the cost 
of diagnostic tests (Knight-Jones and Rushton, 2013; Robinson et al., 2011). For 
example, the UK 2001 outbreak resulted in losses of over £8 billion, and other than 
over £1.3 billion for additional costs, included £4.5-£5.4 billion in foregone tourism 
revenue and £1.4 billion in compensation to farmers (House of Commons, 2002; 
Knight-Jones and Rushton, 2013). In FMD endemic regions, the application of control 
measures may also have negative consequences such as the construction of fences that 
may damage wildlife habitats and behaviours. Additionally, if control measures are not 
effective, farmers may lose trust and become reluctant to comply in the future (Knight-
Jones et al., 2016). Even in FMD free regions, costs are still incurred to maintain this 
free status, including potential vaccination schemes, import controls to prevent new 
disease introductions, maintenance of vaccine banks and supporting scientific research 
(Knight-Jones and Rushton, 2013). 
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1.3 Control of foot-and-mouth disease  
1.3.1 Epidemiological patterns of FMD 
Foot-and-mouth disease is not evenly distributed around the world. It is prevalent in 
most developing countries, and circulates in approximately 77% of the global livestock 
population (Rushton et al., 2012). To date FMD has been observed in every region of 
the world known to contain livestock, apart from New Zealand (Poonsuk et al., 2018).  
The World Organisation for Animal Health (OIE) has classified FMD as a listed disease 
according to the Terrestrial Animal Health Code (OIE, 2019a). Consequently countries 
are listed according to their official FMD status into either: (i) FMD-free country or zone 
without vaccination (NV); (ii) FMD-free country or zone with vaccination (WV); or (iii) 
FMD endemic (see Figure 1.2). Any unclassified member state is assumed to be 
endemic. Member countries can apply for disease-free status by providing evidence 
that FMD has been eliminated for at least 12 months (OIE, 2019a).  
Currently, 68 countries are classified as FMD free without vaccination, and 2 countries 
as FMD free with vaccination. Additionally, some countries have FMD free zones, but 
they are yet to provide evidence for virus elimination throughout the whole country. 
Often the country may also have zones with different classifications, i.e. some zones 
free WV and some free NV, for example in Argentina and Brazil (OIE, 2019b).  
 
1.3.2 Control measures 
Effective control strategies are imperative if the burden of disease is to be reduced, or 
if disease-free status is desired. Control measures can include vaccination, culling, 
restriction of animal movements, and removing contact of livestock with potentially 
infectious wildlife such as African buffalo (Syncerus caffer) (Rweyemamu, 1984; Paton 
et al., 2009; Picado et al., 2011; Kasanga et al., 2012; Namatovu et al., 2013). 
Implementation of the most effective control measures may be challenging due to 
variations in global livestock management practices, and consequently different 
regions require a tailored approach. For example, movement restrictions are difficult 
to enforce in areas where livestock management practices are based on pastoralism, 
such as in East Africa (Di Nardo et al., 2011; Brito et al., 2015).  
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Several types of FMD vaccines exist. Conventional inactivated vaccines are the most 
commonly used, and are produced by amplifying the live virus of interest on baby 
hamster kidney-21 (BHK-21) cells, then inactivating the amplified virus with binary 
ethyleneimine (BEI) to remove non-structural proteins (NSP). An appropriate oil-
based adjuvant or aqueous-based adjuvant such as aluminium hydroxide/saponin is 
also added. These vaccines vary in potency, they are normally either 3 or 6 times the 
50% protective dose (PD50), and can be prepared against one, or multiple 
serotypes/topotypes (Doel, 1996; Cao et al., 2016; Kamel et al., 2019). Although these 
vaccines can be highly efficacious, additional frequent boosters are required, and 
production requires expensive bio-containment facilities. Additionally, decreased 
vaccine efficacy may be impacted by low capsid stability which is reliant on the 
maintenance of a cold chain, low vaccine potency, incorrect dosing, and poorly purified 
vaccines (Parida, 2009; OIE, 2017a). To overcome some of these limitations, newer 
vaccine types have also been developed including live-attenuated, DNA, peptide and 
live viral vector vaccines. For example, most of these do not require biocontainment 
facilities for production, and are able to differentiate between infected and vaccinated 
animals, which can often be a problem with poorly purified inactivated vaccines 
(Kamel et al., 2019).   
However, although efficacious vaccines for FMD are available, many endemic countries 
do not have effective vaccination campaigns, due to a lack of incentives and resources, 
poor veterinary services or problems with cold chain maintenance (Smith et al., 2014). 
In many regions, it is also unclear exactly which serotypes/subtypes are circulating, 
with many exhibiting high antigenic variation (for example in pool 4), and the 
possibility of the emergence of new variant viruses. Additionally, infection or 
vaccination with one serotype/topotype may not protect against another (Parida, 
2009). Therefore there is a requirement for vaccine strains to be carefully selected 
based on epidemiological data collected from a region, and the ongoing monitoring of 
vaccine efficacy due to virus evolution. Also, even though vaccines may fully or partially 
protect animals from acute clinical infection, animals may still present mild or 
subclinical infection (no clinical signs), leading to an epidemiological threat from 
carrier animals (Hutber et al., 1999; Parida, 2009; Rodriguez and Gay, 2011; Lloyd-
Jones et al., 2017). 
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Effective control of FMD relies on successful co-operation between stakeholders 
including livestock owners, animal health workers, FMD experts and government 
personnel (Roberts and Fosgate, 2018). Additionally, thorough surveillance and 
accurate and timely identification of current and emerging field strains is required to 
better understand and predict patterns of viral circulation and to inform and improve 
vaccine selection, especially in endemic regions such as East Africa (Paton et al., 2009; 
Jamal and Belsham, 2013). This would allow a region to progress through the early 
stages of the Progressive Control Pathway for Foot and Mouth Disease (PCP-FMD) 
(Food and Agriculture Organization of the United Nations (FAO), 2011). This is a tool 
developed by the FAO to facilitate and assist FMD endemic countries to increase the 
level of FMD control so that countries/regions may apply for FMD free status, with or 
without vaccination, through a set of FMD control activity stages. These include active 
monitoring of virus circulation to understand the epidemiology of FMD, applying 
specific control measures in order to reduce the burden of FMD, and monitoring of 
outcomes (see Figure 1.3) (Food and Agriculture Organization (FAO), 2011; Jamal and 
Belsham, 2013). 
 
 
Figure 1.3 The Progressive Control Pathway for Foot-and-Mouth Disease (PCP-FMD). 
Adapted from the Food and Agriculture Organization (FAO) (2018). 
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1.4 Diagnosis of foot-and-mouth disease 
1.4.1 Clinical signs 
Diagnosis of FMD is primarily based on the observation of clinical signs. These become 
apparent after a short incubation period, typically between 2 – 6 days, and include a 
high temperature, excessive salivation, and the formation of vesicles on the oral 
mucosa, nose, teats, and the inter-digital spaces and coronary bands of the feet (Figure 
1.4). Additionally, there may be fever, depression, lameness, mastitis and reduced milk 
production. Pigs often suffer from severe clinical disease, while in small ruminants the 
signs are generally more subtle, or even unapparent (Alexandersen et al., 2003). The 
clinical signs of FMD are often indistinguishable from those of other vesicular diseases 
such as swine vesicular disease (SVD), vesicular stomatitis (VS), vesicular exanthema 
of swine, and the signs associated with Seneca Valley virus-1 infection (SVV-1) 
(Nardelli et al., 1968; Gelberg and Lewis, 1982; Rodriquez and Nichol, 1999; Singh et 
al., 2012). Therefore, rapid and accurate detection of disease is imperative to confirm 
the disease causing agent, and to initiate the implementation of control processes. Data 
collected from clinical samples may assist in evaluating the epidemiological situation 
of FMDV in a region, detecting the presence of virus, identifying circulating serotypes 
and variants within serotypes, identifying vaccine strain candidates, and monitoring 
the effectiveness of control strategies (Paton et al., 2009; Jamal and Belsham, 2013). 
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(A) (B) (C) 
   
(D) (E) (F) 
   
 
Figure 1.4 Clinical signs of foot-and-mouth disease, including excessive salivation (A), 
and vesicles on the gums (B), tongue (C), inter-digital spaces of the feet (D and E), and 
teats (F). Photographs taken by Bryony Armson. 
 
1.4.2 Sample collection 
A range of sample types may be collected for the diagnosis of FMD, with vesicular 
epithelium or fluid being favoured due to the high concentrations of virus, although are 
only available for collection during the acute stage of the disease (Figure 
1.5)(Alexandersen et al., 2001; Ferris et al., 2006). Therefore, alternatives are required 
when infection is present but lesion material cannot be collected, for example on 
suspected farms before clinical signs become apparent (‘pre-clinical’ stage), during 
convalescence, in mild cases such as in small ruminants, or in ‘sub-clinical’ cases where 
no lesions are apparent.  
Other sample types submitted to reference laboratories for confirmatory diagnostics 
include blood, oesophageal–pharyngeal (OP) fluid and oral, nasal or lesion swabs (OIE, 
2018). The detection of FMD virus in blood samples is limited to the acute viremia stage 
of disease, although FMDV-specific antibodies may be detected for much longer 
periods (>1 year)(Alexandersen et al., 2003; Elnekave et al., 2015). Additionally, FMD 
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virus/viral RNA may be detected in oral or lesion swabs for up to at least 14 days post 
infection (Alexandersen et al., 2003; Stenfeldt, Lohse and Belsham, 2013), and in 
‘carrier animals’, in OP fluid for up to 3 years in cattle (Stenfeldt et al., 2013) or 5 years 
in buffalo (Condy et al., 1985).  
 
Figure 1.5 Approximate clinical window of FMD virus detection from different sample 
types: oral swab (A), OP fluid (B), blood (C), and vesicular epithelium (D). Day 0 
indicates the day vesicular lesions are first noticed. Based on data from Alexandersen 
et al., 2003, King et al., 2012 and Stenfeldt et al., 2013. Oral swab photograph courtesy 
of Emma Howson, 2016.  
 
1.4.3 Laboratory diagnosis 
Clinical samples collected from suspect cases are usually transported for routine 
diagnostic testing to local laboratories or centralised reference laboratories containing 
high containment facilities that are equipped for handling infectious pathogens. In the 
laboratory, detection of current or previous FMDV infection can be carried out using 
virological, molecular and serological tests according to the OIE Terrestrial Manual 
(OIE, 2018) which are explained in further detail below.  
 
1.4.3.1 Detection of live FMD virus 
Conventional detection of live virus is by virus isolation (Snowdon, 1966), usually from 
vesicular epithelial tissue or fluid, although this method can be used with other sample 
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types. Briefly, the sample is removed from the transport media (ideally composed of 
equal amounts of glycerol and 0.04 M phosphate buffer to maintain a pH of 7.2 – 7.6), 
then a 10% epithelial suspension is prepared by grinding the sample with sterile sand 
in a pestle and mortar and clarified in a centrifuge. This suspension is inoculated onto 
a primary or established cell-line such as primary bovine (calf) thyroid (BTY) cells or 
IB-RS-2 cells respectively, and the cell cultures examined for cytopathic effect (CPE) for 
up to 96 hours (OIE, 2018). Other susceptible cell lines include Baby Hamster Kidney-
21 (BHK-21) cells, lamb kidney cells, swine kidney cells (SK6), fetal goat cells (ZZ-R) 
and bovine kidney cells (LFBK-αVβ6)(Kasza et al., 1972; Ferris et al., 2006; Brehm et al., 
2009; LaRocco et al., 2013). This method is highly sensitive, and the resulting cell 
culture isolates may be utilised further, for example for vaccine matching. However, 
testing by this method can take up to four days to report a result, and it does not 
provide a definitive diagnosis of FMD, as CPE may be caused by other vesicular viruses. 
Therefore, in order to confirm infection of the sample with FMDV, additional diagnostic 
tests are required, such as the detection of FMD virus genome by molecular methods. 
 
1.4.3.2 Detection of FMD virus genome 
Reverse transcription polymerase chain reaction (RT-PCR) assays have been 
developed with a much greater sensitivity, and detect viral genomes (or fragments) 
instead of intact viral antigens and/or live virus. This detection method can be used on 
several sample types, including those that may be partially degraded and no longer 
infectious. Additionally, they can be easily automated, and produce relatively rapid 
results (<4 hours) (Reid et al., 1998; Reid et al., 2003; Shaw et al., 2007).  
The viral RNA must be extracted from the sample so that it may be used as a template 
for the RT-PCR assay. Additionally, this process inactivates the potentially infected 
sample, and can remove potential PCR inhibitors, such as RNases, proteins and lipids 
from a wide range of sample types (Wilson, 1997). A number of methods have been 
evaluated for the extraction of FMDV RNA. Many commercial kits or reagents include a 
lysis solution that contains guanidine isothiocyanate, which disrupts the cells and cell 
components by denaturing proteins, whilst maintaining the integrity of the RNA. For 
example, the use of Trizol® reagent produces high yields of RNA (Simms et al., 1993), 
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however samples are extracted manually and this method requires the use of 
potentially dangerous chloroform. Consequently, safer, higher throughput protocols 
have more recently been employed, for example using magnetic bead-based kits such 
as the MagMAX™-96 Viral RNA Isolation Kit (Applied Biosystems™, UK), and the LSI 
MagVet™ Universal Isolation Kit (Thermo Fisher Scientific, Loughborough, UK). RNA 
extraction using these kits may be performed manually, or in combination with 
automated extraction robots such as the KingFisher magnetic particle processors 
(Thermo Fisher Scientific), allowing for the processing of up to 96 samples in under 30 
minutes (Figure 1.6). Alternatively, silica-based spin column kits such as the QIAamp 
Viral RNA Mini Kit (Qiagen, Germany) may also be used in combination with automated 
extraction robots, and use silica matrices to bind nucleic acid, however due to the 
potential for clogging the filter, only limited sample types can be processed with this 
method.  
 
 
Figure 1.6 Examples of automated RNA extraction and real-time RT-PCR technologies. 
For RNA extraction: (A) - The KingFisher magnetic particle processor (Thermo Fisher 
Scientific) and (B) - QIAcube Connect (Qiagen). For laboratory rRT-PCR: (C) - Applied 
Biosystems™ 7500 Fast Dx Real-Time PCR Instrument. rRT-PCR technology for field 
settings:  (D) - T-COR 8™ Real-time PCR Thermocycler (Tetracore, Inc) and (E) – Mic 
qPCR cycler (Bio Molecular Systems). 
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After the nucleic acid has been isolated from the sample, RT-PCR can be performed to 
determine the presence and quantity of FMDV RNA in the sample. Conventional RT-
PCR methods involve three separate steps:  (i) conversion of the RNA into single-
stranded complementary DNA (cDNA) using a reverse transcriptase enzyme, (ii) 
amplification of template cDNA by PCR and (iii) the examination of PCR product by 
agarose gel electrophoresis (Reid et al., 1998). The process of PCR involves the 
denaturation (melting) of the double stranded DNA into single strands by heat, to 
which two oligonucleotide primers are annealed that are complementary to sequences 
on the target gene. The presence of a thermostable enzyme (e.g. Taq DNA polymerase) 
allows extension of the primers in opposite directions by DNA synthesis. As these 
primers are located apart from each other on the target gene, two complementary 
strands are consequently generated. Repetition of this process results in an 
exponential increase in the number of copies of the specific nucleic acid (see Figure 
1.7) (Guatelli et al., 1989; Holland et al., 1991).     
More recent developments to reduce the number of user dependent steps has resulted 
in real-time (r), one-step fluorogenic RT-PCR assay procedures that can be automated, 
with an increased throughput of samples (Reid et al., 2003). These methods are 
modified versions of the RT-PCR process described above, which allow the results to 
be monitored in real-time. A number of different chemistries exist although the most 
commonly used for FMDV detection is the addition of a fluorogenic TaqMan® probe 
specific to the target gene that is dual-labelled with a reporter (e.g. FAM) and quencher 
dye (e.g TAMRA). During the extension phase of the PCR reaction, the Taq polymerase 
enzyme cleaves the probe by nuclease degradation, and fluorescence is emitted when 
the two dyes are physically separated (Figure 1.7) (Heid et al., 1996; Didenko, 2001; 
Johansson, 2006). The increase in fluorescence intensity is proportional to the number 
of copies of nucleic acid produced, and can be visualised using a number of systems 
including the Applied Biosystems™ 7500 Fast Dx Real-Time PCR Instrument (Figure 
1.6), the CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad Laboratories Ltd.), 
and the AriaMx qPCR System (Agilent Technologies Inc.). 
To ensure the detection of all serotypes/topotypes of FMDV by (r)RT-PCR, highly 
conserved regions of the genome must be targeted. Conventional and real-time RT-PCR 
assays have been developed using primers based on sequences from the 1D and 2A/2B 
Chapter 1 
 
16 
 
region (Amaral-Doel et al., 1993), the 3D polymerase (Callahan et al., 2002; Nishi et al., 
2019) and the internal ribosomal entry site located in the 5’untranslated region (UTR) 
(Reid et al., 2002) (see Figure 1.1). The 5’UTR and 3D FMDV rRT-PCR assays are 
recommended by the OIE, are highly specific, and are as sensitive as the ‘gold standard’ 
method of virus isolation in cell culture (Shaw et al., 2004; OIE, 2018).  
 
  
Figure 1.7 Schematic of the real-time polymerase chain reaction (PCR) process. (1-2): 
double stranded DNA is denatured into 2 separate strands by heat. (2-3): The forward 
primer (FP), reverse primer (RP) and fluorogenic probe (P) are annealed to the 
template. (4): primer extension causes physical separation of the reporter (R) and 
quencher (Q) dyes on the probe causing fluorescence to be emitted. (5): after primer 
extension there are 2 sets of double stranded DNA and the process begins again with 
an exponential increase in the number of copies of specific nucleic acid. Figure adapted 
from Guatelli, Gingeras and Richman (1989) and the ThermoFisher Scientific website. 
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1.4.3.3 Identification of the FMDV serotype/strain  
Identification of the serotype responsible for a particular outbreak is of the utmost 
importance to inform vaccine selection and for tracing outbreaks. The antigen 
detection ELISA (enzyme-linked immunosorbent assay) (Ferris and Dawson, 1988) 
can identify the serotype of the causal FMDV and can be performed in 4-5 hours. 
However, the analytical sensitivity is often limited, and the test is only suitable for 
epithelium tissue/fluid and cell culture derived FMDV material. With the advent of 
molecular technology, various authors have demonstrated the utility of typing of FMDV 
by conventional RT-PCR assays (Callens and De Clercq, 1997; Giridharan et al., 2005; 
Bao et al., 2008; Saeed et al., 2011; Liu et al., 2018). However, due to the heterogeneity 
of FMDVs in different areas of the world, assays tailored to circulating virus strains are 
required (Jamal and Belsham, 2015). Recently, rRT-PCR assays for the detection of 
strains specific to a particular region, for example the Middle East (Reid et al., 2014; 
Knowles et al., 2015; Saduakassova et al., 2017), West Eurasia (Jamal and Belsham, 
2015), North (Ahmed et al., 2012) and East Africa (Bachanek-Bankowska et al., 2016) 
have been developed. Most of these characterisation rRT-PCR assays are designed to 
target the VP1 coding region, as it is the least conserved region of the FMDV genome, 
with a high degree of sequence variation (Baxt et al., 1984; Wittwer and City, 1989; 
Jamal and Belsham, 2013). In order for these to be continually sensitive and specific, 
sequences of circulating strains must be assessed and if necessary, primer sets adapted 
(Jamal and Belsham, 2015; Bachanek-Bankowska et al., 2016). 
 
1.4.3.4 Virus sequencing 
Nucleotide sequence analysis is also used for the characterisation of circulating FMDV 
strains. Most of the nucleotide sequences of FMDV published are of the VP1 coding 
region using Sanger sequencing (Sanger et al., 1977). VP1 sequencing is frequently 
used to deduce evolutionary dynamics, genetic and epidemiological relationships, in 
the tracing of outbreaks and monitoring the transboundary movements of the disease 
(Wittwer and City, 1989; Marquardt and Adam, 1990; Knowles and Samuel, 2003; 
Kasambula et al., 2012; Logan et al., 2014). However, the VP1 region represents less 
than ten percent of the full genome (i.e., 639/8300 nucleotides), and can only identify 
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the predominant consensus sequence (Cottam et al., 2008; Logan et al., 2014). With 
recent technological advances, whole genome sequencing (WGS) has become much 
more accessible and has been used for high resolution molecular epidemiological 
studies, such as investigating the transmission pathways of the 2007 UK FMDV 
epidemic (Cottam et al., 2008). WGS tools have been refined with the development of 
next-generation sequencing (NGS) (Marston et al., 2013; Gilchrist et al., 2015). 
Recently, a NGS protocol has been adapted to sequencing the whole genome of FMDV 
(Logan et al., 2014). NGS offers a rapid, robust, and high throughput method for the 
generation of high resolution viral genome sequences enabling the identification of 
minority variants (viral swarm structure) beyond the consensus level of which would 
usually only identify the most frequently appearing strains (Wright et al., 2011; Orton 
et al., 2013; Logan et al., 2014; King et al., 2016).  
 
1.4.3.5 Detection of FMDV antibody 
Natural infection induces antibodies to both FMD viral structural proteins (SP) and 
non-structural proteins (NSP) (Paton et al., 2009; Sørensen et al., 1998), and these can 
be detected using serological tests. The virus neutralisation test (VNT) (Karber, 1931) 
and the liquid phase blocking ELISA (LPBE) (Hamblin et al., 1986) can detect serotype 
specific anti-SP antibodies. However, the VNT takes several days to perform, and 
requires the use of live virus and therefore must be carried out in specialised 
biocontainment laboratories.  
Vaccination however, induces only anti-SP antibodies (providing the vaccines in use 
are purified to remove NSPs) and therefore tests which can detect anti-NSP antibodies 
can be used as differentiation of infected from vaccinated animals (DIVA) tests (Shen 
et al., 1999; Paton et al., 2006; Uttenthal et al., 2010). Tests based on anti-NSP 
antibodies can detect infection with all serotypes, however they are unable to identify 
with which serotype/topotype the animal has been infected with, due to the conserved 
nature of the NSP coding region (Grubman and Baxt, 2004). Additionally, many regions 
use poorly purified vaccines that may still contain NSP, and so differentiation is not so 
effective. Anti-NSP antibodies may persist for a long time (Elnekave et al., 2015), and 
as anti-NSP antibody ELISA testing is inherently retrospective these tests can therefore 
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only identify whether the animal has previously been infected with FMDV. 
Consequently, unlike virological methods, serological tests are unable to determine the 
current infectious status of an animal.  
 
1.4.4 Methods to reduce time to result for FMD diagnosis  
Rapid and accurate diagnosis is essential for surveillance and effective control of FMD. 
Although the more recently developed laboratory methodologies described above have 
been designed to reduce the time to result and minimise user intervention, samples 
from suspect cases still need to be transported to centralised reference laboratories for 
routine testing, as many countries lack the infrastructure to be able to carry out their 
own diagnosis (Fowler et al., 2014; Niedbalski, 2016; Howson et al., 2017). Transport 
of samples to these centralised facilities often involves lengthy travel times, including 
costly international shipments which can delay result reporting and critical decision 
making for days or even weeks after clinical signs have been observed. Also, transport 
times mean that results may not only be delayed, but also not as reliable if sample 
degradation could have taken place if a cold chain was not maintained (Fowler et al., 
2014; Howson et al., 2017).  
To overcome these difficulties, simple to use technologies that can be deployed either 
in the field or in local laboratories exist so that countries are able to improve their 
capacity for surveillance. Various portable platforms have been developed to enable 
local FMDV detection including the lateral-flow device (LFD)(Ferris et al., 2009) and 
closed tube tests that have been adapted for the use of thermostable lyophilised 
reagents such as the Enigma® Field Laboratory (FL) (Madi et al., 2012; Howson et al., 
2017), and the T-COR 8™ (Tetracore, Inc)(Howson et al., 2018) (see Figure 1.6). 
Furthermore, serotype specific assays have been adapted for use with some of these 
technologies, allowing for rapid identification of the serotype either in local 
laboratories or at the point of sample collection (Chen et al., 2011; Howson et al., 2018). 
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1.5 FMD surveillance 
1.5.1 Limitations of established FMD surveillance systems 
Surveillance activities are designed to improve the epidemiological understanding of 
disease in a population of interest, and can be useful for informing disease prevention 
and control strategies (Falzon et al., 2019). In order to improve knowledge of the 
epidemiology of FMD in endemic regions, efficient, cost-effective surveillance systems 
are essential. Data collected through passive surveillance from clinical samples may 
assist in evaluating the epidemiological situation of FMDV in a region (Paton et al., 
2009; Jamal and Belsham, 2013). However, although approximately 77% of the global 
FMD susceptible livestock population reside in FMD endemic regions (e.g. see Figure 
1.8 for the global distribution of cattle), few clinical samples are sent to national 
reference laboratories for diagnostic testing (Rushton et al., 2012; Namatovu et al., 
2013; Robinson et al., 2014). For example in 2018, only 442 clinical samples from 25 
countries were received in the WRLFMD for FMD diagnosis (see Table 1.1), yet it is 
estimated that FMD affects 32 million livestock units (LSU), although it could be up to 
79 million, globally per year (1 LSU = 1 cow, 3.3 pigs, or 10 sheep or goats) (Sumption 
et al., 2008; Knight-Jones and Rushton, 2013). Consequently it is evident that an 
incomplete global picture of the epidemiology of the disease exists based on 
established surveillance methods. 
 
Figure 1.8 The global distribution of cattle. Reproduced from Robinson et al. (2014). 
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Table 1.1 Summary of samples collected and received to WRLFMD (January to 
December 2018). Adapted from WRLFMD (2018a, 2018b, 2018c, 2018d) 
Country 
Number 
of 
samples 
Virus isolation/ELISA 
O A C SAT 1 SAT 2 SAT 3 ASIA 1 NVD* 
Hong Kong SAR of 
PRC 
27 7 - - - - - - 16 
Israel 14 8 6 - - - - - - 
Kenya 28 6 3 - 1 1 - - 17 
Mongolia 24 17 1 - - - - - 7 
Nepal 18 3 - - - - - 8 7 
Palestinian 
Autonomous 
Territories 
12 12 - - - - - - - 
Swaziland 3 - - - - - - - 3 
Afghanistan 22 3 1 - - - - 1 17 
Bhutan 11 4 3 - - - - - 4 
Ethiopia 28 11 7 - - 1 - - 9 
Iran 25 11 9 - - - - 4 1 
South Korea 5 - 2 - - - - - 3 
Sri Lanka 16 9 - - - - - - 7 
Vietnam 40 20 13 - - - - - 7 
Zambia 3 3 - - - - - - - 
Algeria 2 2 - - - - - - - 
Malaysia 12 11 - - - - - - 1 
South Sudan 29 - - - - - - - 29 
Sudan 38 6 13 - - 5 - - 14 
Burkina Faso 18 7 - - - - - - 11 
Gambia 2 2 - - - - - - - 
Laos 1 - - - - - - - 1 
Senegal 11 6 - - - - - - 5 
Sierra Leone 34 - - - - - - - 34 
Thailand 19 8 8 - - - - - 3 
TOTAL 442 156 66 0 1 7 0 13 196 
*NVD: no virus detected 
 
Conventional surveillance often relies on the recognition and reporting of obvious 
clinical cases by farmers, livestock workers or animal health service providers (Bates 
et al., 2003; Picado et al., 2011; Machira and Kitala, 2017). In areas where FMD is 
common, farmers may be able to easily identify the disease based on clinical 
presentation (Nyaguthii et al., 2019), and this has been shown to be comparable to the 
results of serological testing (Morgan et al., 2014).  
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Although passive surveillance is valuable, there are several limitations to this 
approach. For example, it is possible that farmers may not observe or correctly identify 
FMD, especially where clinical signs are mild (Knight-Jones et al., 2014), or in regions 
where FMD is uncommon. Furthermore, even when farmers identify FMD, they may 
not view it as serious enough to report to veterinary services, or may be deterred due 
to the repercussions of imposed control measures, as has also been observed for other 
diseases (Falzon et al., 2019). Moreover, where outbreaks are reported, extensive 
spread of the disease may have occurred between noticing the disease and actual 
reporting (Vosloo et al., 2002; Knight-Jones et al., 2016). As a consequence FMD is often 
under-reported, and it is difficult to determine the true incidence of the disease. 
Passive surveillance activities may be supplemented by targeted case finding activities, 
but these may be infrequent due to the costs and labour involved (Hadorn and Stärk, 
2008; Kasanga et al., 2012). Alternative risk-based surveillance methods such as 
serological surveys can provide valuable information by identifying the presence of 
unreported infection (Caporale et al., 2012; Hoinville et al., 2013; Dhikusooka et al., 
2016). Many studies have used the detection of NSP antibodies in serum samples for 
FMD surveillance (Kibore et al., 2013; Ehizibolo et al., 2014; Lyons et al., 2017; Souley 
Kouato et al., 2018), however due to the length of time that NSP antibodies may persist 
in the blood, these tests are unable to identify when exposure occurred (Elnekave et 
al., 2015), although stratifying animals into age groups and performing expensive 
longitudinal studies with frequent testing intervals may improve accuracy (Bertram et 
al., 2018; Farooq et al., 2018). Additionally NSP antibody tests are unable to identify 
the causal viral lineage, are time consuming, labour-intensive and expensive to 
perform, and they may be influenced by the use of non-NSP purified vaccines (Lee et 
al., 2006; Caporale et al., 2012). 
Additionally, the capacity for undertaking outbreak investigation and collection of 
clinical specimens in resource-limited countries is often restricted (Kasanga et al., 
2012; Namatovu et al., 2013). Even when samples are collected from suspect cases, the 
insufficient maintenance of a cold chain during sample transport, and/or poor quality 
sample laboratory storage due to failures in power supply, may lead to sample 
degradation and therefore potentially false negative test results (Vosloo et al., 2002; 
Namatovu et al., 2013; Zinsstag et al., 2016).  
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When outbreaks are reported and clinical samples collected, the recommended sample 
types submitted to laboratories for FMD diagnosis are epithelial tissue or fluid in 
vesicular lesions from acutely diseased animals, although blood and OP fluid are often 
received (King et al., 2006; OIE, 2018). Consequently, the majority of samples are taken 
from animals with recognisable clinical signs often at a single time point. This may 
result in sampling bias towards visibly clinically infected animals, in comparison to 
sub-clinically infected animals (such as vaccinated herds), although the role of 
subclinical infection in disease transmission is still to be elucidated (Sutmoller and 
Casas, 2002).  
 
1.5.2 Reducing sampling bias 
In order to reduce sampling bias, methods for sample collection using alternative 
sample types at points other than during the acute stage of disease have also been 
explored. For example, FMDV RNA has been detected in saliva and nasal swabs, and air 
samples before clinical signs became apparent (Alexandersen et al., 2003; Marquardt 
et al., 1995; Nelson et al., 2017; Stenfeldt et al., 2013). This may enhance early detection 
so that control measures may be put in place, if resources allow, before extensive 
spread of the disease may occur (Charleston et al., 2011; Nelson et al., 2017). The 
Chinese national surveillance program has also successfully identified FMDV in lymph 
node samples at slaughter (OIE, 2017b). Detection of FMDV has also been 
demonstrated in nasal fluid, saliva and OP fluid during late-stage infection (Stenfeldt et 
al., 2013; Parthiban et al., 2015), and in OP fluid in persistently infected (carrier) 
animals (Stenfeldt et al., 2013; Lohse et al., 2018). Surveillance of animals using this 
method may facilitate the clarification of freedom from disease in a herd or region, and 
may identify the likelihood of onward transmission (Caporale et al., 2012; Parthiban et 
al., 2015). Detection of virus at these late stages may identify infected animals that were 
previously overlooked due to mild clinical signs, or sub-clinical infection.   
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1.5.3 Detection of sub-clinical FMD infection 
Several studies have identified the presence of FMDV RNA in sub-clinically infected 
animals, including cattle (Bertram et al., 2018; Hayer et al., 2018), Asian water buffalo 
(Bubalus bubalis) (Farooq et al., 2018) and African buffalo (Syncerus caffer) (Vosloo et 
al., 2007; Wekesa et al., 2015; Dhikusooka et al., 2016; Maree et al., 2016), although the 
proportion of animals affected is unknown. Additionally, the occurrence of sub-clinical 
FMDV infection in vaccinated animals has also been reported (Hafez et al., 1994; 
Hutber et al., 1999; Lyons et al., 2017; Hayer et al., 2018; Stenfeldt et al., 2018), and 
that newly infected sub-clinical animals may shed considerable amounts of infectious 
FMDV, despite no manifestation of clinical signs (Stenfeldt et al., 2015). Consequently, 
this information may affect control policies where vaccination is practiced, if FMDV can 
continue to circulate sub-clinically. Although the detection of NSP antibodies is a 
valuable tool in the identification of sub-clinical animals (Lyons et al., 2017; Farooq et 
al., 2018), previous infection of subject animals must be ruled out, which may involve 
costly longitudinal studies. Consequently, most studies have used the detection of 
FMDV in OP fluid to identify sub-clinically infected animals. This method however, 
must be performed by a trained individual, is labour intensive, and highly invasive for 
the animal (Kitching, 2002; Stenfeldt et al., 2013). Additionally, OP fluid samples are 
less likely to be collected from smaller animals such as sheep and goats, due to the 
invasive nature of the technique and the different sizes of instrumentation required.   
The potential risk and significance for FMD epidemiology from sub-clinically infected 
animals is not fully understood. Further studies focussing on the detection of natural 
sub-clinical infection utilising novel surveillance strategies may reduce the bias 
observed with conventional surveillance methods and facilitate improved knowledge 
on viral prevalence, dynamics and the emergence of new lineages  (Hutber et al., 1999; 
Sutmoller and Casas, 2002; Farooq et al., 2018; Stenfeldt et al., 2018).  
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1.6 Milk 
Milk is a non-invasive sample type, collected from lactating cattle on a daily basis, and 
has the advantage that both FMD virus and antibodies can be detected (Blackwell and 
McKercher, 1982; Armstrong, 1997). Milk has been utilised for the detection of several 
pathogens and the antibodies raised against them, including Brucella spp. (Vanzini et 
al., 1998; Hamdy and Amin, 2002), bovine viral diarrhoea virus (BVDV) (Drew et al., 
1999; Renshaw et al., 2000a; Hill et al., 2010), Schmallenberg virus (Daly et al., 2015), 
Coxiella burnetti  (Kim et al., 2005), bovine respiratory syncytial virus (Elvander et al., 
1995), and Neospora caninum (González-Warleta et al., 2011). Furthermore, the use of 
pooled milk samples from individual animals, or collecting samples of milk from a bulk 
tank or milk line enables a cost-effective surveillance approach which has been 
validated for the routine surveillance of diseases such as brucellosis (DEFRA, 2015a) 
and mastitis caused by Mycoplasma spp. (APHIS, 2008).  
An example of using pooled milk in a national surveillance system is for brucellosis in 
the United Kingdom (U.K.). The Brucellosis (England) Order 2000 (DEFRA, 2015a) 
aims to maintain the ’Officially Brucellosis Free’ status by ensuring animals are free 
from infection. This programme involves the submission of quarterly bulk milk 
samples from commercial dairy farms to the Animal and Plant Health Agency (APHA) 
for testing by the Brucellosis Bulk Milk ELISA (DEFRA, 2015b; Musallam et al., 2017). 
This method is non-invasive, involving milk already collected and destined for 
consumption, and therefore is more cost-effective than the serological sampling of 
individual animals (Rolfe and Sykes, 1987). 
Additionally, many studies have investigated the surveillance of bovine viral diarrhoea 
virus using pooled milk samples (Niskanen et al., 1991; Paton et al., 1998; Kuijk et al., 
2008, among others), determining this method to be useful for cost-effective 
surveillance. Consequently, as a part of the BVDFree Scheme in the U.K. (BVDFree, 
2019), bulk milk samples are collected from dairy farms, and sent to various 
laboratories for either antibody or virus detection by ELISA and RT-PCR respectively. 
This scheme identifies infected herds so that control measures may be implemented, 
with the aim of eliminating BVDV from all cattle by 2022.  
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It is hypothesised that similar schemes could be designed for FMD surveillance in 
endemic regions or during outbreak scenarios in FMD free countries. However, unlike 
infection with BVDV, in which animals may become persistently infected and shed 
large amounts of virus throughout their lifetime (Brock et al., 1998), FMD infection is 
generally not maintained within an individual or herd for long periods, other than in 
OP fluid (Stenfeldt et al., 2013), which requires invasive sampling. Consequently, the 
window of detection for cost-effective FMD surveillance is much smaller than that of 
BVDV. The potential of milk as a suitable sample type for FMD surveillance is discussed 
in more detail below. 
 
1.6.1 Detection of FMDV in milk 
Experimental inoculation of the mammary gland with FMDV has shown that it is an 
organ that is highly susceptible to viral replication (Burrows et al., 1971), and that virus 
is readily excreted in the milk of infected animals (Lebailly, 1920; Terbruggen, 1932; 
Burrows, 1968). After experimental infection of dairy cattle with FMDV, live virus has 
been detected in milk by virus isolation and plaque assay before the appearance of 
clinical signs (Burrows, 1968; Hedger and Dawson, 1970; Blackwell and McKercher, 
1982). Live FMDV was also detected up to 51 days post-infection (Burrows et al., 1971), 
although this experiment involved inoculation of virus directly into the udder, which is 
unlikely to be a natural route of infection. Additionally, experiments have inoculated 
FMDV infected milk into various animals such as suckling mice, guinea pigs and calves 
(Sellers, 1969; Felkai et al., 1970) to determine virus infectivity and the onward risk of 
transmission with similar limitations from the unnatural inoculation routes. 
Nevertheless, these experiments demonstrate the possible extended excretion periods 
of virus into milk, when compared to other sample types such as serum and vesicular 
epithelium, and highlight the potential risk of infected milk for virus transmission.  
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1.6.2 Detection of FMDV RNA in milk 
With a transition towards rapid, automated and high-throughput diagnostic methods, 
it has also been demonstrated that FMDV RNA can be detected in the milk of infected 
animals by real-time RT-PCR (Reid et al., 2006; Ahmed et al., 2017), multiplex PCR and 
RT-LAMP (Ranjan et al., 2016). A study by Reid et al. (2006) showed that after lactating 
cattle were kept in direct contact with experimentally infected lactating cattle to 
simulate a natural route of infection, virus was detected in milk by rRT-PCR for a longer 
time period than by conventional virus isolation methods. In some of the animals, 
FMDV RNA was detected before the appearance of clinical signs, and up to 23 days post 
infection in milk from the inoculated cattle. Additionally, in a study by Ahmed et al., 
(2017) FMDV RNA could be detected by rRT-PCR in the milk of apparently healthy NSP 
positive vaccinated Asian water buffaloes (Bubalus bubalis), suggesting the presence of 
sub-clinical infection in this species.  
Serotype identification of FMDV in milk samples has also been demonstrated by 
molecular methods (Saeed et al., 2011; Ahmed et al., 2017). Furthermore, Saeed et al. 
(2011) reported successful FMDV sequence analysis of milk collected from acutely 
infected animals, and studies on different viruses support the potential of obtaining 
sequence data from milk samples, for example vaccinia virus in milk from dairy cattle 
(Abrahão et al., 2009) and human immunodeficiency virus from human breast milk 
(Salazar-Gonzalez et al., 2011).   
 
1.6.3 Detection of FMD antibodies in milk 
It has also been demonstrated that antibodies to FMDV can be detected in cattle milk, 
from 7 days post infection and up to 12 months post vaccination (Stone and DeLay, 
1960). Antibodies to FMDV in milk samples have been detected using a liquid-phase 
blocking ELISA (LPBE) and a specific isotype assay (SIA) for bovine Immunoglobulin G, 
(Armstrong, 1997; Armstrong et al., 2000), and the authors hypothesised that both of 
these tests could be applied in surveillance schemes to identify exposed cattle/herds. 
A significant correlation between antibody levels in serum and milk has also been 
observed (Armstrong and Mathew, 2001; Fayed et al., 2013) and it has been 
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hypothesised that milk collected from infected cattle may contain higher levels of 
virus-specific antibody than serum, as serum antibody is concentrated into mammary 
secretions (Stone and DeLay, 1960). However in a study using milk from Asian 
buffaloes, Yadav et al. (2007) observed lower levels of FMDV-specific antibodies than 
in serum. Nonetheless, milk could be a useful alternative sample type to blood for 
surveillance or post-vaccination monitoring (Fayed et al., 2013), to complement 
current systems. 
 
1.6.4 The impact of FMDV infection on milk yield 
For milk to comprise a suitable sample type for FMD surveillance, it is important to 
have confidence that the ability to collect this sample is not affected by disease 
presence. Many studies document a reduction in milk yield during FMDV infection (see 
Table 1.2)(James and Rushton, 2002; Senturk and Yalcin, 2005; Knight-Jones and 
Rushton, 2013; Jemberu et al., 2014; Casey-Bryars et al., 2018). Interestingly, local 
breeds were estimated to have significantly smaller losses than Holstein dairy cattle 
(Senturk and Yalcin, 2005). These studies report highly variable losses although are all 
estimates based on farm surveys or expert opinion with relatively few empirical 
studies quantifying the reduction in milk output (see Table 1.2). One such example is 
from a longitudinal study in Pakistan carried out by Ferrari et al., (2014) that 
demonstrated a significant reduction in milk yield from individual cattle and buffaloes 
in the 60 days following the onset of acute clinical FMD. Additionally, Ansari-Lari et al., 
(2017) demonstrated a significant decline in individual daily milk production after an 
FMD outbreak compared to before the outbreak, although the drop was small (up to 
8% over a 42 day outbreak period). Furthermore, Lyons et al., (2015) aimed to quantify 
objectively the impact of FMD in milk yields. During an outbreak of FMDV SAT 2 on a 
large scale dairy farm housing mainly European breed cattle in Kenya, they observed 
that although there was up to an approximate 35% decrease in milk production at the 
herd level, no statistical evidence was found to indicate a significant decrease in milk 
yield between FMD clinical animals and non-clinical cases (Lyons et al., 2015).  
Interestingly, reports to date on the effect of FMDV infection on milk yield based on 
empirical data do not specify a complete cessation of milk production at any time. This 
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demonstrates the potential availability of milk as a diagnostic sample type during 
infection, as it is expected that it would still be possible to collect milk from individual 
lactating cows before, during and after FMD infection. However, factors such as the 
development of clinical mastitis as a result of vesicular lesions on the teats (Kitching, 
2002; Sharma, 2010; Lyons et al., 2015), may mean that milk from this animal is not 
contributed for herd level milk sampling. 
(Power and Harris, 1973; Kazimi and Shah, 1980; Chowdhury et al., 1993; Saxena, 
1994; Barasa et al., 2008; Mazengia et al., 2010; Bayissa et al., 2011; Onono et al., 2013; 
Ali et al., 2017) 
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1.6.5 FMDV detection in pooled or bulk tank milk 
The potential for detection of FMDV in milk samples from individual animals has been 
described above. Theoretically, sampling of milk at the herd level or even further up 
the milk production chain could also offer a cost-effective framework for FMD 
surveillance. Currently, the impact of pooling on the detection sensitivity of FMDV in 
milk has not been sufficiently studied. Using milk samples from experimentally ‘in-
contact’ infected cattle diluted in uninfected whole milk, Reid et al., (2006) 
demonstrated that FMDV RNA could be detected by rRT-PCR down to a dilution of 10-
4, and by virus isolation down to a dilution of 10-3. Consequently, they hypothesised 
that the FMDV rRT-PCR assay could detect the presence of a single infected animal in a 
sample from the bulk milk of a herd of up to 10,000 animals. Utilising these data, 
simulation modelling studies by Thurmond and Perez, (2006), and Garner et al., (2016) 
aimed to estimate when FMD virus could be detected by rRT-PCR in bulk milk during 
an outbreak, and found that this approach could be useful for the detection of pre-
clinical infection, before the appearance of clinical signs in the herd. As a result, they 
suggested that pooled milk could be a useful tool in enhancing a surveillance system 
for FMD, and that this approach should be considered for regional FMD surveillance.  
However, to estimate prevalence of FMDV infection from bulk tank milk, pooling and 
sampling schemes should be carefully assessed, taking into account the analytical 
sensitivity of the chosen detection assay (Christensen and Gardner, 2000; Reichel et al., 
2016). Ahmed (2015) investigated the effect of pool size and found that larger pool 
sizes maximised pooling efficiency at low disease prevalence, whereas smaller pool 
sizes maximised efficiency at a higher prevalence. It is likely then that a bulk tank milk 
testing system could indeed detect small quantities of FMD virus, and identify the 
presence of even one newly infected animal, which may provide a useful surveillance 
tool for rapidly detecting infected herds. Additionally, farm/farmer selling trends 
which are difficult to quantify and therefore may not be incorporated into models, 
should be taken into consideration as these may have a large impact on the utility of 
pooled milk for FMD surveillance. 
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1.7 Scientific aims 
Milk has the potential to be a suitable alternative sample type to those currently used 
for FMD diagnosis. The benefits of this sample type are clear:  
 Simple to collect – it may already be collected as part of routine surveillance of 
other pathogens 
 Non-invasive compared to other sample types such as vesicular epithelium or 
blood 
 FMD live virus, FMDV RNA and FMDV antibody can be detected  
 FMDV RNA may be detected by rRT-PCR for a longer window than other sample 
types i.e. before, during and after the appearance of clinical signs 
 Potential for the identification of sub-clinical infected animals and herds 
 rRT-PCR assay can detect FMDV in heavily diluted milk demonstrating the 
potential for bulk tank milk testing. 
Despite the clear advantages of milk as an alternative sample type, and although FMDV 
detection in milk samples has been well described during in-vivo experiments 
(Burrows et al., 1971; Blackwell and McKercher, 1982; Reid et al., 2006), only a small 
number of studies have described the detection of FMDV RNA in milk from naturally-
infected animals. These include FMDV detection in milk from cattle and buffaloes in 
Pakistan (Saeed et al., 2011; Ahmed et al., 2017) and in cattle in India (Ranjan et al., 
2016). Furthermore, the limited milk samples used in these studies were collected 
either as an additional sample type to validate molecular assays, or to investigate the 
possible role of milk in FMDV transmission. 
Given the benefits described above, further investigation into the potential of milk as 
an alternative sample type for routine FMDV detection and surveillance is warranted, 
especially as this approach is already successfully utilised for a number of other 
pathogens. Sampling of milk both at an animal and herd level could offer a more 
representative sampling framework compared to established surveillance methods, 
reducing sample selection bias, increasing surveillance sensitivity, and may facilitate a 
more thorough understanding of herd/district level epidemiology.  
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It is hypothesised that sampling of milk at the herd level, for example by taking aliquots 
of milk from bulk tanks, may be useful for targeted/risk-based surveillance to: 
 improve knowledge on the epidemiology of FMD in endemic areas, including 
determination of circulating serotypes, and identification of sub-clinical infections 
 rapidly identify infected herds in response to an outbreak in a disease-free country 
 screen infected premises after an outbreak to ensure disease freedom 
Therefore the aim of this thesis was to expand on previous studies to determine 
whether milk may be utilised for FMDV detection and surveillance. Consequently, this 
thesis is organised to answer five specific research objectives (see figure 1.9): 
(i)  Optimise a high-throughput nucleic acid extraction and one-step real-time RT-
PCR method to detect foot-and-mouth disease virus (FMDV) in milk samples.  
(ii) Determine the utility of milk samples compared with sample types currently 
used, collected from individual experimentally and naturally infected animals. 
(iii) Evaluate the stability of FMDV in milk samples during transportation. 
(iv)  Determine the effects of pooling milk on the sensitivity and specificity on the 
FMDV detection system. 
(v) Assess the potential of FMDV testing of pooled milk in different farming systems 
as an alternative surveillance approach, by comparison with established 
surveillance methods. 
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Chapter 2: 
Optimisation and evaluation of a high-throughput screening method for the detection 
of foot-and-mouth disease virus in milk samples 
(i),(ii),(iv) 
 
Chapter 3: 
Opportunities for enhanced surveillance of foot-and-mouth disease in endemic 
settings using milk samples from individual cattle 
(ii) 
 
Chapter 4: 
Moving from individual to pooled milk: considerations for the treatment of samples 
collected from herds in endemic countries  
(iii),(iv) 
 
Chapter 5: 
Utilising milk from pooling facilities as a novel approach for foot-and-mouth disease 
surveillance 
(v) 
 
Chapter 6: 
Pooled milk for foot-and-mouth disease surveillance on large-scale dairy farms in 
endemic settings 
(v) 
 
Chapter 7: 
Discussion and future research 
Figure 1.9 Overview of thesis. Numerals in parenthesis indicate the research 
objectives focussed on in each chapter.  
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CHAPTER 2  
Optimisation and evaluation of a high-
throughput screening method for the detection 
of foot-and-mouth disease virus in milk samples 
 
Data presented in this chapter has been published in Veterinary Microbiology: 
https://doi.org/10.1016/j.vetmic.2018.07.024 
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2.1 Summary 
This study aimed to assess the performance of an optimised nucleic acid extraction 
protocol utilising robotic equipment in combination with a one-step real-time RT-PCR 
method to detect foot-and-mouth disease virus (FMDV) in milk samples, in order to 
assess the utility of milk as a non-invasive sample type for surveillance. Four milking 
Jersey cows were infected via direct contact with two non-milking Jersey cows that had 
been previously inoculated with FMDV (isolate O/UKG/34/2001). Milk and blood were 
collected throughout the course of infection to compare two high-throughput real-time 
reverse transcription polymerase chain reaction (rRT-PCR) protocols with different 
RT-PCR chemistries. Using both methods, FMDV was detected in milk by rRT-PCR one 
to two days before the presentation of characteristic foot lesions, similar to detection 
by virus isolation. Furthermore, rRT-PCR detection from milk was extended, up to 28 
days post contact (dpc), compared to detection by virus isolation (up to 14 dpc). 
Additionally, the detection of FMDV in milk by rRT-PCR was possible for 18 days longer 
than detection by the same method in serum samples. FMDV was also detected with 
both rRT-PCR methods in milk samples collected during the UK 2007 outbreak. 
Dilution studies were undertaken using milk from the field and experimentally-
infected animals, where for one sample it was possible to detect FMDV at a dilution of 
10-7. Based on the peak CT values detected in this study, these findings indicated that it 
was possible to identify one acutely-infected milking cow in a typical-sized dairy herd 
(100-1000 individuals) using milk from bulk tanks or milk tankers. These results 
motivated further studies using milk in FMD-endemic countries for FMD surveillance. 
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2.2  Introduction 
Rapid and accurate detection is central to facilitate the control of FMD. Real-time 
reverse transcription polymerase chain reaction (rRT-PCR) assays have been 
developed with high diagnostic and analytical sensitivity (Shaw et al., 2004), and since 
they detect viral RNA (or even degraded genome) instead of intact viral antigens 
and/or live virus, these assays can be used on a number of sample types (Reid et al., 
1998; Reid et al., 2003).  
Milk is a non-invasive sample type that does not require qualified veterinary 
practitioners for collection, unlike traditional sample types such as vesicular lesion 
tissue or fluid, oesophageal-pharyngeal fluid, and blood. Previous experiments have 
shown that the mammary gland is highly susceptible to FMDV replication, and that 
FMDV can be detected in milk before the appearance of clinical signs (Burrows et al., 
1971; Blackwell and McKercher, 1982; Reid et al., 2006). Milk therefore represents a 
potentially valuable sample source for FMDV detection and surveillance during, and in 
recovery from a disease outbreak. 
Previous studies have investigated FMDV detection by rRT-PCR in milk samples from 
experimentally infected Holstein-Friesian cattle (Reid et al., 2006) using two-step 
amplification protocols. This chapter aims to build on this previous work, to assess the 
performance of a more recently developed nucleic acid extraction protocol utilising 
rapid, higher throughput robotic equipment and newer one-step real-time RT-PCR kits 
to detect FMDV in milk. Two protocols were compared employing the MagMAX™ 
Pathogen RNA/DNA Kit (Applied Biosystems®) for RNA extraction, in combination 
with either the TaqMan® Fast Virus 1-Step kit (Applied Biosystems®) (Method A), or 
the Superscript III Platinum® One-Step qRT-PCR Kit (InvitrogenTM) (Method B). 
Although these methods are currently utilised in FMD diagnostic laboratories for the 
traditional samples mentioned above, they have not been fully validated for use on milk 
samples. Unlike the other sample types, milk contains high concentrations of calcium, 
proteinases and fat globules that have been shown to inhibit amplification efficiency 
(Rossen et al., 1992; Bickley et al., 1996). Although this was not observed in the 
previous study by Reid et al. (2006), they used milk from Holstein-Friesian cattle, 
which has a lower fat concentration than milk from Jersey cattle, for example 
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(Palladino et al., 2010). Therefore, in order to fully challenge the RNA extraction 
conditions of the methods tested in this chapter, Jersey cows, which produce milk with 
a high fat content, were used. Additionally, the effect of FMD on milk yield in Jersey 
cows was also assessed. 
It is anticipated that the results from this study can be used to support the development 
of an FMD surveillance plan utilising pooled milk in endemic settings, or from bulk 
tanks as part of preparedness for combating a possible FMD outbreak in disease-free 
settings.  
 
2.3  Materials and Methods 
2.3.1 Experimental samples 
In-vivo studies were carried out in the high containment unit at The Pirbright Institute, 
UK and all procedures were approved by the Home Office (Project Licence 
number:70/718) and complied with the Animals (Scientific Procedures) Act 1986, EU 
Directive 2010/63/EU. Four naïve Jersey dairy cows (aged between 2 years, 9 months, 
and 8 years, 1 month), were infected via direct contact (day 0) with two non-milking 
Jersey cows that had been inoculated by intra-dermolingual injection with 105 TCID50 
FMDV O/ME-SA/PanAsia, O/UKG/34/2001 (0.25 mL per inoculation site [n=2]) two 
days previously, and that were displaying clinical signs. Animals were observed for 
clinical signs, and sampled every day for blood and milk on days -5 to 7, and 10, 12, 14, 
19, 21, 26 and 28 days post contact (dpc). Blood was collected in plain vacutainers and 
serum used in the testing. Milk was collected by machine twice a day until 7 dpc, and 
once a day thereafter on the days stated, and daily milk yields recorded by weight. 
Skimmed milk was separated from the cream and cell fraction by centrifuging an 
aliquot of each whole milk sample at 3000xg (Hettich Rotanta 460R) for ten minutes. 
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2.3.2 Field samples 
Twelve milk samples collected during the FMDV outbreak in the UK in 2007 (caused 
by a derivative of FMDV O1 BFS 1860) were used to compare diagnostic screening 
methods. These samples were from individual cows displaying clinical signs held at 
one of the infected premises (IP) 2 (Cottam et al., 2008; Ryan et al., 2008). 
 
2.3.3 Cell culture isolates 
FMDV cell culture isolates (isolated once in primary bovine thyroid [BTY] cells) were 
obtained from the FMDV repository held at the World Organisation for Animal Health 
(OIE) Reference Laboratory and United Nations Food and Agriculture Organization 
(FAO) World Reference Laboratory for foot-and-mouth disease (WRLFMD), Pirbright, 
UK. Positive controls for rRT-PCR assays were prepared by spiking unpasteurised 
whole Jersey milk with a 10-2 dilution of cell culture isolate O/SAU/1/2016. Analytical 
sensitivity of the diagnostic screening methods was assessed using a ten-fold dilution 
series (10-1 to 10-8) of cell culture isolate A/KEN/6/2012 in whole Jersey milk. 
 
2.3.4 Virus Isolation 
Virus isolation was carried out on primary bovine thyroid (BTY) cell cultures 
(Snowdon, 1966), on all experimental samples on the day of collection. Titrations were 
later performed on milk samples using BTY cell cultures after storage at -80oC, and the 
viral titre was calculated using the Spearman-Kärber method, as described by the FAO 
(Karber, 1931; OIE, 2018) and expressed in units of TCID50/mL. 
 
2.3.5 Diagnostic screening methods 
Diagnostic screening methods for the detection of FMDV genome in milk samples are 
defined as Method A and Method B for the purpose of this study, and are described in 
Table 2.1.  
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Table 2.1 Comparison of the two high-throughput foot-and-mouth disease virus 
detection methods. 
 A B 
Extraction kit 
MagMAX™ Pathogen RNA/DNA 
Kit (Applied Biosystems®) 
MagMAX™ Pathogen RNA/DNA Kit 
(Applied Biosystems®) 
Internal Control 
VetMAX™ Xeno™ Internal Positive 
Control RNA (Applied 
Biosystems®) 
VetMAX™ Xeno™ Internal Positive 
Control RNA (Applied Biosystems®) 
Sample input  200 µL  200 µL 
rRT-PCR kit 
‘TaqMan® Fast’ Virus 1-Step 
Master Mix (Applied 
Biosystems®) 
‘Superscript’ III Platinum® One-Step 
qRT-PCR Kit (InvitrogenTM) 
Internal control assay 
VetMAX™ Xeno™ Internal Positive 
Control LIZ™ Assay (Applied 
Biosystems®) 
VetMAX™ Xeno™ Internal Positive 
Control LIZ™ Assay (Applied 
Biosystems®) 
Primers and Probes 
Targeting 3D polymerase 
(Callahan et al., 2002)  
Targeting 3D polymerase  
(Callahan et al., 2002) 
RNA template input 2.5 µL 5 µL 
 
2.3.6 RNA extraction 
RNA extractions for both methods were carried out using the MagMAX™ Pathogen 
RNA/DNA Kit (Applied Biosystems®) on a MagMAX™ Express 96 Extraction Robot 
(Applied Biosystems®) with a sample input of 200 µL, and elution volume of 90 µL. 
One µL per reaction of VetMAX™ Xeno™ Internal Positive Control RNA (10,000 
copies/µL) (Applied Biosystems®) was also added to the lysis buffer prior to 
extraction. 
 
2.3.7 rRT-PCR 
Two commercially available rRT-PCR kits were evaluated as listed in Table 2.1. In 
Method A, the TaqMan® Fast Virus 1-Step Master Mix (Applied Biosystems®) was 
used with the following thermal cycling conditions: 50oC for 5 min, 95oC for 20 sec, 
then 45 cycles of 95oC for 3 sec and 60oC for 30 sec. For this method 2.5 µL of RNA 
template were added to the rRT-PCR reaction mix containing 6.25 µL of 1-step 
mastermix (4x, supplied with the kit), 0.25 µL each of forward and reverse primer (20 
µM), 0.25 µL probe (10 µM), and 14.5 µL of nuclease free water. In Method B, the 
Superscript III Platinum® One-Step qRT-PCR Kit (InvitrogenTM) was used with the 
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reagents, parameters and thermal cycling conditions previously reported (Shaw et al., 
2007), with an RNA template volume of 5 µL. Primers and probes targeting the 
conserved 3D region of the FMDV genome (Callahan et al., 2002) were used for both 
methods. This assay has been previously shown to reliably detect viral RNA 
representing all seven FMDV serotypes (King et al., 2006) and is a widely adopted 
diagnostic assay recommended by the OIE for use in FMD Reference Laboratories. One 
µL VetMAX™ Xeno™ Internal Positive Control LIZ™ Assay (Applied Biosystems®) per 
reaction was also included in the reaction mix. The Applied Biosystems® 7500 Real-
time PCR System was used on the ‘fast’ setting for Method A and the ‘standard’ setting 
for Method B. Evaluation of the RNA extraction and rRT-PCR methods were performed 
using experimental and field milk samples. Samples were considered positive for all CT 
values observed until the end of the assay: ≤45 for Method A and ≤50 for Method B. 
 
2.3.8 Statistics 
In order to measure the agreement between the two methods using experimental 
whole milk samples, Cohen’s Kappa statistic (κ) and the proportion of observed 
agreement (Aobs) were performed in R version 3.5.3 (R Core Team, 2019) using the 
package ‘fmsb’ (Nakazawa, 2017), and interpreted as described by Landis and Koch 
(Landis and Koch, 1977), and linear regression was used to compare CT values. A paired 
t-test was used to compare CT values from both methods using field samples. Unpaired 
t-tests were used to compare average milk yields before (-6-0 dpc) and during infection 
(1-6 dpc), both performed in Prism version 7 (GraphPad Software, Inc.). 
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2.4  Results 
2.4.1 Comparison of detection methods with field samples 
Twelve milk samples positive for FMDV collected from individual cows during the UK 
2007 FMD outbreak were tested using both methods (A and B). Comparisons between 
the methods demonstrated lower CT values in all samples when using Method B (Table 
2.2) (p = <0.001), with a mean CT difference of 5.00 between the two methods. Positive 
rRT-PCR results were observed in 12/12 (100%) for both methods. 
 
Table 2.2 CT values of individual milk samples collected from individual cows obtained 
from infected premises (IP) 2, from the 2007 UK outbreak of foot-and-mouth disease 
(FMD) for both methods. (Verification of clinical signs from these animals and formal 
confirmation of the FMD outbreak was completed by the Pirbright Institute (Ryan et 
al., 2008)). 
Sample ID Age of oldest lesion Method A Method B 
c27 Not dated 21.19 (±0.45) 16.50 (±0.28) 
105 2 days 21.59 (±0.22) 17.18 (±0.20) 
036 5 days 26.18 (±0.17) 22.03 (±0.28) 
027 6 days 27.07 (±0.15) 21.46 (±0.15) 
369 6 days 24.98 (±0.17) 19.67 (±0.15) 
341 6 days 27.15 (±0.14) 21.81 (±0.12) 
069 4 days 25.26 (±0.11) 20.15 (±0.20) 
030 5 days 27.79 (±0.25) 21.78 (±0.43) 
161 2 days 29.58 (±0.08) 24.38 (±0.19) 
092 5 days 32.27 (±0.19) 27.94 (±0.30) 
241 3 days 22.04 (±0.39) 16.81 (±0.29) 
093 5 days 24.64 (±0.27) 20.09 (±0.74) 
Data shown are mean CT values of rRT-PCR performed for Methods A and B, with standard deviations in 
parentheses. CT values are the mean of three replicates from independent extractions. 
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2.4.2 Comparison of detection methods by limit of detection 
The limit of detection of both methods was compared using the ten-fold dilution series 
of FMD A/KEN/6/2012 spiked into whole Jersey milk (10-1 to 10-8) (Figure 2.1). 
Without normalising for different sample input volumes, Method B demonstrated a one 
log10 increase in the limit of detection when compared with Method A when all wells 
were positive, and a range in the difference in average CT value of between 5.33 and 
6.30, for Methods A and B. For each dilution, the maximum standard deviation between 
three technical replicates was 3.55 (Method B, 10-7). 
 
Figure 2.1 Comparison of the limit of detection for Methods A (used the TaqMan® Fast 
Virus 1-Step Master Mix (Applied Biosystems®)) and B (used the Superscript III 
Platinum® One-Step qRT-PCR Kit (InvitrogenTM)). CT values are the average of three 
replicates, and bars represent standard deviation.  ■ : Method A,  : Method B. Open 
symbols indicate where no amplification was observed in at least one of the three 
replicates. 
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2.4.3 Experimental samples 
The dairy cows (identified as animal numbers 108, 825, 867 and 951) exhibited clinical 
signs within 3-4 days after exposure to the inoculated cattle. Cows 108 and 825 
developed mastitis and were euthanised at 3 dpc and 14 dpc, respectively. Both 867 
and 951 survived to 28 dpc when the experiment was terminated.  
Experimental samples were tested with both methods, after a freeze thaw and storage 
at -80oC for five years. Based on the testing of 67 whole milk samples, there was 
agreement (in at least one replicate) between positive and negative results in 61/67 
(91.0%) samples across both methods (Figure 2.2).  
re  
Figure 2.2 Comparison of both methods tested with whole milk samples from four 
experimentally infected cows.  Each square represents the average CT value of the 
whole milk sample at each day post contact (DPC). White squares represent a ‘No CT’ 
value – no detection. Black squares represent any CT value ≤45 (Method A) or ≤50 
(Method B) in all replicate wells – FMDV positive. Grey squares represent instances 
where a ‘No CT’ value was observed in one or two wells, but a positive result was 
observed in the other replicates. N/A represents where there was not sufficient sample 
available for testing.  
 
When comparing the two methods, almost perfect agreement was observed between 
the number of positive/negative samples identified (κ = 0.811; p = <0.001; Aobs = 0.910) 
(Table 2.3). Additionally, for the milk samples that were positive using both methods, 
the average CTs generated were lower when using Method B (R2 = 0.704, p = 0.001) 
(see Appendix I, Figure 8.1). CT values of the internal controls in all whole milk samples 
(n=67) were considered positive by both methods (Method A: mean: 35.37±0.83, 
Method B: mean: 38.23±2.42). Results from Method B were therefore used to 
determine the window of virus detection in dairy cows. 
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In most instances at the onset of infection, FMDV detection in milk by rRT-PCR 
coincided with detection by virus isolation, 1-2 days before the appearance of 
characteristic foot lesions, and concurrent with the development of nasal discharge in 
animals 867 and 951. FMDV detection by rRT-PCR in whole milk was observed for 
animals 108 and 825 until they were euthanised at 3 dpc and 14 dpc respectively 
(Figure 2.3). In addition to early detection, FMDV detection in both milk fractions 
(whole and skimmed) by rRT-PCR was prolonged, and was extended in whole milk 
(detected up to dpc 28 for animals 867 and 951), in comparison to virus isolation 
(detected up to dpc 7 for all three remaining cows). At the onset of infection, rRT-PCR 
detection of FMDV in serum coincided with FMDV detection in milk, 1 day prior 
(animals 867, 825 and 951) and the same day (108). In contrast, rRT-PCR FMDV 
detection in serum ended at 7dpc and 10 dpc, compared to at 28dpc in milk for animals 
951 and 867, respectively. 
 
Table 2.3 Comparison of Method A and Method B using experimental whole milk 
samples.  
  
Method B 
  
Positive* Negative Total 
Method A 
Positive* 38 2 40 
Negative 4 23 27 
Total 42 25 67   
κ = 0.811; p = <0.001; Aobs = 0.910   
*Positive results are those with at least one well giving a CT of ≤45 (Method A)/≤50 (Method B). 
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Figure 2.3 FMDV detection in samples collected at regular intervals from all cows. 
Virus titrations in BTY cells (A) and rRT-PCR using Method B (B) for skimmed and 
whole milk fractions and serum (B only). Average CT is derived from the mean of 2 
replicates. The development of lesions in at least one foot indicates the onset of clinical 
signs. : Onset of clinical signs, : whole milk,   : skimmed milk,  : serum.  
 
2.4.4 Impact of FMDV infection on milk yields 
Milk yields were recorded by weight on -5 to 6 dpc. The average daily milk yield before 
cows were infected by direct contact (-6 to 0 dpc) was 22.14±0.51kg, 20.29±0.45kg, 
18.17±0.86kg and 18.36±0.43kg for animals 108, 825, 867 and 951, respectively, these 
values were used as a baseline to calculate the change in milk yield after infection. The 
average daily milk yield after infection between days 1-6 dpc, was 23.00±0.58kg, 
22.44±0.82kg, 16.58±1.96kg and 15.08±1.59kg, with an average change of +3.88%, 
+12.15%, -8.73% and -17.85% for animals 108, 825, 867 and 951, respectively. No 
significant difference was observed between average yields before and after infection 
[p = 0.356 (108), p = 0.450 (867), p = 0.056 (951)], apart from for animal 825 [p = 0.032 
(825)], which demonstrated an increase in average milk yield after infection. The 
maximum reduction in milk yield recorded on any one day was 50.47% for cow 867, 
on 6 dpc. The mean difference in milk yield between -6 to 0 dpc and 1 to 6 dpc was 
greatest for cow 951 (-17.85%, range:-48.26% to +3.49%). 
 
2.4.5 Limit of detection 
To estimate the dilution at which FMDV may still be detected from a pooled milk 
sample, the limit of detection was determined using the more sensitive Method B, using 
one milk sample from the animal experiment (867, 4.5 dpc, mean CT value: 19.65) and 
one milk sample from the 2007 outbreak (animal number c27, mean CT value: 16.50 
[Table 2.2]). Ten-fold serial dilutions were conducted in clean Jersey milk (Figure 2.4). 
Limits of detection were 10-7 for sample c27 and 10-5 for sample 867 (4.5 dpc) with 
mean CT values of 40.61 and 38.70, respectively. 
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Figure 2.4 Detection of FMDV by rRT-PCR using Method B on ten-fold dilutions in 
Jersey whole milk of two milk samples: animal 867 (4.5 days post contact infection) 
and 200017, a field sample from the UK 2007 outbreak (Table 2.2). CT values are the 
average of three replicates with standard deviation error bars. : 867 (4.5 dpc), : 
200017. Open symbols indicate where no amplification was observed in at least one of 
the three replicates. 
 
2.5  Discussion 
Two RNA extraction and rRT-PCR combinations (Methods A and B) were evaluated 
utilising experimental milk and serum samples, and opportunistic milk samples 
collected in the field during the UK 2007 outbreak (Ryan et al., 2008). These two 
methods employ different RT-PCR kits (with different thermocycling conditions) and 
have been optimised for different RNA template volumes (2.5 µL and 5 µL for Methods 
A and B, respectively). These specific methods were selected for comparison since they 
were already used in two of the laboratories that participated in this study. Comparison 
of these RT-PCR kits using milk samples collected from the UK 2007 outbreak 
generated lower CT values for all samples with Method B (the MagMax™ Pathogen 
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RNA/DNA kit in combination with the SuperScript™ III Platinum™ One-Step qRT-PCR 
Kit). It is possible that increasing the RNA template volume for Method A to 5 µL would 
reduce the number of PCR cycles required to generate signal in the assay. However, the 
CT differences (i.e., >4) observed in these comparative experiments were greater than 
would be expected from a two-fold dilution in the volume starting template. Samples 
from experimentally infected cows were tested by both methods, where more samples 
were identified as positive using Method B, than Method A, and a higher limit of 
detection was also observed for Method B using the spiked milk dilution series. Based 
on these results, Method B was used to determine the window of virus detection during 
FMDV infection and was carried forward as the method of choice for FMDV genome 
detection in milk samples, for chapters 3 – 6 of this thesis. It was demonstrated that 
FMDV could be detected in whole milk by rRT-PCR coincident with, and up to 24 days 
after the onset of early clinical signs of FMD (28 dpc). This was longer than when tested 
by virus isolation, and for a longer period than with traditional surveillance samples 
such as serum, from which FMDV was detected only up to six days after the onset of 
clinical signs. Reid et al. (2006) were only able to detect FMDV RNA in milk up to 23 
days post infection, but identified the presence of low copy numbers of FMDV RNA in 
the mammary lateral lymph node on post-mortem analysis at day 28 post infection. 
However, for this study, Jersey cattle were used, instead of the Holstein-Friesian cattle 
that were utilised by Reid et al. (2006), and therefore it is unknown if this extended 
detection is due to the higher fat content of the milk from this breed, as FMDV has been 
shown to be particularly concentrated in the cream component (Reid et al., 2006). 
Additionally, it is likely that it could be due to the higher limit of detection of the newer 
detection methods, although as there was no absolute quantification of the virus stocks 
in my study, analytical sensitivity cannot be directly compared. Ranjan et al. (2016) 
demonstrated the presence of FMDV in milk samples up to 37 days post clinical 
manifestation by multiplex (m) PCR and reverse transcription loop-mediated 
isothermal amplification (RT-LAMP). In this study, animals 867 and 951 were 
terminated at 28 days post contact, and therefore it is unknown how much longer 
FMDV RNA might have been detected in these animals. Previous studies have reported 
FMDV detection up to 51 days post inoculation (Burrows et al., 1971), however this 
involved the inoculation of FMDV directly into the mammary gland which is not a 
method of transmission in field situations.  
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During the study, animal 108 displayed lesions on the teats, and animals 108 and 825 
developed clinical mastitis (108 and 825). Vesicular lesions on the teats are common 
in lactating cows with FMD, with infection of the ruptured lesions predisposing animals 
to the development of secondary mastitis (Kitching, 2002), and field studies have 
supported this association between FMD and clinical mastitis (Sharma, 2010; Lyons et 
al., 2015). FMDV infection has been shown to cause a reduction in milk yield (Knight-
Jones and Rushton, 2013), where secondary mastitis may play a part. However, in our 
study, when average milk yields were compared before (-6 to 0 dpc) and after (1 – 6 
dpc) infection, no significant decrease was observed, even in cow 108 with secondary 
mastitis, although the maximum decrease observed on any one day was 50.47% for 
animal 867. This is comparable to previous experimental studies that demonstrated a 
maximum reduction of 62.1% on 10 dpc (Reid et al., 2006), and during an outbreak of 
FMDV in Iran, a total reduction of 8.0% and 4.7% in mean milk production for first and 
second lactation cows, respectively (Ansari-Lari et al., 2017).  These published studies 
and our study support data reported by Lyons et al. (2015) who observed that although 
there was a decrease in milk production at the herd level, clinical FMD was shown to 
be a poor predictor of milk yield, and that no statistical evidence was found to indicate 
a significant decrease in milk yield between FMD clinical animals and non-clinical cases 
when lactation curves were modelled. 
This study has demonstrated that milk from individual animals could be utilised as a 
less invasive sample type with simple collection procedures. Pooling these milk 
samples, or collecting milk from bulk storage tanks would allow for a testing method 
where there would be no requirement to test all samples individually, thus reducing 
the cost of testing. Bulk tank milk is used as a sample for a number of other diseases, 
including bovine viral diarrhoea virus (BVDV) (Renshaw et al., 2000a; Hill et al., 2010) 
and Coxiella burnetii (Bauer et al., 2015). In our study, the limit of detection was 
determined using the better performing Method B, to establish how far a positive milk 
sample could be diluted in whole Jersey milk and still be detected, simulating the 
detection of one infected animal from a herd. As expected, the ability to detect FMDV 
at high dilutions was related to the viral load of FMDV in the individual positive milk, 
and for one sample, FMDV was detected at a dilution of up to 10-7. Based on the peak 
CT values detected in this study, these observations of the limit of detection indicate 
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that it should be possible to identify one acutely-infected milking cow in a typical sized 
dairy herd (100-1000 individual) using bulk milk sampling. However, further research 
on the impact of pooling on detection sensitivity is recommended, and is performed in 
chapters 5 and 6. If virus can be detected in bulk tank milk, this may provide a useful 
surveillance tool for rapidly detecting infected herds, whilst involving minimal stress 
to the animal for sample collection. Additionally, the likelihood of detecting FMDV 
infected animals may be increased due to the extended period of FMDV detection in 
milk compared to serum. 
Before investigating pooling, research is required to demonstrate that FMDV can be 
detected in milk samples collected from individual cattle in endemic settings, and 
therefore this is investigated in Chapter 3. This may be particularly important where 
multiple serotypes are circulating, and vaccination may be practiced, as it unknown 
what effects these factors may have on the detection of FMDV in milk from animals in 
these regions. Data obtained in these experiments may then inform and facilitate the 
design and implementation of surveillance testing plans for FMD. This could be in 
readiness for a potential outbreak, for example by testing bulk milk samples to rapidly 
identify infected herds in response to an outbreak in a disease-free country. 
Additionally, alternative surveillance approaches using pooled milk from large-scale 
dairy farms or pooling facilities may be useful for FMD epidemiological studies in 
endemic regions, to identify disease presence and the circulating serotypes. 
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CHAPTER 3 
Opportunities for enhanced surveillance of 
foot-and-mouth disease in endemic settings 
using milk samples from individual cattle 
 
Data presented in this chapter has been published in Transboundary and Emerging 
Diseases: https://doi.org/10.1111/tbed.13146 
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3.1 Summary 
The aim of this study was to examine the application of milk from individual cattle as 
an alternative sample type for FMDV detection and typing, and to evaluate milk as a 
novel approach for targeted surveillance of FMD in East Africa. FMDV RNA was 
detected in 73/190 (38%) individual milk samples collected from naturally infected 
cattle in northern Tanzania. Further, typing information by lineage-specific rRT-PCR 
assays was obtained for 58% of positive samples, and correlated with the virus types 
identified from traditional sample types collected during outbreak investigations in the 
study area. The VP1-coding sequence data obtained from milk samples matched the 
sequence data generated from paired epithelial samples collected from the same 
animal. This study demonstrates that milk represents a potentially valuable sample 
type for FMDV surveillance and might be used to overcome some of the existing biases 
of traditional surveillance methods. However, it is recommended that care is taken 
during sample collection and testing to minimise the likelihood of cross-contamination. 
Such approaches could strengthen FMDV surveillance capabilities in East Africa, both 
at the individual animal and herd level. 
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3.2  Introduction 
Accurate and rapid identification of the FMDV serotype responsible for a particular 
outbreak is of the utmost importance for informing appropriate control strategies. 
Current methods of detection and characterisation of FMDV include virological [e.g. 
virus isolation (Snowdon, 1966)], molecular [e.g. reverse transcription polymerase 
chain reaction (rRT-PCR)(Reid et al., 1998)] and serological tests [e.g. virus 
neutralisation test (OIE, 2018)]. Various pan-serotypic rRT-PCR assays (which detect 
all serotypes but which do not differentiate between them) have been described 
(Callahan et al., 2002; Reid et al., 2002; King et al., 2006; Shaw et al., 2007). For serotype 
identification, the antigen detection ELISA (enzyme-linked immunosorbent assay) 
(Ferris and Dawson, 1988) is traditionally employed. However, the analytical 
sensitivity is often limited, and the test is only suitable for epithelium samples and cell 
culture material.  
Various authors have demonstrated the utility of typing of FMDV by conventional RT-
PCR assays (Callens and De Clercq, 1997; Giridharan et al., 2005; Bao et al., 2008), and 
more recently, rRT-PCR assays for the detection of strains specific to a particular 
region, for example the Middle East (Reid et al., 2014; Knowles et al., 2015), West 
Eurasia (Jamal and Belsham, 2015; Saduakassova et al., 2017), and East Africa 
(Bachanek-Bankowska et al., 2016). To enable the characterisation of circulating FMDV 
strains, nucleotide sequence analysis is also commonly used (Baxt et al., 1984; Wittwer 
and City, 1989; Jamal and Belsham, 2013). VP1 sequencing (Sanger et al., 1977; 
Knowles et al., 2016) has value in deducing evolutionary dynamics, genetic and 
epidemiological relationships, and in the tracing of outbreaks and monitoring of the 
transboundary movements of the disease (Marquardt and Adam, 1990; Knowles and 
Samuel, 2003; Logan et al., 2014).  
Currently, the most common sample type submitted to laboratories for FMD diagnosis 
is epithelial tissue or sometimes the fluid found within a vesicular lesion. These are 
labour intensive to collect (King et al., 2006) and consequently, reporting of disease is 
inherently biased towards clinical animals, and samples are often not collected due to 
the effort involved. Therefore viruses circulating sub-clinically may not be represented 
and the true prevalence of the disease is under-recognised (Knight-Jones et al., 2016).  
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Milk is a simple-to-collect, non-invasive sample type that has already been utilised for 
the surveillance of a number of diseases (Sekiya et al., 2013; Bauer et al., 2015; Nielsen 
et al., 2015). Although FMDV detection in milk samples has been well described during 
in-vivo experiments as shown in Chapter 2 and by others (Burrows et al., 1971; 
Blackwell and McKercher, 1982; Reid et al., 2006), only a small number of studies have 
demonstrated that FMDV RNA can be detected in milk from naturally-infected animals. 
These include FMDV detection in milk during the 2007 FMD outbreak in the United 
Kingdom (Armson et al., 2018, Chapter 2), in cattle and buffaloes in Pakistan (Saeed et 
al., 2011; Ahmed et al., 2017) and in cattle in India (Ranjan et al., 2016). The limited 
milk samples used in these studies were collected either as an additional sample type 
to validate molecular assays, or to investigate the possible role of milk in FMDV 
transmission. Nonetheless these studies provide useful evidence that FMDV RNA can 
be detected in milk from naturally infected animals and typed by rRT-PCR. 
Consequently, further investigation into the potential of milk as an alternative sample 
type for routine FMDV detection and surveillance is warranted, particularly in areas 
where surveillance infrastructure is limited.  
For example, Tanzania has the third largest cattle population in Africa, and a report 
prepared in 2012 estimated milk production at 1.6 billion litres per annum (Kurwijila 
et al., 2012). However, FMD is of a high concern in Tanzania, with adverse impacts on 
livestock production, trade, and farmer livelihoods (Kivaria, 2003; Casey-Bryars et al., 
2018). Although the recent introduction of the Progressive Control Pathway for FMD 
control (PCP-FMD) in eastern Africa has driven improved knowledge of the 
distribution of FMD, the epidemiology is still inadequately understood. Additionally, 
control of the disease remains challenging for many reasons, including insufficient 
surveillance and diagnostic capacity, a lack of comprehensive animal movement 
records, and inconsistent, costly vaccination programmes. The presence of at least 4 
serotypes (O, A, SAT 1 and SAT 2) with multiple topotypes further complicates the 
control of the disease (Food and Agriculture Organization (FAO), 2011; Kasanga et al., 
2012; Namatovu et al., 2013; Casey-Bryars et al., 2018; Kerfua et al., 2018). 
Consequently, there is a requirement for improved surveillance of FMD, utilising 
simple, cost-effective tools.  
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Therefore, the aim of this chapter was to examine the use of milk from individual cattle 
for FMD surveillance in Tanzania where this approach had not been investigated 
previously. It is anticipated that results from this chapter may inform future studies 
focussing on the use of pooled milk samples for the simple, cost-effective herd-level 
surveillance of FMD.   
 
3.3  Materials and Methods 
3.3.1 Viruses and field samples 
Milk samples (n=190) (see Appendix II, Table 8.1) were collected by hand from clinical 
and healthy cows during FMD outbreak investigations in northern Tanzania (Serengeti 
and Bunda Districts) between 2012 and 2015 (Casey-Bryars et al., 2018). For four of 
the FMD clinically affected cows (subsequently referred to as animals A – D) that 
supplied a milk sample, vesicular lesion material (epithelium or fluid) was also 
collected on the same day.  This lesion material was submitted to the WRLFMD for 
confirmatory diagnostics, sequencing and phylogenetic analyses (WRLFMD, 2015). 
Cell culture isolates (isolated once in primary bovine thyroid [BTY] cells) 
TAN/39/2012 (serotype O), TAN/6/2013 (A), TAN/33/2014 (SAT 1) and 
TAN/19/2012 (SAT 2) from the EA region spiked in negative milk from a UK farm were 
used as positive controls for molecular assays. All samples had been stored at -80oC 
(milk, epithelium and vesicular fluid) or -20oC (isolates) before use.  
 
3.3.2 RNA extraction and rRT-PCR 
As samples in this chapter were tested before the molecular method optimisation 
occurred (see Chapter 2), the MagMAX™-96 Viral RNA Isolation Kit (Applied 
Biosystems®) was utilised, which is currently used for nucleic acid extraction from 
clinical samples in the WRLFMD. This kit uses the same chemistry as that described in 
method B, only the sample input volume is smaller (50 µL compared to 200 µL), 
resulting in an increase of approximately 1-2 CTs. 
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The pan-serotypic rRT-PCR assay described in Method B (Chapter 2) was carried out 
on an Applied Biosystems® 7500 Real-time PCR System, using the Superscript III 
Platinum® One-Step qRT-PCR Kit (InvitrogenTM), with primers and probes targeting 
the conserved 3D region of the FMDV genome (Callahan et al., 2002; OIE, 2017a), and 
thermal cycling conditions as previously reported (Shaw et al., 2007). Positive samples 
were then tested using the O, A, SAT 1 and SAT 2 East Africa (EA) typing rRT-PCR 
assays, as previously described (Bachanek-Bankowska et al., 2016). For all rRT-PCR 
assays, positive samples were defined as those with a CT value of ≤ 50. 
 
3.3.3 VP1 nucleotide sequencing 
Paired epithelial/fluid samples had been previously typed as SAT 1 (WRLFMD, 2015), 
therefore SAT 1 assay conditions were used. For amplification of the VP1 region of 
FMDV, a one-step RT-PCR described previously (Sanger et al., 1977; Knowles et al., 
2016) was performed with the primers shown in table 3.1.  Amplification products 
were visualised by electrophoresis on a 1.5% agarose-Tris-borate-EDTA gel containing 
0.5ug/ml Gel Red, and compared with DNA size markers (GeneRuler 100 bp DNA 
Ladder Plus, Fermentas Inc, USA). Post-PCR purification was carried out using the 
Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare Life Sciences, UK) 
according to the manufacturer’s instructions, and the products eluted in 20 μL of 
elution buffer. 
DNA sequencing of PCR products was carried out using the BigDye® Terminator v3.1 
Cycle Sequencing Kit (Life Technologies), reactions cleaned up by ethanol/EDTA 
precipitation, and loaded onto the ABI 3730 DNA Analyser. Primers used are listed in 
table 3.1. VP1 sequences were assembled using SeqMan Pro (Lasergene package, 
DNAstar Inc., Madison, WI, USA), and further sequence analysis performed using 
BioEdit v7.2.5 (Hall, 1999). 
Phylogenetic analyses of the FMDV VP1 coding sequences of FMD virus isolates from 
milk and clinical samples were performed in MEGA7 (v0.26)(Kumar et al., 2016). The 
evolutionary history was inferred using the Neighbor-Joining method (Saitou and Nei, 
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1987). The evolutionary distances were computed using the Kimura 2-parameter 
method (Kimura, 1980) in the units of the number of base substitutions per site.  
 
Table 3.1. One step RT-PCR (A) and DNA sequencing primers (B) for SAT 1. Sequences 
are described previously (Knowles et al., 2016) 
(A) One step RT-PCR  (B) DNA Sequencing 
Forward primers Reverse primers Sequencing primers 
SAT1-1C559F SAT-2B-208R NK72 
SAT1U-OS SAT-2B-208R SAT1U-OS 
  SAT 1-1D200F 
  SAT 1-1D394R 
 
3.4  Results  
3.4.1 Detection of FMDV serotypes within milk samples 
An initial screen of all the milk samples was performed. FMDV RNA was detected in 
73/190 (38%) milk samples (Figure 3.1A) and the FMDV type was identified in 42/73 
(58%) FMDV positive milk samples (Figure 3.1B). SAT 1 was the most prevalent 
serotype detected (45%), followed by serotypes O (29%) and A (12%), with no 
evidence of SAT 2 in the milk samples tested (Figure 3.1B and Appendix II, Table 8.1). 
Typing of milk samples that were observed to have a CT value of above 38 using the 
pan-serotypic rRT-PCR assay was not possible. In addition, a positive signal from more 
than one typing assay was identified in eighteen milk samples, including three samples 
each positive for multiple serotypes (O, A and SAT 1). In samples with a positive signal 
for two FMDV types, O and SAT 1 were the most common types detected, while types 
A and SAT 1 were identified in one sample only.  
Published reports of clinical samples from the study region indicate circulation of all 
four serotypes during the study period (WRLFMD, 2015) (Figure 3.1C) and are mainly 
consistent with rRT-PCR typing results of the milk samples, apart from the absence of 
SAT 2 detection in the milk samples. 
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Figure 3.1 (A) CT values from the pan-serotypic rRT-PCR assay (  ) for milk samples 
collected from individual cows in northern Tanzania throughout the study period 
(n=190). (B) CT values for each East African serotyping rRT-PCR assay for samples that 
tested positive (CT ≤ 50) in the pan-serotypic rRT-PCR assay. (C) Collection dates and 
the reported serotypes of clinical samples (vesicular epithelium/fluid) submitted to 
the World Reference Laboratory for Foot-and-mouth disease (WRLFMD). : Serotype 
A.  : Serotype SAT 1. : Serotype O. : Serotype SAT 2. : Sample that could not be 
typed. 
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3.4.2 Detection of FMDV RNA in milk samples, compared to lesion material 
To determine if milk is a suitable alternative sample type to vesicular lesion material 
(epithelium/fluid) for FMDV detection and typing, both sample types collected from 
the same animal were tested and the results compared (Table 3.2). In the pan-serotypic 
assays, the CT values of the lesion material samples were stronger (lower CT values) 
than of the milk samples. Typing results were comparable for all pairs, with the 
exception of Animal A, where no signal was observed in any of the typing assays. In 
three animals (B, C and D), SAT 1 was detected in both milk and lesion material samples 
(Table 3.2). In animals C and D, the CT values of the pan-serotypic and the SAT 1-specific 
assays were comparable, while in animals A and B the differences in the values were 
greater. In animal A, SAT 1 was detected in the vesicular lesion sample only. Two 
different FMDV types (O and SAT 1) were detected in both milk and vesicular fluid in 
animal B, but type O was not detected in the vesicular epithelium sample. 
 
Table 3.2 FMDV detection in milk samples and epithelial samples. 
Animal 
Reference 
WRLFMD 
reference/ 
Milk sample Sample Type 3D O A SAT 1 SAT 2 
A 
TAN/20/2014 Vesicular epithelium 18.30 No CT No CT 24.98 No CT 
7736 Milk 33.31 No CT No CT No CT No CT 
B 
TAN/22/2014 Vesicular epithelium 10.19 No CT No CT 21.06 No CT 
TAN/23/2014 Vesicular fluid 9.94 38.07 No CT 19.76 No CT 
7609 Milk 29.04 33.13 No CT 33.42 No CT 
C 
TAN/28/2014 Vesicular epithelium 16.00 No CT No CT 20.33 No CT 
TAN/29/2014 Vesicular fluid 9.05 No CT No CT 10.3 No CT 
7805 Milk 26.48 No CT No CT 29.17 NP 
D 
TAN/34/2014 Vesicular epithelium 16.51 No CT No CT 16.77 No CT 
7815 Milk 25.08 No CT No CT 25.69 NP 
CT values are the mean of duplicates for each rRT-PCR assay. NP – not performed. 
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3.4.3 VP1 nucleotide sequencing of milk samples, compared to lesion 
material 
To determine if milk is a suitable alternative to the commonly used epithelial tissue 
and vesicular fluid sample types for characterisation of FMDV by VP1 sequencing, two 
sequences derived from the milk samples from northern Tanzania (7805 and 7815) 
were compared with previously reported sequences of paired epithelial/fluid samples 
from the same animal, held in the WRLFMD archive. 
VP1 sequences obtained from milk samples 7805 (animal C; accession number 
MH791039) and 7815 (animal D; accession number MH791040) were found to be 
identical (animal D) or within one nucleotide difference (animal C) to reported 
sequences of paired vesicular samples from the same animals (animal C: accession 
number MF592687, animal D: accession number MF592691) (Figure 3.2). The 
nucleotide difference for animal C was a non-synonymous change at VP1 amino acid 
position 204.  
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Figure 3.2 Phylogenetic analyses of FMDV VP1 coding sequences of FMD virus isolates 
(accession number in parentheses) collected from Tanzania in 2014. Blue triangles 
represent milk samples from cows 7805 and 7815, and red triangles represent clinical 
lesion material from the same animal. The tree is drawn to scale, with branch lengths 
in the same units as those of the evolutionary distances used to infer the phylogenetic 
tree. Evolutionary analyses were conducted in MEGA7(Kumar et al., 2016). 
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3.5 Discussion 
The aim of this chapter was to examine the suitability of milk from individual cattle for 
FMD detection and typing so that it could be used for FMD surveillance in endemic 
settings such as East Africa. FMDV RNA was detected in 38% of the 190 milk samples 
tested, and of these, 58% of samples could be typed, with some milk samples positive 
for more than one serotype. It is possible that these animals were co-infected with 
multiple FMDV serotypes, as has been previously described in endemic areas 
(Woodbury et al., 1994; Ferris et al., 1995; Casey-Bryars et al., 2018). However, 
alternative explanations should also be considered, including the possibility that these 
results represent (i) contamination due to contact with materials infected with other 
FMDV types during sample collection in the field, transport or testing in the laboratory; 
or (ii) cross-reaction between the individual typing rRT-PCR assays, although no 
evidence of this has been observed during the validation of these tests (Bachanek-
Bankowska et al., 2016). Samples that could not be typed were those with a low level 
of FMDV specific RNA, indicated by high CT values (> 38) detected in the pan-serotypic 
assay. It is likely that these samples were beyond the analytical sensitivity of the typing 
assays, and methods to concentrate virus could be investigated to improve this in the 
future. 
During the study period, all four serotypes were detected in clinical samples, as 
reported by WRLFMD (2015), which was mainly concurrent with the results of rRT-
PCR testing of milk samples. However, there was an absence of serotype SAT 2 
detection in the milk samples, likely due to milk samples not being collected from the 
specific locations where serotype SAT 2 was identified in clinical samples at the start 
of the study period. Additionally, on some dates, FMDV RNA was detected in a milk 
sample, but there were no confirmed diagnostic reports of this serotype in the region 
at this time. This could be due to poor farmer recognition of clinical signs, lack of 
disease reporting, or sample contamination (as discussed above). Alternatively, these 
results may indicate that FMDV can be detected in milk samples during the pre-clinical 
or convalescence phases of infection, as reported previously (Blackwell and 
McKercher, 1982; Reid et al., 2006; Armson et al., 2018 [see Chapter 2]), or even during 
subclinical infection. 
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In order to substantiate the use of milk as an alternative sample type for surveillance, 
typing assay results and VP1 sequences from both milk and the traditional diagnostic 
sample types (epithelium or vesicular fluid) from the same animal and collection date 
were compared. The stronger CT values of the lesion material samples compared to 
those of the milk samples when tested by the pan-serotypic rRT-PCR confirm previous 
observations of higher virus concentrations in vesicular lesions (King et al., 2006; 
Stenfeldt et al., 2015). Typing results were comparable, with SAT 1 detected in all 
samples apart from the milk sample from animal A, possibly due to the reduced viral 
load observed in this animal.  Additionally, the presence of type O in the milk and 
vesicular fluid from animal B, but not in the vesicular epithelium sample was 
interesting. As discussed above, contamination cannot be excluded as a reason for this 
result.  
Additionally, two sequences derived from the milk samples from northern Tanzania 
were compared with previously reported sequences of paired epithelial/fluid samples 
from the same animal, held in the WRLFMD archive. Sequences from the same animal 
were found to be identical, or with one nucleotide difference, which may be explained 
by a mutation that could have occurred during viral replication, as sequences from the 
vesicular samples were obtained from virus isolated on primary bovine thyroid (BTY) 
cells. Upon comparison of the SAT 1-specific primers/probe with the VP1-coding 
sequence data obtained from milk and vesicular samples, it was evident that the 
difference in CT values between the pan-serotypic and the SAT 1-type specific assay 
may occur due to nucleotide differences at the 3’ end of the primer binding region of 
the typing assay. At least one nucleotide difference was identified within the SAT 1-
specific typing assay binding region in sequences obtained from animals A and B, while 
no such differences were observed in sequence data obtained from animals C and D. As 
the VP1-coding sequence is the most variable genome region, mismatches between the 
primers and probes of the typing assays and the template are expected. Therefore, it is 
recommended to use typing assays alongside the more sensitive pan-serotypic assay 
as a screening tool (Bachanek-Bankowska et al., 2016). Only limited vesicular samples 
were available from the same animal for this study, therefore, generation of additional 
data when more samples are available will continue to further validate these 
preliminary results. Additionally, the detection of FMDV RNA in milk samples should 
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also be compared with that of other excretory samples such as nasal swabs, oral swabs, 
and OP fluid from the same animals at different stages of infection. Overall however, 
observations from paired samples indicate that, despite a weaker rRT-PCR signal, milk 
can be useful for the detection and typing of FMDV from individual animals. 
This study demonstrates that milk could represent a valuable sample type as an 
alternative to the traditional diagnostic samples collected for FMD surveillance: 
vesicular epithelium or fluid. Milk from individual animals can be routinely collected 
and FMDV RNA can be detected and typed by rRT-PCR in milk samples in a region 
where FMD is endemic, albeit with weaker CT values than from vesicular samples. 
Additionally, the identification of multiple FMD serotypes in an individual milk sample 
suggests the likely possibility of co-infection, however contamination should not be 
excluded. The study demonstrates that VP1 sequence data may be obtained from milk 
samples, enhancing the possibility of further, in-depth virus characterisation. Milk 
sampling as a targeted surveillance approach shows promise given the concordance 
between typing data from milk samples and confirmed reports from outbreak 
investigations. Due to the high analytical sensitivity of molecular tests used to detect 
FMDV, appropriate care needs to be taken to minimise the possibility for cross-
contamination during sample collection, transport and testing in the laboratory.  In 
conclusion, milk is a simple-to-collect, non-invasive sample type which might be 
utilised in targeted surveillance campaigns in FMD endemic regions. Follow-on studies 
are required to assess the application of pooled milk in combination with herd clinical 
status for improved FMDV surveillance. 
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CHAPTER 4 
Moving from individual to pooled milk: 
considerations for the transport and storage of 
samples collected from herds in endemic 
countries  
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4.1 Summary 
The cost-effective, non-invasive collection of pooled milk samples for herd-level 
surveillance in endemic settings may help to improve the current understanding of 
FMD epidemiology. However, in many developing countries where FMD is endemic, a 
lack of infrastructure and resources can pose challenges in maintaining the cold chain 
for sample storage and transportation to testing laboratories. This chapter aimed to 
address some of the logistical challenges that might impact on the use of milk samples 
for surveillance purposes in endemic settings, including determination of the stability 
of FMDV RNA in milk samples in different scenarios, simulating conditions that might 
be experienced during storage and transport. Experiments performed demonstrated 
that FMDV detection was not significantly affected during long-term storage at -20oC, 
after multiple freeze-thaw cycles (-20oC/room temperature) or treatment with a 
common preservative (Bronopol). However, heat treatment at 56oC as a method to 
inactivate virus is not recommended when rRT-PCR testing is to be performed, due to 
the large increase in CT values that occurs, potentially resulting in a loss in diagnostic 
sensitivity. Separate experiments aimed to determine the occurrence of non-specific 
amplification, and the level of intra-assay contamination that may occur when testing 
milk samples. In these studies, only, 3/884 wells in the FMDV rRT-PCR assay were 
found to be weakly positive for FMDV RNA, resulting in a specificity of 99.66%. With 
these considerations in mind, experiments performed in this chapter further support 
the utility of pooled milk as an alternative sample for FMD surveillance, especially 
when samples may need to be shipped long-distances for FMDV testing.  
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4.2  Introduction 
The potential of milk as an alternative sample type for FMDV detection has been 
described in Chapters 2 and 3 (Armson et al., 2018, 2019). Milk sampling is non-
invasive and can be cost-effective as milk is routinely collected from dairy farms. Milk 
is also potentially less susceptible to selection bias than the routine sample type 
(vesicular material), as it does not rely on the observation of clinical signs. Of particular 
interest is the potential use of pooled milk for routine, low-cost, herd surveillance of 
FMD in endemic settings to determine disease prevalence and improve our 
understanding of FMD prevalence and epidemiology, so that appropriate control 
measures may be employed. 
In many developing countries where FMD is endemic, a lack of infrastructure and 
resources can pose challenges in maintaining the cold chain for sample storage and 
transportation to reference laboratories (Fowler et al., 2014; Niedbalski, 2016). 
Consequently, temperature and/or pH changes may affect the preservation of clinical 
samples (Bachrach et al., 1957), which may be partially degraded upon arrival for 
testing, resulting in difficulties in fully characterising the field FMDV isolate (Shaw et 
al., 2004).  
The same may be true for milk samples, although several publications have reported 
an increased survival of FMDV in milk samples subjected to high-temperature 
pasteurisation, pH variation, freeze-drying, and the preparation of dairy products 
(Felkai et al., 1970; Blackwell and Hyde, 1976; Tomasula and Konstance, 2004; Spickler 
and Roth, 2012). It is hypothesised that the high fat and protein content of milk may 
partially protect the virus from inactivation procedures (Spickler and Roth, 2012).  
These experiments mostly involved the use of non-molecular testing methods, and 
were mainly focussed on the stability of live virus under extreme inactivation 
conditions, to assess the risk of milk and milk products for onward transmission of 
disease. Consequently, little is currently known about how these conditions affect the 
stability of FMDV RNA genome, and the ability to detect it using the FMDV rRT-PCR 
assay described in Chapter 2 (Armson et al., 2018).  
Chapter 4 
 
70 
 
It is anticipated that variations in temperature and consequently a decrease in pH (due 
to an increased growth of contaminating bacteria [Christiansson, Bertilsson and 
Svensson, 1999]) may cause degradation of full length, high quality RNA in the sample 
(Wilson, 1997), although this may still be detectable by the rRT-PCR assay.  
Additionally, PCR inhibition may occur due to substances found in milk such as 
bacterial contamination, antibiotics, RNases, fats and proteins, although an efficient 
RNA extraction method should remove many of these factors (Wilson, 1997; Radström 
and Al-soud, 2001; Schrader et al., 2012). Consequently, if milk samples from 
developing countries may be utilised as an alternative sample for FMDV detection, 
more research is required on the effects that these small changes in temperature or pH, 
which may occur during transportation, may have on FMDV RNA genome stability and 
the ability to detect it using the rRT-PCR assay. 
Milk samples collected from field settings in this project (see chapters 3, 5 and 6) show 
that FMDV RNA genome is detected by rRT-PCR consistently with high CT values (>30 
for pooled milk). Although limit of detection studies performed in Chapter 2 (Armson 
et al., 2018) demonstrate positive CT values of up to 41, it is possible that results may 
be due to false amplification. False amplification may occur for three main reasons: 
(i) Environmental contamination during sample collection, for example transferring 
equipment between farms without sufficient disinfection. 
(ii) Intra-assay or inter-assay contamination of the plate wells during set-up, RNA 
extraction or rRT-PCR from the laboratory environment or positive controls.  
(iii) Non-specific amplification of other template (e.g. from other organisms) present 
in milk.  
During work performed for this thesis, environmental contamination was controlled 
as far as was reasonably practicable for example sample collectors wore disposable 
gloves and used disinfectant appropriately. It was therefore assumed to be negligible 
for the purpose of this study. ‘False positives’ may have occurred due to non-specific 
amplification, i.e. amplification of other nucleic acid other than that of the target gene 
found in milk samples, although it is anticipated to be negligible due to the high 
analytical specificity of the primers and probes used (targeting the 3D polymerase) 
(Callahan et al., 2002; Reid et al., 2009). Furthermore, the possibility for intra-assay 
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contamination during set-up and testing cannot be ignored, as this might lead to 
amplification in samples of known negative origin (Reid et al., 2009). However, in the 
study by Reid et al. (2009) a different RNA extraction protocol and sample matrices 
were used. Therefore, the specificity of the method used for FMDV detection in this 
project still requires assessing.  
This chapter is divided into two main parts. First, experiments were performed to 
simulate a range of scenarios that may occur from the point of milk sample collection 
to final testing. These include investigating the effects of various factors on the stability 
of FMDV RNA and the ability of detection by the rRT-PCR. These factors include heat 
inactivation and the addition of a common preservative (Bronopol) prior to shipment, 
and variations in temperature during long term storage and transportation. 
Second, sensitivity and specificity experiments were performed to test more robustly 
the FMDV rRT-PCR detection method used throughout this thesis. It was anticipated 
that results from these experiments would help to better inform the conditions 
employed for the storage, transport and testing of pooled milk samples from endemic 
regions. 
 
4.3  General materials and methods 
4.3.1 Clinical samples 
FMDV viruses used in this chapter were obtained either from archival stocks of cell 
culture isolates (isolated once in primary bovine thyroid [BTY] cells) held in the 
WRLFMD repository (The Pirbright Institute, UK), or were archival samples previously 
collected from experimental studies as described in Chapter 2 (Armson et al., 2018). 
Negative unpasteurised milk from Jersey cattle used for preparing dilution series or as 
controls was purchased from a UK farm. Unpasteurised milk samples as a negative 
cohort used for specificity testing were kindly provided by the Animal and Plant Health 
Agency (APHA), collected from UK farms every quarter as part of the national 
Brucellosis surveillance programme (DEFRA, 2015a).  
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4.3.2 RNA extraction 
All RNA extractions were carried out using the MagMAX™ 96 Viral RNA Isolation Kit 
(Applied Biosystems®) using a sample input of 50 µL on a MagMAX™ Express 96 
Extraction Robot (Applied Biosystems®) according to manufacturer’s instructions. 
Negative extraction controls consisted of unpasteurised whole milk added to lysis 
buffer.  
 
4.3.3 Real-time reverse transcription PCR 
All rRT-PCR assays were carried out on an ABI7500 rRT-PCR machine (Applied 
Biosystems®) using the reagents, parameters and thermal cycling conditions as 
previously described in Chapter 2 (Method B) (Callahan et al., 2002; Shaw et al., 2007; 
Armson et al., 2018). Replicates of samples with a CT value of >50 were considered 
negative, and weren’t included in statistical analyses. 
 
4.3.4 Virus Isolation 
Virus isolation of milk samples was carried out on primary bovine thyroid (BTY) cell 
cultures (Snowdon, 1966), with the following modification. After the 30 minute 
incubation of the test-sample cell-culture tubes to allow adsorption of virus into the 
cells, all tubes were washed 3-5 times with phosphate buffered saline (PBS, Severn 
Biotech Ltd.) before the addition of 2mL Eagle’s maintenance medium (serum free, 
MEM with HEPES, phenol red & GlutaMax)(Gibco®, Life Technologies). Tubes were 
then returned to the incubator for 72 hours and observed each day for cytopathic effect 
(CPE). Titrations of the original virus spiked milk sample were performed and the viral 
titre was calculated using the Spearman-Kärber method, as described by the UN, Food 
and Agriculture Organization (FAO) and expressed in units of TCID50/mL (Karber, 
1931; OIE, 2017a). 
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4.4 The stability of FMDV RNA in milk samples  
4.4.1 Treatment of milk samples prior to shipment 
This section investigates the effect of preservative treatment, heat inactivation and 
storage of milk samples on the ability of the rRT-PCR assay described above to detect 
FMDV RNA genome. The latter two methods could be employed prior to shipment in 
order to increase the time before spoiling or to inactivate the virus, and consequently 
may reduce the cost of shipment to international reference laboratories by allowing 
shipment at a lower category level.  
 
(A) Does treatment with a common preservative affect the ability to detect FMDV by rRT-
PCR? 
As part of the national brucellosis surveillance programme, bulk milk samples collected 
by large-scale farms and submitted to national laboratories are often treated with a 
preservative to increase their storage duration before spoiling. A common preservative 
used in the UK is Bronopol (2-bromo-2-nitro-1,3-propanediol) plus natamycin. If a 
similar scheme was employed for FMD surveillance in the UK, milk samples may 
contain this preservative.  
Alternatively, this preservative could be added before shipment, so that samples may 
only need to be refrigerated during transportation. A previous experiment, using a 
different RNA extraction and rRT-PCR method to the one employed in this project, 
demonstrated that treatment with a similar Bronopol-based preservative had no 
significant effect on the detection of FMDV RNA in milk samples (Reid et al., 2006).  
Method 
One ‘Broad Spectrum Microtabs II™’ (Advanced Instruments) tablet, containing 8 mg 
Bronopol and 0.30 mg Natamycin, was added to 25 mL unpasteurised Jersey milk, to 
simulate the method used in samples collected in the UK for the surveillance of other 
diseases such as brucellosis and bovine viral diarrhoea. Two ten-fold serial dilutions 
(10-1 to 10-8) of cell-culture isolate A/KEN/6/2012 were prepared, one in the 
preservative-treated milk, and one in untreated negative milk as a control. RNA 
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extraction and the rRT-PCR assay were performed on each dilution series in triplicate. 
A paired t-test was performed comparing the results of preservative treated versus 
untreated dilution series. 
Results 
Results showed that the limit of detection for the untreated sample was one log10 
higher than for the treated sample, although this was near the limit of analytical 
sensitivity of the rRT-PCR assay (Figure 4.1). However, there was no significant 
difference between the mean CT values of the treated and untreated dilution series 
(p=0.139). 
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Figure 4.1 rRT-PCR results for the milk samples treated with preservative added ( ) 
and untreated ( ). Each point represents the mean of three replicates. Black symbols 
indicate where no amplification was observed for one or more replicate. Error bars 
indicate the standard deviation. 
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(B) What effect does heat-inactivation of samples have on the ability to detect FMDV RNA 
by rRT-PCR? 
Strict procedures exist for the shipment of samples containing live FMD virus (IATA, 
2019) and it is recommended that samples of unknown FMD status (i.e. could contain 
live virus) be shipped according to category A (The Pirbright Institute, 2019), which 
requires expensive packaging and shipping. Prior validated inactivation of any live 
virus present may therefore allow shipment of milk samples at a reduced cost, as 
samples may be sent at a lower category level. This allows more samples to be included 
in one shipment, and the requirements for packaging are fewer (IATA, 2019).  
Heat inactivation is a cheap, simple inactivation protocol currently used for serum 
samples (The Pirbright Institute, 2019), involving heating samples in a water 
bath/heat block for two hours. It is anticipated that this method could be applied to 
milk samples, and could be performed by local low-resource laboratories before 
reduced-cost shipment to national/international reference laboratories for diagnostic 
testing. This section investigates the stability of FMDV RNA in milk and consequent 
detection by the rRT-PCR after heat-inactivation. 
Method 
A 10-1 dilution of cell culture isolate A/SAU/6/2015 was prepared in unpasteurised 
whole milk, and fifteen replicates of this dilution were aliquoted into 1.8 mL cryotubes. 
An additional four aliquots of milk were also prepared, as an FMD-negative control. 
Three tubes of the 10-1 dilution and an FMD negative control were placed in a water 
bath at 56oC for different time periods (60 mins, 45 mins, 30 min or 15 mins). An 
additional 3 tubes and an FMD-negative control were placed at +4oC for 60 minutes as 
non-treated controls. 
After heat inactivation (or no treatment), virus isolation and RNA extraction-FMDV 
rRT-PCR were performed on all milk samples and FMD-negative controls. Additionally, 
virus titrations of the original virus spiked milk sample were performed on BTY cells 
(10-1 – 10-8) to calculate the virus titre. 
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Results 
The virus titre of the FMDV A/SAU/6/2015 sample when spiked in unpasteurised milk 
was 6.0 log TCID50/mL.  
No CPE was observed after heat inactivation of FMD infected milk samples for 30 
minutes or more (Table 4.1). As observed by eye, a large difference in CT value was 
observed when comparing no heat treatment with all heat inactivation times (CT 
difference >10).  
 
Table 4.1 Results of the pan-serotypic rRT-PCR assay and virus isolation after heat 
inactivation. 
Heat inactivation at 56oC CT value (SD) CPE observed in BTY cells 
None 17.97 (0.08) 3/3 
15 mins 28.47 (0.99) 3/3 
30 mins 32.59 (0.42) 0/3 
45 mins 34.28 (0.63) 0/3 
60 mins 33.17 (0.44) 0/3 
SD: standard deviation. CPE: cytopathic effect. BTY: bovine thyroid. CT values are the mean of three 
biological and three technical replicates (n=9).  
 
(C) Does long-term storage at -20oC affect the ability to detect FMDV by rRT-PCR? 
International reference laboratories typically maintain those samples not preserved in 
glycerol for long-term storage in a -80oC freezer. However, low-resource laboratories 
may only have access to ‘regular’ freezer space that maintains a temperature of -20oC. 
Consequently, milk samples may need to be stored at this temperature for long periods 
until enough samples are collected for shipment. 
Method 
A ten-fold dilution series (10-1 – 10-8) of cell culture isolate A/TAN/1/2013 was 
prepared in unpasteurised whole milk. Nine 500 µL aliquots of each dilution were 
prepared, and four aliquots of each dilution series stored at either -20oC or -80oC. At 3-
month time intervals over a period of one year (i.e., at 0, 3, 6, 9 and 12 months), an 
aliquot stored at -20oC and -80oC was removed for testing. RNA was extracted in 
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triplicate from each dilution series and the pan-serotypic rRT-PCR performed on each 
replicate.  
Paired t-tests were performed comparing the two storage temperatures at each time 
interval (3, 6, 9 and 12 months). Additionally, paired t-tests were carried out to 
compare the CT values at Day 0, with -20oC storage at each time interval.   
Results 
There was no significant difference in the CT values obtained between storage at -80oC 
and -20oC at any of the time intervals, apart from at 6 months (p = 0.02) (Figure 4.2). 
However, the difference in average CT values for the 6 month time interval was small 
(mean of difference = 1.22, 95% CI = 0.18 – 2.25). Additionally, when long term storage 
(12 months) is compared with testing on Day 0, no significant difference in the limit of 
detection was observed (p = 0.08).  
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4.4.2 Storage of milk samples during transportation  
This section aims to determine the effect of temperature on rRT-PCR detection of 
FMDV changes that may occur during storage and transportation, in a number of 
experiments, described below. 
 
(D) What is the effect of freeze-thawing samples on FMDV detection by rRT-PCR? 
From sample collection through to testing, milk samples may be freeze-thawed 
multiple times, for example if further aliquoting of the sample is required, or during 
transportation, especially where delays may result in inadequate maintenance of the 
cold-chain. 
Method 
For experiments (D) and (E) two milk samples collected from the in-vivo experimental 
infection study (Chapter 2) were chosen with different levels of FMDV RNA present 
(based on original CT value): Animal 867, 4 days post infection (DPI) (average CT = 
19.65) and Animal 867, 7 DPI (average CT = 26.61), named ‘high’ and  ‘low’ respectively. 
In order to ensure enough material was available, samples were diluted 1/20 in 
unpasteurised whole milk, and separated into different aliquots for each experiment 
(D) and (E).  
For this experiment (D), each sample (‘high’ and ‘low’) underwent five freeze-thaw 
cycles: samples were stored at -20oC for at least 3 hours, and then defrosted for at least 
30 minutes at room-temperature (RT) (approximately 21-23oC). RNA was extracted in 
triplicate and the pan-serotypic rRT-PCR performed on each replicate at the start of 
the experiment, and also at each ‘thaw’ step (Figure 4.3). Additionally, the pH was 
measured at each ‘thaw’ step by adding a drop of each sample to universal pH indicator 
paper. This was to determine whether these temperature fluctuations also affected the 
pH of the milk sample, for example due to an increase in the growth of contaminating 
bacteria, as a decrease in pH may cause degradation of intact virus and nucleic acid, 
potentially leading to a ‘false negative’ result. One-way ANOVA tests were performed 
to compare CT values obtained at each thaw stage for the ‘high’ and ‘low’ samples. 
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Figure 4.3 The freeze-thaw process carried out for each sample (‘high’ and ‘low’), 
indicating the point at which rRT-PCR and pH testing was carried out. 
 
Results 
There was no significant difference between the mean CT values between any of the 
thaw steps for the ‘low’ sample (p = 0.23) (Figure 4.4). A significant difference between 
thaw steps was observed for the ‘high’ sample (p = <0.01), however the difference 
between the lowest and highest CT value for this sample was small (CT=1.29). At each 
thaw step, the pH of each sample remained at 7. 
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Figure 4.4 CT values from the pan-serotypic rRT-PCR measured at each thaw (T) step 
for the ‘high’ sample ( ) and ‘low’ ( ) sample. Each point represents the mean of 
three replicates. Error bars indicate the standard deviation. 
 
(E) What is the effect of short term storage at +4oC or room-temperature on FMDV 
detection by rRT-PCR? 
If freeze-thawing samples does have a negative effect on FMDV detection, an 
alternative to shipping samples on dry ice to maintain samples in a frozen state would 
be to transport refrigerated samples. This may also reduce cost and the package size 
required. 
Method 
Thirteen aliquots of each sample (‘high’ and ‘low’) were prepared, and four aliquots of 
each were stored at +4oC, room temperature, and -20oC as a control (Table 4.2). 
Samples were stored for four days, and on each day, an aliquot was removed, RNA 
extracted in triplicate and the pan-serotypic rRT-PCR performed on all replicates. 
Additionally the pH was measured, as above.  
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Table 4.2 Storage temperatures and rRT-PCR testing intervals for samples ‘high’ (H) 
and ‘low’ (L). 
Day 0 Day 1 Day 2 Day 3 Day 4 
Untreated -20oC +4oC RT -20oC +4oC RT -20oC +4oC RT -20oC +4oC RT 
H H H H H H H H H H H H H 
L L L L L L L L L L L L L 
Results 
Using a paired t-test, there was no significant difference between short term storage at 
-20oC (control) and +4oC for the ‘low’ sample (p = 0.57) or the ‘high’ sample (p = 0.08) 
over the 4 days (Figure 4.5). However, using a one way-ANOVA, there was a significant 
difference with these two temperatures compared with room temperature storage for 
the high sample (p = 0.001). Additionally, over the 5 days there was a significant 
difference in CT value for the ‘high’ sample (p = 0.02), with an overall decrease in CT 
value during storage at -20 oC and +4 oC, in contrast to an increase in CT value for 
storage at room temperature. The pH remained at 7 for all samples/days, apart from 
for days 3 and 4 when both samples were stored at room temperature, where the pH 
lowered to 6. 
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Figure 4.5 CT values from the pan-serotypic rRT-PCR measured on each day after 
storage at -20oC ( ), +4oC ( ), and room temperature (RT) ( ) for the ‘high’ and ‘low’ 
samples. CT values for the untreated high ( ) and low ( ) milk samples prior to 
storage are also indicated. Each point represents the mean of three replicates, apart 
from ‘high’-RT-D4, as no amplification was observed for one replicate. Error bars 
indicate the standard deviation.  
 
 
 
 
 
 
 
Chapter 4 
 
84 
 
4.5 Assessing the FMDV detection system using milk 
samples. 
(F) Reproducibility of the limit of detection 
Although limit of detection (LOD) experiments have previously been performed using 
the FMDV detection method employed in this project (see Chapter 2, Armson et al., 
2018), these experiments have shown that at the LOD of the rRT-PCR assay 
amplification often only occurs in a proportion (e.g. one replicate out of two) of samples 
containing low amounts of viral RNA, as seen elsewhere in this chapter in experiments 
(A), (C) and (G-ii). This experiment aims to determine how consistently samples 
containing low amounts of viral RNA are detected at the LOD of the rRT-PCR. 
Method 
Ten-fold serial dilutions of FMDV cell culture isolate A/SAU/6/2015 were prepared in 
negative unpasteurised milk. The virus titre at a 10-1 dilution was 6.0 log TCID50/mL 
(see experiment [B]). RNA was extracted from the dilutions 10-3 to 10-8 and 10 
replicates of each dilution were tested using the pan-serotypic rRT-PCR.  
Results 
Amplification was observed for all ten replicates at a dilution of 10-6 (Figure 4.6). 
However, amplification was also observed for 4/10 (40%) of replicates at a dilution of 
10-7.  
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Figure 4.6 rRT-PCR (CT) values of ten replicates of the ten-fold dilution series of cell 
culture isolate A/SAU/6/2015 spiked in unpasteurised milk. Dotted lines represent the 
mean of the ten replicates. 
 
(G) Diagnostic specificity 
In order to determine the diagnostic specificity of the FMDV detection system in milk, 
two experiments were performed:  
(i) Checkerboard test to assess intra-run cross-contamination 
(ii) FMDV rRT-PCR of milk samples from a known FMDV negative cohort 
 
(G-i) Checkerboard test 
Method 
In these experiments (G-i and G-ii), cell culture isolate O/SAU/1/2016 was diluted to 
10-2 in unpasteurised whole milk to prepare a FMDV positive control. Unpasteurised 
whole milk was used for the negative control.  
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Positive and negative control samples were added to the RNA extraction plate in a 
checkerboard layout as displayed in figure 4.7, and then an rRT-PCR performed in the 
same layout.  
Results 
No rRT-PCR signal indicative of contamination was observed in any of the negative 
wells. The mean CT value of the positive wells was 24.24±0.71, with an inter-well 
coefficient of variation of 2.91%. 
22.5 NEG 23.5 NEG 24.4 NEG 24.9 NEG 24.4 NEG 23.8 NEG 
NEG 22.6 NEG 24.1 NEG 23.8 NEG 24.1 NEG 24.1 NEG 23.9 
24.2 NEG 24.4 NEG 24.6 NEG 24.6 NEG 23.8 NEG 25.2 NEG 
NEG 24.5 NEG 24.5 NEG 24.5 NEG 24.0 NEG 24.9 NEG 24.0 
23.8 NEG 24.9 NEG 24.5 NEG 24.8 NEG 24.5 NEG 26.0 NEG 
NEG 23.9 NEG 23.7 NEG 24.1 NEG 24.2 NEG 25.1 NEG 24.3 
23.4 NEG 25.2 NEG 25.3 NEG 24.2 NEG 24.0 NEG 24.1 NEG 
NEG 24.1 NEG 23.0 NEG 22.8 NEG 24.7 NEG 23.9 NEG 25.6 
 
Figure 4.7 Checkerboard layout and CT values after rRT-PCR of positive and negative 
spiked milk (white and grey wells, respectively). NEG: CT value >50.  
 
(G-ii) FMDV rRT-PCR of known negative samples 
Method 
Bulk milk samples (n = 442) collected from UK farms as part of the national brucellosis 
surveillance programme for England (DEFRA, 2015a) and submitted to the Animal and 
Plant Health Agency (APHA), Surrey, UK were used in this experiment. Broad Spectrum 
MicroTabs were added to each sample as a preservative, and they were refrigerated 
until tested. As the UK was free from FMD when these samples were collected, it was 
expected that all samples should be negative for FMDV on the rRT-PCR assay, allowing 
the specificity of the assay to be calculated.  
RNA was extracted from the bulk milk samples, and then the rRT-PCR was performed 
on each sample in duplicate. Two positive and two negative control wells were 
included on each of the 11 rRT-PCR plates. 
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Results 
Results of the rRT-PCR assays are shown in Table 4.3. Three wells (a maximum of one 
per plate) demonstrated false positive results with CT values ranging between 39.11 
and 41.09, leading to a specificity of the rRT-PCR assay of 99.66% (95% CI: 99.01% - 
99.91%). Taking a ‘positive’ result as amplification in both duplicate wells the 
specificity of the rRT-PCR assay for the 442 milk samples tested was 100%. All controls 
were correct. 
 
Table 4.3 rRT-PCR assay results of the 442 bulk milk samples tested.   
rRT-PCR plate 
number 
Number of Bulk 
milk samples 
tested  
Number of wells 
containing bulk milk 
samples 
Number of wells 
positive* for FMDV (CT 
value, % of total) 
1 43 86 0 (0%) 
2 43 86 0 (0%) 
3 43 86 0 (0%) 
4 43 86 1 (41.09, 1.16%) 
5 43 86 0 (0%) 
6 43 86 0 (0%) 
7 43 86 1 (39.39, 1.16%)) 
8 43 86 1 (39.11, 1.16%)) 
9 43 86 0 (0%) 
10 43 86 0 (0%) 
11 12 24 0 (0%) 
Total 442 884 3 (0.34%) 
*A positive result is defined as a CT value ≤ 50 
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4.6 Discussion 
Experiments performed in the first part of this chapter (section 4.4) aimed to simulate 
the storage, treatment and transport conditions of milk samples that may occur when 
they are collected from cattle in an endemic or outbreak setting.  
After collection, milk samples may be stored locally either on the farm, or at a local 
laboratory. In order to increase the robustness of the samples during this temporary 
storage period, samples may be treated with a preservative, for example Bronopol, 
currently used in the UK when bulk milk samples are collected for the surveillance of a 
number of diseases (DEFRA, 2015a). Experiment (A) aimed to determine whether 
treatment with this common preservative has an inhibitory effect on the detection of 
FMDV, using the methods described in this thesis. Although there was no significant 
difference between the mean CT values of the treated and untreated milk samples for 
the samples containing higher concentrations of FMDV RNA, there was a one log10 
reduction in the limit of detection with treatment. Consequently, this method is only 
recommended where may be anticipated difficulties with maintenance of the cold 
chain, and where milk samples are not likely to contain low levels of FMDV RNA (e.g. 
pooled samples from large herds).  
Together with treatment of milk samples with preservative, it was anticipated that 
prior inactivation of any live virus present  may help to reduce the high cost of sample 
shipment by allowing milk samples to be sent at a lower category level. It has been 
demonstrated at TPI that FMDV infected serum samples that were heat treated for 2 
hours at 56°C resulted in an inability to propagate the virus in tissue culture (The 
Pirbright Institute), although shorter time periods have also been reported to be 
effective (personal communication, Alison Morris). Prior to my study the ability to 
detect FMDV RNA following this treatment had not been investigated. However, it was 
anticipated that heat treatment for up to 2 hours may degrade FMDV RNA. 
Consequently, experiment (B) was designed to investigate whether the inactivation of 
live FMD virus was possible over shorter heat treatment times in milk samples, and 
following this, whether this affected FMDV RNA genome detection by rRT-PCR. Indeed, 
treatment of milk samples at 56oC for over 30 minutes did inactivate any live virus 
present, however, it also significantly increased the resulting CT value (>10). Although 
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this may be suitable for milk samples collected from individual cattle at the peak of 
FMD infection, this would not be appropriate for convalescing animals, or indeed 
pooled milk samples that typically demonstrate weaker CT values. This experiment 
used a cell-culture isolate spiked milk sample, instead of milk from a naturally infected 
cow and it is thought that virus shed within cells of the milk from an infected cow may 
be further protected from inactivation procedures (Sellers, 1969; Tomasula et al., 
2007). Therefore it is possible that the changes in CT values/limit of detection may be 
reduced in this case, after heat inactivation or indeed after treatment with 
preservative. Consequently, further research should be performed to test heat 
inactivation of naturally infected milk samples, but also serum and other sample types, 
to determine whether the recommended 2 hour inactivation period could be shortened 
with the same inactivation effectiveness. 
After collection in endemic countries, milk samples may need to be stored for a number 
of months in a -20oC freezer, prior to testing or shipment to international reference 
laboratories. Experiment (C) demonstrated that, when compared to the ‘gold standard’ 
sample storage for international reference laboratories (-80oC), there was no 
significant difference in FMDV RNA detection after 12 months of storage at -20oC. This 
indicates that storage of milk samples in -20oC freezers, which are more widely 
available in low resource laboratories, for up to 12 months would not affect the results 
of the rRT-PCR. However, for this experiment the temperature of the freezers remained 
in range (-90oC to -50oC for the -80oC freezer, -30oC to -5oC for the -20oC freezer), but 
in some endemic settings, power outages are a common occurrence, which may lead to 
freeze-thawing of the milk sample.    
Consequently, experiment (D) aimed to simulate a scenario where multiple freeze-
thaws of a milk sample may occur before testing. This may occur during storage, due 
to power outages as mentioned above, aliquoting of samples before transportation, or 
during a delayed/prolonged shipment. This experiment showed that even after five 
freeze-thaw steps, there was little change in CT value (maximum change from starting 
value = 1.29 CT). This indicates that unintentional freeze-thaws that may occur 
between sample collection and testing should not negatively affect the results 
generated by rRT-PCR.  
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In addition, experiment (E) was carried out to determine whether milk samples may 
be refrigerated during transportation to reduce shipping costs, instead of being 
maintained in a frozen state as currently recommended. Interestingly, CT values of 
samples stored at +4oC were not significantly different from those stored at -20oC for 
four days for both the ‘high’ and ‘low’ samples. Storage at room temperature was also 
tested, and for the ‘high’ sample had a negative effect on the resulting CT value after 
storage for 4 days. Interestingly however, no negative effect on the resulting CT value 
for the ‘low’ sample was observed. The reason for this difference in the behaviour of 
the two samples is unknown. It is hypothesised that spoiling of the milk and lowering 
of the pH may have led to degradation of virus/nucleic acid, although it has been 
demonstrated that FMDV RNA detection is still possible from lateral flow device strips 
treated with citric acid (Romey et al., 2018). Consequently, it is possible that samples 
may be refrigerated during transportation, as long as this temperature can be 
maintained, as RNA detection from samples stored at higher temperatures is 
unpredictable. This may be used as a method to reduce shipment costs without 
affecting the viability of the RNA by permitting the use of simpler packaging types, 
decreasing the  dimensions of packages, and removing the need to ship samples on dry 
ice.  
Although these experiments demonstrate potential opportunities to reduce shipping 
costs, the use of a temperature monitor included in the shipment may be useful to 
record any fluctuations in the temperature of samples that may occur. This may then 
assist in informing the true status of test results, for example, whether there may be 
false negatives due to a prolonged increase in temperature during shipment. These 
experiments used limited isolates to test these methods and, although it is anticipated 
that differences in FMDV serotype/lineage would have little effect, this should be 
considered if a milk sampling surveillance system is to be implemented. 
In the next part of this chapter (section 4.5), experiment (F) demonstrated the potential 
for false negative results when the levels of FMDV RNA genome in a pooled sample may 
be low, and at the limit of detection of the assay. Replicate rRT-PCR testing (e.g. 
duplicate/triplicate) is therefore recommended to increase the likelihood of FMDV 
detection. 
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Previous studies have investigated the diagnostic specificity of the FMDV rRT-PCR. For 
example, Reid et al. (2009) observed a 98.9% specificity for 3,004 samples collected 
from FMD-negative farms during field outbreaks in the United Kingdom in 2007. 
Additionally, as part of the collaborative work carried out for Chapter 2, the Foreign 
Animal Disease Diagnostic Laboratory (FADDL) observed a diagnostic specificity of 
100% when testing 1,005 individual bulk milk tank samples in 5 US states 
(unpublished). However, both studies used different reagents/equipment/sample 
types to those used in this project. Therefore, in order to have confidence in the results 
from this project, it was important to determine the possibility of non-specific 
amplification, and the level of intra-assay contamination that may occur when testing 
milk samples by the chosen FMDV rRT-PCR assay. 
For both experiments (G-i) and (G-ii), over 99% of samples known to be negative for 
FMDV were correctly identified as negative, with a 100% diagnostic specificity if a 
‘positive’ result requires the presence of amplification in all replicate wells. It can 
therefore be assumed that amplification due to the presence of other template present 
in the milk cross-reacting with the FMDV rRT-PCR assay, is negligible, as observed 
previously. However, there were three samples where amplification did occur, 
indicating that some intra-assay contamination may occur during set-up or testing. CT 
values of these false positives were those that may be expected from truly FMDV 
positive pooled milk samples. It is possible that this level of intra-assay contamination 
and the associated CT values may be due to the strong positive controls used in this 
experiment (approximately CT = 20), and using controls with higher CT values may 
reduce this level of contamination. It is therefore necessary that great care is taken to 
minimise the risk of contamination when performing these assays, as it is difficult to 
determine whether a positive result is the result of false amplification, especially when 
samples containing low concentrations of FMDV RNA may not demonstrate 
amplification in all replicates tested. Additionally, this experiment was limited by the 
cost of reagents and the availability of samples. To more accurately determine the 
specificity of the rRT-PCR assay, it is recommended that a greater number of negative 
milk samples are tested, including those from a range of cattle breeds from different 
geographical regions. Indeed it should be considered that although the FMDV pan-
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serotypic assay has been shown to be highly specific, organisms that may be present in 
the milk of animals not from the UK have the potential to cause false positive results.  
 
4.7  Conclusion 
Experiments performed in this chapter have tackled some of the logistical issues that 
might impact the use of pooled milk collected from outbreak scenarios or endemic 
settings, and shipment to national/international reference laboratories for FMDV 
detection by rRT-PCR.  
Experiments in this chapter have demonstrated that the integrity of FMDV RNA 
present in milk samples does not seem to be significantly affected by changes such as 
chemical treatment with Bronopol, during freeze-thaw, and during refrigerated 
storage. It is likely, as alluded to previously (Blackwell and Hyde, 1976; Tomasula and 
Konstance, 2004; Spickler and Roth, 2012), that the high fat and protein content of 
whole milk may offer protection against these changes, making milk a particularly 
suitable sample type for FMDV detection.  
Additionally, although the high analytical sensitivity of the FMDV rRT-PCR assay is 
encouraging, care should be taken when interpreting the test results of pooled milk 
samples from cattle in the field. In order to maximise the likelihood of FMDV detection 
in pooled milk samples containing a low FMDV RNA concentration, it is recommended 
that multiple replicates of samples are tested. In addition, great care should also be 
taken to minimise the likelihood of intra-assay contamination during testing using 
appropriate methods. These include the use of individual laboratory space and 
personal protective equipment for each stage of the testing process to minimise 
contamination of ‘clean’ reagents, laboratory/workspace disinfection and regularly 
changing gloves (Wilson, 1997; CDC, 1999; Schrader et al., 2012). 
With these considerations in mind, experiments performed in this chapter further 
support the utility of pooled milk as an alternative sample for FMD surveillance, 
especially when samples may need to be shipped long distances for FMDV testing. 
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CHAPTER 5 
Utilising milk from pooling facilities as a novel 
approach for foot-and-mouth disease 
surveillance 
 
Data presented in this chapter has been published in Transboundary and Emerging 
Diseases: https://onlinelibrary.wiley.com/doi/10.1111/tbed.13487   
 
© 2020 The Authors. Transboundary and Emerging Diseases published by Blackwell Verlag GmbH. 
 
Additionally, description of the study area and sample size calculations for Survey 1 
have been described in the following research article, published in Veterinary Research 
(See Appendix III, Figure 8.2): https://doi.org/10.1186/s13567-019-0652-0.   
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5.1 Summary 
Surveillance systems for foot-and-mouth disease (FMD) have several limitations and 
biases, and are often not effective in resource-limited countries. Using milk for the 
detection of FMD virus (FMDV) as a non-invasive, routinely-collected and cost-effective 
surveillance tool could address some of these limitations. This chapter aimed to 
investigate the potential of pooled milk sampling for FMD surveillance using real-time 
RT-PCR (rRT-PCR) which was compared with reports of household-level incidence of 
FMD in Nakuru County, Kenya. Pooled milk samples were collected weekly from five 
pooling facilities that were supplied by smallholder dairy farmers. Alongside this, 
periodic cross-sectional surveys of smallholder farmers were performed which were 
powered to detect a threshold household-level FMD incidence of 2.5%. Information on 
trends in milk production and sales was also collected, where it was observed that up 
to 26% of the smallholder farmers surveyed were contributing milk to pooling 
facilities. FMDV RNA was detected in only 9/219 pooled milk samples, with SAT 1 
identified in 3 out of the 9 positive samples using a type-specific rRT-PCR. This finding 
was consistent with the laboratory confirmed serotype responsible for outbreaks in 
the study area at the time of milk sampling. Milk samples were positive for FMDV RNA 
on 4/21 half-month periods when at least one farmer reported observing FMD on their 
farm, i.e. the clinical FMD incidence at the household level was above a threshold of 
2.5%. This indicates that the pooled milk surveillance system can detect FMD 
household level incidence at a threshold of 2.5%. Additionally, milk samples were 
positive for FMDV RNA on 5/21 half-month periods when there were no reports of 
FMD by farmers during the surveys, indicating that this surveillance system may be 
able to reveal the presence of FMD at even lower levels of infection in the population 
(i.e. below a threshold of 2.5%), or when conventional disease reporting systems fail. 
This pilot study highlights that surveillance based on molecular detection of FMDV in 
pooled milk samples has the potential to address some of the existing limitations of 
traditional surveillance methods. However, to fully evaluate the reliability of this 
surveillance approach in FMD endemic settings, further studies are required aimed at 
establishing a more precise correlation with estimates of household-level clinical 
incidence. 
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5.2  Introduction 
Foot-and-mouth disease (FMD) has been described as a high impact disease among 
pastoralists in East Africa (Onono et al., 2013; Nthiwa et al., 2019). According to recent 
studies and reports by the OIE/FAO World Reference Laboratory for FMD (WRLFMD) 
four serotypes are currently known to circulate in East Africa, and within each serotype 
a number of topotypes/lineages also exist (Bachanek-Bankowska et al., 2016; Casey-
Bryars et al., 2018; WRLFMD, 2018c, 2019). However, there are still  major knowledge 
gaps about the distribution and epidemiology of circulating FMD viruses (Brito et al., 
2015). This is particularly the case in areas where surveillance is dependent upon the 
recognition and reporting of clinical cases by farmers and livestock workers (Bates et 
al., 2003; Picado et al., 2011; Machira and Kitala, 2017) due to under-reporting. In these 
settings, limited capacity to undertake outbreak investigation and collection of clinical 
specimens following reports renders laboratory confirmation problematic (Kasanga et 
al., 2012; Namatovu et al., 2013). As a result, evidence-based strategies to respond to 
outbreaks are often not implemented, which reduces farmers’ willingness to report 
even further. It is therefore difficult to determine the true incidence of the disease 
(Vosloo et al., 2002; Knight-Jones et al., 2016). Although targeted case finding or 
serological surveys are valuable, they are generally infrequent due to the costs and 
labour involved (Hadorn and Stark, 2008; Kasanga et al., 2012). Consequently, the 
requirement exists for a simple, cost effective approach for the surveillance of FMD that 
does not rely on farmer reporting.  
Pooled milk is a routinely collected, non-invasive sample type that has the potential to 
be utilised for the herd-level surveillance of FMDV, as demonstrated by the surveillance 
of a number of other diseases including bovine viral diarrhoea (Dubovi and Section, 
1995; Drew et al., 1999; Hill et al., 2010), brucellosis (Hamdy and Amin, 2002; Chand 
et al., 2005), and Q fever (Kim et al., 2005; Bauer et al., 2015). Limit of detection studies 
have highlighted the potential of identifying one acutely-infected milking cow in a herd 
of up to 1000 using pooled milk sampling (Armson et al., 2018, see Chapter 2). 
Additionally, simulation modelling suggested the earlier detection of FMDV by RT-PCR 
screening of pooled milk samples compared with farmer reporting, and encouraged 
Chapter 5 
 
97 
 
empirical studies to investigate the use of pooled milk for regional FMD surveillance 
(Thurmond and Perez, 2006; Garner et al., 2016; Kompas et al., 2017).  
This chapter therefore describes a proof-of-concept pilot study performed in Nakuru 
County Kenya to explore the use of pooled milk as a non-invasive alternative sample 
matrix for the surveillance of FMD. Clinical FMD has been frequently reported in this 
region, and confirmed during outbreak investigations as part of the ‘real-time’ training 
courses organised by the European Commission for the Control of Foot-and-Mouth 
Disease (EuFMD) (Machira and Kitala, 2017; Nyaguthii et al., 2019). Indeed, in the six 
months prior to the commencement of this study, 13/220 smallholder farmers 
surveyed in Nakuru County reported having a case of FMD in at least one animal on 
their farm, as described by Nyaguthii et al. (2019) (Figure 5.1) 
 
Figure 5.1. Map of occurrence of FMD cases in Nakuru County, Kenya in the six months 
prior to the study described in this chapter. Reports are according to cross-sectional 
smallholder farmer surveys performed by Nyaguthii et al. (2019) (Survey 1 – see 
section 5.3.3). Farmer-reported FMD outbreak locations within the study area are 
represented in red. Adapted from Figure 3 in Nyaguthii et al. (2019). 
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Although several studies have examined the impact of FMD outbreaks on large-scale 
farms in Kenya (Mulei et al., 2001; Kimani et al., 2005; Lyons et al., 2015), the majority 
of livestock is owned by smallholder dairy farmers, who contribute to an estimated 70-
80% of all milk sold to the dairy production chain. This milk directly or indirectly 
supplies consumers, milk pooling facilities or private processors (Omore et al., 1999; 
Karanja, 2003; Rademaker et al., 2016). Generally, a small amount of milk produced by 
smallholder farmers is retained at home, while the rest is traded either to local shops, 
hotels or neighbours, or sold to milk pooling facilities directly or indirectly via hawkers 
(Karanja, 2003; TechnoServe Kenya, 2008; Muriuki, 2011) (Figure 5.2). Therefore, for 
the study described in this chapter it was anticipated that milk supplied by smallholder 
farmers and collected from pooling facilities could represent a useful resource for FMD 
surveillance in this endemic region.  
 
Figure 5.2. The dairy value chain in Kenya for milk supplied by smallholder and 
medium/large-scale dairy farmers. Based on data from Karanja (2003); TechnoServe 
Kenya (2008); Muriuki (2011). Adapted from Recheis (2019). 
 
The aim of this study was therefore to (i) validate the use of milk collected from pooling 
facilities as a sample matrix for FMDV detection and characterisation and (ii) assess 
the usefulness of pooled milk as a simple, non-invasive alternative for FMD surveillance 
in Kenya whilst improving our knowledge on milk production and selling trends. To 
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achieve this, results obtained by FMDV rRT-PCR of milk samples collected from pooling 
facilities were tested for correlation with reports of clinical disease from surveys of 
smallholder farmers. 
 
5.3  Materials and Methods 
5.3.1 Study area and population 
The study area is outlined by Nyaguthii et al. (2019). Briefly, the study area consisted 
of neighbouring catchment areas of five milk pooling facilities that were recruited for 
sample collection, located within Molo, Njoro and Rongai sub-counties of Nakuru 
County, Kenya (Figure 5.3). This area was selected due to the large numbers of FMD-
susceptible livestock present, regular outbreaks of FMD, and the presence of a large 
number of smallholder dairy farmers. The milk pooling facilities were approached and 
informed consent acquired prior to participation in the study. Catchment areas were 
constructed with the guidance of facility managers using Google Earth (Google Inc., 
USA), and as some of the catchment areas bordered or overlapped each other, a single 
spatial polygon layer was created using QGIS version 2.18.10 (QGIS Development 
Team, Las Palmas, USA) to define the entire study area (Figure 5.3).  
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Figure 5.3 Map of the study area located in Molo, Rongai and Njoro sub-counties of 
Nakuru County, Kenya. Capitalised letters indicate the location of each milk pooling 
facility (A-E). Catchment areas for each facility are colour coded. Catchment area D 
overlaps that of B. Additionally, catchment area E overlays C. The survey area is 
bordered with a dashed black line, and the white area indicates parts of the study area 
that were not within the catchment areas of any of the milk pooling facilities. Red 
triangles indicate the locations of smallholder farms where FMD was reported during 
Survey 2 (see section 5.3.3). 
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5.3.2 Study objectives 
The primary goal of the study was the detection of viral RNA by rRT-PCR in pooled milk 
samples collected from the milk pooling facilities described above to be compared with 
the presence of clinical FMD (as reported by smallholder farmers) above a defined 
threshold in the entire study area. In order to achieve this objective, two concurrent 
studies were performed: 
(i) Repeat cross-sectional surveys of smallholder dairy farmers - to determine FMD 
incidence in the entire study area, and improve knowledge on milk production and 
selling trends in the catchment areas of the five milk pooling facilities. 
(ii) The collection of pooled milk samples from the five milk pooling facilities, at 45 
weekly time points - for subsequent FMDV detection by rRT-PCR. 
 
5.3.3 Cross-sectional surveys for clinical disease 
Three cross-sectional smallholder farmer surveys (S) were carried out for the study in 
this chapter.  
For all surveys the eligibility criteria for the study population to be interviewed was 
smallholder dairy farmers described as those that owned at least one, but no more than 
fifty dairy cattle, and had cattle located within the premises. A systematic set of spatial 
points was randomly generated within the study area polygon using QGIS version 
2.18.10 (QGIS Development Team, Las Palmas, USA). During the field surveys, the 
closest smallholder dairy farm to a randomly generated coordinate that fitted the 
eligibility criteria was surveyed. This was considered the optimal approach in the 
absence of a sampling frame or recent census data (with the last being done in 2009). 
The limitation of this approach is the assumption that smallholder farmers were evenly 
distributed throughout the study area. The spatial coordinates of surveyed farms were 
assigned to a facility catchment area using ArcGIS version 10.6.1 (Environmental 
Systems Research Institute, Inc.) based on approximate descriptions of the catchment 
areas from facility managers (Figure 5.3).  Questionnaire data were collected using the 
EpiCollect+ mobile phone application (Aanensen et al., 2009). 
Survey 1 (S1) was a baseline survey conducted between 16th November and 1st 
December 2016 to provide information on herd size, milk production and milk sales 
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only, as results on FMD clinical incidence from this survey do not correlate with milk 
sampling periods. This survey is described in more detail (including sample size 
calculations) by Nyaguthii et al., (2019) (see Appendix III, Figure 8.2). Briefly, based on 
an estimated prevalence of 15%, a total of 237 GPS coordinates were assigned, which 
included accounting for non-responsiveness and the potential inaccessibility of some 
farms. 
Two subsequent smallholder farmer surveys (S2 and S3) were carried out during 23rd 
- 29th March 2017 (S2) and 20th - 26th September 2017 (S3), to provide further 
information on herd size, and the temporal trends of milk production and milk sales 
throughout the study period. During S2 and S3 farmers were asked how many cattle 
they owned, how many were lactating, how much milk their cows produced, how much 
milk they sold, and where they sold it (e.g. neighbours, ID of pooling facility). The full 
questionnaire is included in Appendix III, Figure 8.3. Additionally, epidemiological 
information was also obtained, including determination of the FMD clinical incidence 
in the study area since the previous survey. Farmers were asked if they had observed 
FMD on their farm sequentially since the time of the last survey (i.e. since S1 for S2, and 
since S2 for S3), and to provide an indication of the time of the outbreak (either the 
first half or second half of the month). This allowed FMD household-level clinical 
incidence to be estimated in two-week blocks of time (see statistical analysis section 
for further details). The case definition for FMD was defined as farmers observing at 
least two of the clinical signs listed by the African Union – Inter African Bureau for 
Animal Resources (AU-IBAR, 2014) in at least one of their animals. Due to a limitation 
on resources, S2 and S3 surveys were powered to detect a threshold household-level 
FMD incidence of 2.5% based on perfect sensitivity and specificity, a 95% confidence 
interval and an infinite study population. Based on these parameters, using the online 
epidemiological calculator EpiTools (http://epitools.ausvet.com.au) (Sergeant, 2019), 
the required number of households for each survey was 120. Consequently, 120 spatial 
points were randomly generated within the study area for each survey, as described 
above.  
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5.3.4 Pooled milk samples 
Milk samples were collected once per week for 45 weeks (16th November 2016 – 20th 
September 2017) from each of the five recruited milk pooling facilities (denoted A – E). 
Milk was collected in 15 mL sterile Falcon tubes directly from the pooling tank for 
facilities A and B (Figure 5.4). A pooling tank was either not available or in use for 
facilities C, D and E. and so milk was pooled into 50 litre cans (<25 cans per facility). 
Therefore, to obtain a representative milk sample at these facilities, 3 mL of milk was 
taken from each can, pooled in a jug, and mixed. A 15 mL aliquot was then taken (Figure 
5.4). At each collection the total volume of milk in the tank/cans, and the number of 
farmers contributing was recorded. Sample collection was organised so that one 
person could visit all facilities within a few hours. Immediately upon collection, all milk 
samples were stored on ice during transportation to a local -20oC storage facility that 
was equipped with a temperature monitor.  Milk samples were shipped on dry ice to 
The Pirbright Institute (TPI) for subsequent laboratory analysis. Additionally, at the 
time of milk sample collection, information was obtained from the pooling facility 
regarding the tank volume and number of farmers supplying milk.  
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(i)    (ii) 
  
(iii) (iv) (v)  
   
 
Figure 5.4 Milk sample collection from tanks (i, ii, iii) and 50L cans (iv, v) at milk 
pooling facilities in Nakuru County, Kenya.  
 
5.3.5 Laboratory testing of pooled milk samples 
RNA extraction and the pan-serotypic rRT-PCR assay were carried out in duplicate on 
all pooled milk samples using an optimised method as previously described (Armson 
et al., 2018, see Chapter 2). Briefly, RNA was extracted from whole milk samples using 
the MagMAX™ Pathogen RNA/DNA Kit (Applied Biosystems®) on a MagMAX™ Express 
96 Extraction Robot (Applied Biosystems®). rRT-PCR assays were performed using 
the reagents, parameters and thermal cycling conditions previously reported (Shaw et 
al., 2007) , with primers and probes targeting the conserved 3D region of the FMDV 
genome (Callahan et al., 2002). Any milk sample with a CT value of ≤ 50 was considered 
positive, and was subsequently tested by the East Africa (EA) typing rRT-PCR assays 
[O, A, Southern African Territories (SAT) 1 and SAT 2]. These assays were designed to 
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detect FMDV lineages currently circulating in East Africa, namely: topotype EA-2 and 
EA-4 (serotype O); topotype AFRICA, lineage G-I (serotype A); topotype I (NWZ) 
(serotype SAT 1); and topotype IV (serotype SAT 2) (Bachanek-Bankowska et al., 
2016). However, the fluorophores used on each probe were modified to: A – Cy5, SAT 
1 – JOETM, SAT 2 – TAMRATM. This modification does not affect the sensitivity of the 
rRT-PCR assays. Positive samples for the EA rRT-PCR typing assays were also defined 
as those with a CT value of ≤ 50. 
FMDV cell culture isolates (isolated once in primary bovine thyroid [BTY] cells) were 
obtained from archival stocks held in the FAO/OIE World Reference Laboratory for 
foot-and-mouth disease repository (WRLFMD), TPI, UK. Cell culture isolates 
O/SAU/1/2016, O/TAN/39/2012, A/TAN/6/2013, SAT1/KEN/72/2010, and 
SAT2/TAN/19/2012 were used to prepare positive control material for the pan-
serotypic and EA-O, EA-A, EA-SAT 1 and EA-SAT 2 rRT-PCR assays, respectively, using 
a 10-2 dilution spiked into unpasteurised whole milk from Jersey cattle. Two negative 
extraction controls consisting of unpasteurised whole milk were also included on each 
plate. 
 
5.3.6 Statistical analysis 
Descriptive and statistical analyses were carried out using R 3.5.3 (R Core Team, 2019) 
within RStudio IDE (RStudio Team, 2019). Paired t-tests were performed to compare 
information on milk yield and milk supply data between each survey.  
Analyses tested the degree of association between the incidence of clinical FMD in the 
entire study area (either above or below the 2.5% household-level FMD incidence 
threshold) and the rRT-PCR testing, both at the study area level and within the 
individual milk pooling facility catchment area level. Mixed effect logistic regression 
analysis was performed including the milk pooling facility variable as a random effect 
on the intercept. This was to examine associations between the binary outcome of the 
rRT-PCR for weekly testing of the pooled milk samples in the entire study area (i.e. 
FMDV RNA detected yes/no), and the following explanatory variables: (1) clinical FMD 
incidence, (2) tank volume, (3) number of farmers contributing to the facility, (4) the 
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average number of adult female cows per farm, (5) the percentage of famers selling to 
a milk pooling facility, and (6) the average milk yield per cow per day. Variables 2 and 
3 utilised weekly data collected from the pooling facility at the time of milk sampling, 
using increments of 1000L for tank volume (variable 2) and 100 for the number of 
farmers contributing to the facility (variable 3). For FMD incidence (variable 1), 
farmers were asked if they observed FMD on their farm, and when it occurred (in which 
half of the month) to create a binary variable. This was applied to each week of that 
half month, to enable comparison with the weekly rRT-PCR of pooled milk (i.e. if FMD 
was identified on a farm in the second half of January, both weeks in this half month 
period were assigned as positive for clinical FMD). Variables 4, 5 and 6 utilised data 
from smallholder farmer surveys, so there were only three data points for weeks 3 (S1), 
20 (S2) and 45 (S3). Therefore, for each variable, data points for the unrecorded weeks 
were predicted by linear interpolation. A backward stepwise regression was 
performed to fit a final multivariate model, based on the results of a likelihood ratio 
tests to remove variables with a p value higher than 0.05. 
 
5.4  Results 
5.4.1 Pooled milk 
5.4.1.1 Milk supply to pooling facilities 
The average volume of milk recorded weekly in the tanks/cans over the entire study 
period was 3019.0, 1469.0, 237.5, 473.1 and 176.5 litres for milk pooling facilities A, B, 
C, D, and E, respectively. Variabilities in milk supply were observed over the study 
period, as shown in Figure 5.5 and Table 5.1. This was likely influenced by the number 
of farmers contributing to the milk pools, which also varied with a similar pattern. 
Results for individual milk pooling facilities are shown in Appendix III (Figures 8.4 and 
8.5). The average number of farmers contributing milk to A, B, C, D, and E was 915 
(range [min-max]: 450 – 1500), 29 (17 – 50), 25 (10 - 60), 42 (11 – 57) and 22 (10 - 
33), respectively. The average volume of milk sold to a pooling facility per farmer was 
14.1 litres (range [min-max]: 0.0 – 55.0) for the entire study area during the study 
period. 
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Figure 5.5 Temporal trend of the total volume of milk and the total number of farmers 
contributing to all milk pooling facilities on the dates sampled (week 1 – 16/11/2016, 
week 45 – 20/09/2017). 
 
5.4.1.2 FMDV rRT-PCR results of pooled milk 
A total of 219 pooled milk samples were collected from five facilities and tested using 
the pan-serotypic rRT-PCR. Milk samples were not collected on weeks 41 - 45 from 
facility B, due to a lack of milk supply, and on week 1 for facility E, as it was recruited a 
week later than the others. FMDV RNA genome was detected in 9/219 (4.11%) milk 
samples, 6 samples from facility A, and 1 sample from each of facilities B, C and D (mean 
CT value: 40.57, range [min-max]: 36.15 – 46.74) (Figure 5.6). Additionally, 3/9 
samples (collected at facility A) with the strongest CT values (<39) were also positive 
by the EA SAT 1 rRT-PCR typing assay. No other serotypes were detected by the EA 
rRT-PCR typing assays in the positive milk samples. The detection of SAT 1 in milk was 
concordant with results from clinical lesion material collected within the study area on 
the 27/01/2017 and submitted to the WRLFMD for confirmatory diagnostics, 
sequencing and phylogenetic analyses (WRLFMD, 2017), although these positive milk 
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samples and the clinical sample were collected from different catchment areas (A and 
D respectively).   
 
 
Figure 5.6 (A) Pan serotypic rRT-PCR CT values from pooled milk samples collected 
from milk pooling facilities A, B, C, D and E in Nakuru County, Kenya, over the 45-week 
study period. Points with a grey centre represent samples that were also positive by 
the SAT 1 serotype-specific assay (CT value displayed is for the pan-serotypic rRT-PCR 
assay). (B) Black squares indicate time points of smallholder farmer surveys 1, 2 and 
3. Grey arrows indicate the time period for which FMD incidence questions where 
based for each survey. Grey shading indicates time points where the FMD incidence 
was ≥2.5% in the entire study area (as reported by smallholder farmers during the 
household surveys). 
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5.4.2 Cross-sectional surveys 
Descriptive data from each survey is detailed in Table 5.1 for the entire study area, and 
also for the catchment areas of the individual milk pooling facilities. The number of 
smallholder farmers that took part in S1, S2 and S3 was 220, 117 and 119, respectively. 
Due to compilation of a combined catchment area and randomisation of the spatial 
coordinates generated for surveying smallholder farms throughout the study area, 
some farms were located outside the boundaries of the individual catchment areas of 
any milk pooling facilities (Figure 5.3). Therefore, data from 47, 15, and 18 smallholder 
farms (for S1, S2 and S3, respectively) were not included in the descriptive data for 
individual catchment areas, and only included in the descriptive data and regression 
analysis generalised to the entire study area (Table 5.1). Due to the overlap of some of 
the catchment areas, some farms were also included in the analysis for more than one 
individual catchment area. 
The number of farmers in the entire study area that reported FMD on their farm during 
the 45-week study period was 4/456 (0.88%). All of the reported cases of FMD were 
in S2, when 4/117 (3.42%) farmers reported disease in their animals during either 
January or February (weeks 8-15), representing a household level incidence above 
2.5% during those times (Figure 5.6).  Additionally, reactive FMD vaccination was 
reported by farmers during the study period, where 48.7% of farmers interviewed 
reported vaccination of their cattle during S2, when there were reports of FMD in the 
study area (Table 5.1). During S3, there were no reports of FMD vaccination. 
The average volume of milk yield daily per farm was higher for S1 (11.0 litres, 95% CI 
9.0 – 13.1, p = 0.117) and S3 (13.8 litres, 95% CI 11.1 – 16.5, p = 0.003) compared to S2 
(8.9 litres, 95% CI 7.0 – 10.7), consistent with the milk supply trends to facilities and is 
likely related to a prolonged drought that took place during this time (Figure 5.5). For 
the entire study area, the largest percentage of farmers that sold to a facility at any time 
during the study period was 25.5% (S1), which was found to be lower during the 
subsequent surveys (S2 12.0%, p = 0.04; S3 15.1%, p = 0.20). The same pattern was 
observed for the individual catchment areas, where the largest number of farmers 
contributing at any time was in catchment area B (47.5%) recorded in S1. In the 
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catchment area of facility E none of the farms surveyed sold their milk to a pooling 
facility throughout the study period. 
 
5.4.3 Correlation between FMDV RNA in milk samples from all pooling 
facilities, and clinical FMD in the entire study area. 
Results from the rRT-PCR were cross-tabulated with the household-level FMD clinical 
incidence in the entire study area (where FMD incidence above the 2.5% threshold was 
defined as the gold standard) (Table 5.2). As each parameter was measured in different 
time periods (i.e. pooled milk was collected weekly, whereas the FMD incidence was 
recorded in half-month increments), half-month time periods were employed. 
Consequently, a binary variable was created for the results of the rRT-PCR where a 
half-month period was assigned as positive if there was a positive rRT-PCR result in at 
least one week of that period. Therefore, by using the half-month periods and taking 
the clinical incidence as reported by farmers in the whole study area as the gold 
standard, the pooled milk surveillance system had a sensitivity of 100% (95% CI 51.0% 
– 100%) and specificity of 70.6% (95% CI 46.9% - 86.7%) (Table 5.2). FMDV RNA was 
identified in four pooled milk samples collected during the period from January to 
February 2017 (weeks 8-15) when the clinical incidence at household level across the 
entire study area was ≥2.5% (3.42%) (Figure 5.6).  There were also instances where 
FMDV RNA was detected in the milk samples, but there were no corresponding reports 
by farmers (i.e. the household-level incidence of FMD was not above 2.5%).  
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Table 5.2 Comparison of the FMDV pan-serotypic rRT-PCR results of samples from all 
milk pooling facilities, with FMD incidence by farmer reports for the entire study area. 
 
FMD incidence ≥ 2.5%  
Yes No Total 
Pan-serotypic rRT-PCR of 
pooled milk samples 
 Positive† 4 5 9 
 Negative 0 12 12 
 Total 4 17 21 
Half-month periods were assigned to the results of the rRT-PCR of the pooled milk and deemed 
positive if there was a positive rRT-PCR result in at least one week of that period. There were 
a total of 21 half-month periods for the duration of the study. †A positive pan-serotypic rRT-
PCR result is defined as a CT value of ≤50 in any week of the half-month time period. 
 
Both univariable analyses and the multivariable mixed effect logistic regression 
models were used to determine whether there was any association between the 
household-level incidence being above 2.5% in the entire study area and the FMD rRT-
PCR results from pooled milk, further incorporating other predictors listed in Table 
5.3. Based on the univariable analysis, there was a higher odds of observing a FMD 
positive rRT-PCR result when the clinical incidence in the whole study area was ≥2.5% 
(OR = 4.21, 95% CI = 1.02 – 17.30, p = 0.046), the volume of milk supplied to the facility 
increased (OR = 1.78 for each additional 1000 litres supplied, 95% CI = 1.25 – 2.54, p = 
0.002), and when the number of farmers contributing to the facility increased (OR = 
1.27 for each additional 100 farmers, 95% CI = 1.12 – 1.43, p < 0.001).  During 
multivariate model selection, after model simplification by removing non-significant 
terms (p > 0.05), only the number of farmers contributing to the facility (3) was 
retained as significant (OR = 1.27, 95% CI = 1.12 - 1.43, p < 0.001), and there was no 
longer any association between the household-level incidence being above 2.5% in the 
study area and the FMD rRT-PCR result in the pooled milk.  
Univariable and multivariable logistic regression analysis was also carried out using 
the data for each individual catchment area only (data not shown). The only catchment 
area with any significant associations was for facility A, where there was a higher odds 
of observing an FMD positive rRT-PCR result when there was an increase in the 
number of farmers contributing to the tank (OR = 1.38 for each additional 100 farmers, 
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95% CI = 1.03 – 1.85, p = 0.031). Significant associations were not observed for any of 
the other catchment areas. 
 
Table 5.3 Univariate mixed effect logistic regression analysis for association with a 
positive FMD rRT-PCR result for the total study area. 
Variable 
Type of 
variable 
Odds Ratio (95% CI) P value 
1. FMD incidence  Categorical 4.21 (1.02 - 17.31) 0.046 
2. Tank volume (per 1000 litres) Continuous 1.78 (1.25 - 2.54) 0.002 
3. Number of farmers contributing to 
the facility (per 100 farmers) 
Continuous 1.27 (1.12 - 1.43) < 0.001 
4. Average number of adult female 
cows per farm 
Continuous 0.99 (0.26 - 3.78) 0.990 
5. Percentage of farmers selling to a 
milk pooling facility 
Continuous 1.04 (0.96 - 1.11) 0.358 
6. Average milk yield per cow  Continuous 0.48 (0.15 - 1.49) 0.203 
 
re  
r 
5.5  Discussion 
Previous studies have demonstrated the potential of using milk from individual 
animals as an alternative sample type for FMDV detection and surveillance (Armson et 
al., 2019, Chapter 3), and that it is possible to detect FMDV in highly diluted milk 
samples from individual clinical cases (Armson et al., 2018, Chapter 2). This pilot study 
aimed to expand on this work and explore the use of milk collected from pooling 
facilities supplied by smallholder farmers as a simple, non-invasive alternative sample 
matrix for the surveillance of FMD. In order to achieve this, the household-level 
incidence of clinical disease was compared with FMDV RNA detection by rRT-PCR from 
pooled milk facilities in an endemic region of Kenya.  
According to data collected by milk pooling facilities, the number of farmers 
contributing milk fluctuated throughout the study period, with a similar pattern 
observed for the volume of milk supplied. There was a decrease in the output of milk 
supplied to all facilities in or after March 2017, likely due to the effects of a drought 
that occurred in the first quarter of 2017 (World Food Programme Kenya, 2017). This 
corresponded with data collected from the smallholder farmer surveys, demonstrating 
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the lowest milk yield per farmer, and the lowest percentage of farmers supplying milk 
to a facility (12.0% for the entire study area) occurring at this time. The largest 
percentage of farmers that supplied milk to a facility at any time was 25.5% for the 
entire study area, or 47.5% for an individual catchment area.  
FMDV RNA was detected in milk samples collected from pooling facilities with tanks 
containing up to 5000 litres. Additionally, typing assays confirmed the presence of SAT 
1, which was concurrent with reports from clinical samples collected from reported 
outbreaks for confirmatory diagnostics (WRLFMD, 2017). The average CT values 
obtained for the positive milk samples were high (>36), likely due to the dilution factor 
of the samples, as some were collected from large pools (up to 5000 litres). This 
corresponds with previous limit of detection studies (Armson et al., 2018) that 
predicted similar CT values (>30) for pools of this size. This study observed that an 
increase in tank volume was correlated with an increase in the number of farmers 
contributing milk, and consequently it is probable that the likelihood of an FMD 
infected cow that supplied milk to one of these pools is increased, contrary to what 
might be expected based on rRT-PCR test sensitivity. Univariable analysis supported 
this, suggesting a positive association between an FMD positive rRT-PCR result in the 
pooled milk and the number of farmers contributing to the facility, and also with the 
volume of milk in the tank/cans at the time of sample collection. Based on these results, 
the likelihood of FMDV detection, and therefore surveillance efficiency may be 
optimised by targeting sampling on large milk pooling facilities that have milk supplied 
from a large percentage of farmers in their catchment area. 
During the study period, throughout the entire study area, there were four reports of 
FMD in the smallholder farmer surveys in facility catchment areas A and C, all during 
January and February 2017. As there was at least one FMD report in each half-month 
period during these two months, the household-level incidence in the whole of the 
study area was significantly ≥2.5%. This correlated with FMDV detected in a milk 
sample collected from at least one of the facilities in the study area in each of these half-
month periods, therefore it could be assumed that the pooled milk surveillance system 
might be able to detect FMDV when the household-level incidence is ≥2.5%. This was 
supported by univariable analysis which indicated a positive association between an 
FMD positive rRT-PCR result when the clinical incidence in the entire study area was 
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≥2.5%. Although the sensitivity was 100% when using clinical reports from farmers as 
the gold standard, the authors acknowledge the limitations of using these half-month 
time steps for this comparative analysis. These half-month time periods for FMD 
reporting were used to simplify data recording which was based on farmer recall in the 
absence of written records.  
FMDV RNA was also detected in five pooled milk samples that were collected when 
there were no clinical FMD reports. As there were negative extraction controls and a 
high number of ‘negative’ samples where no amplification was observed on the rRT-
PCR assay, it is unlikely that non-specific amplification of other template (e.g. from 
other organisms) present in milk occurred. The laboratory methodology used in this 
study has been shown to be highly specific, however, inter/intra-assay contamination 
was observed in the negative cohort tested in Chapter 4 and therefore laboratory 
contamination cannot be excluded, even though measures were implemented to 
minimise the likelihood of this occurring. There may also be further alternative 
explanations which are discussed below. 
It is possible that the surveys conducted for this study were underpowered, due to 
limited resources available, and therefore the clinical disease threshold of 2.5% was 
too high to robustly assess specificity. In future studies, a more precise evaluation of 
sensitivity and specificity of the pooled milk detection system may be achieved if 
surveys are powered to detect a lower threshold FMD incidence. Farmers in this region 
of Kenya had good knowledge of FMD (Nyaguthii et al., 2019), which was demonstrated 
by the descriptions of clinical signs by farmers corresponding with the case definition. 
However, it is possible that mild clinical signs or sub-clinical infection could reduce the 
likelihood of farmer reporting and provide explanation for instances where there were 
positive milk samples but no farmer reports of disease. Further investigation is 
required to determine the incidence of sub-clinically infected animals in this region, for 
example by using serological surveys, and whether virus particles may be present in 
the milk of sub-clinically infected animals (Sutmoller and Casas, 2002). Further 
investigation is also required into the impact of vaccination on FMDV excretion in milk. 
During the study period, vaccination was carried out in response to an outbreak. 
Whether vaccination in these herds may increase the likelihood of sub-clinical infection 
is unknown, although there have been reports of sub-clinical infection in vaccinated 
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animals (Donaldson and Kitching, 1989; Hutber et al., 1999; Lyons et al., 2017), and 
virus excretion in the milk of apparently healthy vaccinated animals (Ahmed et al., 
2017).   
Of the milk samples positive by the pan-serotypic rRT-PCR assay, 3 were identified as 
SAT 1, but no amplification was observed in any of the EA typing rRT-PCR assays for 
the other samples. Outbreaks due to the circulation of type O outside of the study area 
were reported in August 2017 (WRLFMD, 2017). It is possible that these samples were 
at the limit of detection for the EA-O rRT-PCR typing assay, as this assay has been 
shown to have a slightly reduced analytical sensitivity compared with the pan-
serotypic rRT-PCR assay (Bachanek-Bankowska et al., 2016). It is also possible that 
another lineage of FMDV was also circulating in the region that cannot be detected by 
the EA typing assays used. 
Several methodological issues arose during this study that may have affected the 
results of FMD clinical incidence and therefore the sensitivity and specificity 
estimations of the pooled milk surveillance system. The original aim of the study was 
to undertake smallholder farmer surveys within the catchment areas of the milk 
pooling facilities. Catchment areas were approximated by facility managers, and as 
some of the catchment areas either bordered or overlapped each other, a single spatial 
polygon was created to define the whole study area. It is unclear how precise these 
catchment areas were, as in some cases farmers from one catchment area reported 
supplying milk to a neighbouring catchment area. This may explain cases where there 
was a positive report of FMD by a farmer in one catchment area, but there were no rRT-
PCR positive milk samples from the area’s pooling facility in that time period (for 
example catchment area C). Additionally, some of the surveyed farms were located in 
more than one catchment area (due to overlap of the catchment areas), or none of the 
catchment areas (due to being between catchment areas), which may have led to bias 
in the descriptive data and analysis. Due to the absence of an available sampling frame, 
it was assumed that smallholder farmers were evenly distributed throughout the 
whole study area. This was a reasonable assumption based on the knowledge of the 
authors and animal health assistants in the area, although any disparity may have led 
to an inaccurate estimation of household-level incidence. In addition, the intention of 
the study was to recruit milk pooling facilities that stored milk in bulk tanks for the 
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collection of milk samples. However, three of the facilities either did not have, or were 
not using their bulk tanks, and instead pooled milk in 50 litre cans. The reasons for not 
using an existing bulk-tank included a low milk supply and not being fully functional. 
Consequently, a small volume of milk from each can was pooled and mixed in order to 
obtain a sample representative of the whole milk pool from this facility. The authors 
recognise the limitations in this approach and further sampling methodologies for 
facilities using cans should be explored.  
This pilot study describes the rRT-PCR testing of milk samples from milk pooling 
facilities as a simple surveillance approach for FMD in this endemic region of Kenya. 
Based on data from the entire study area, by utilising the weekly collection of milk 
samples, it was possible to detect and type FMDV RNA by rRT-PCR from milk pools of 
up to 5000 litres, when the FMD clinical incidence was ≥2.5%, and when fewer than 
25% of farmers were selling their milk to these pooling facilities. Based on the 
encouraging results obtained in this study, further investigation is required to obtain a 
more precise correlation of household-level incidence with pooled milk sample results, 
to fully assess the usefulness of this novel surveillance approach. With more resources 
available, this could be achieved by combining clinical surveys of FMD infection at the 
individual animal level and serological surveys with sufficient statistical powers to 
detect a low incidence of infection or disease. Additionally, the collection of pooled milk 
samples should be focussed on larger facilities, which have a large number of 
contributing farmers from the surrounding area. Furthermore, pooling systems higher 
up the dairy production chain should also be explored as a target for FMD surveillance, 
although the possible reduced ability in detecting FMDV RNA from milk samples after 
pasteurisation. Follow-on studies should also investigate the establishment of sentinel 
systems in the epidemiological surveillance of FMD, and how geographical limits that 
may encompass different farming practices may affect this solution.  
In conclusion, this pilot study highlights that this novel, simple surveillance approach 
has the potential to address some of the well-recognised limitations of more traditional 
surveillance methods in resource-limited countries where there are a high number of 
smallholder dairy farmers, and to improve the capacity for surveillance which could 
contribute to informing and evaluating disease control policies in these endemic 
regions.
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CHAPTER 6 
 
Pooled milk for foot-and-mouth disease 
surveillance on large-scale dairy farms in 
endemic settings 
 
Data presented in this chapter have been submitted as an original research article to 
Frontiers in Veterinary Science (January 2020).  
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6.1 Summary 
Pooled milk has been exploited for the surveillance of several diseases of livestock. 
Previous studies have demonstrated that foot-and-mouth disease virus (FMDV) RNA 
can be detected in the milk of infected animals at high dilutions, suggesting that the 
collection of pooled milk samples from large-scale dairy farms could be used to 
enhance FMD surveillance. The aim of this study was to evaluate pooled milk collected 
via proportional in-line samplers for FMDV surveillance on a regularly vaccinated, 
large-scale dairy farm in Saudi Arabia. During the six-month sampling period, the farm 
experienced two FMD outbreaks caused by strains within the A/ASIA/G-VII and O/ME-
SA/Ind-2001d lineages. FMDV RNA was detected in 5.7% of the 732 pooled milk 
samples, and typing information was concordant with viral isolates obtained from 
animals with clinical disease. The FMDV positive milk samples were temporally 
clustered around reports of new clinical cases, but with a wider distribution. To 
investigate this further, a model was established to predict CT values using individual 
cattle movement data, clinical disease records and virus excretion data from previous 
experimental studies. These predictions explained some of the instances where 
positive results by rRT-PCR were observed, but no new clinical cases and suggested 
that subclinical infection occurred during the study period. The results from this study 
indicate that testing pooled milk by rRT-PCR may be valuable for FMD surveillance and 
suggest probable subclinical virus circulation in vaccinated herds that may play a role 
in the epidemiology of FMD in vaccinated populations. Further studies are required to 
investigate the effect of vaccination on the detection of FMDV in milk and to evaluate 
more representative sampling methods. 
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6.2  Introduction 
Milk has been exploited for the surveillance of several pathogens of livestock including 
bovine viral diarrhoea virus (Renshaw et al., 2000a; Hill et al., 2010), Schmallenburg 
virus (Daly et al., 2015), Coxiella burnetti (Kim et al., 2005), bovine respiratory 
syncytial virus (BRSV) (Elvander et al., 1995), and neospora (González-Warleta et al., 
2011). The use of pooled milk samples has also been validated as a rapid, cost-effective 
approach for the routine surveillance of diseases such as brucellosis (DEFRA, 2015a) 
and mastitis caused by Mycoplasma spp (APHIS, 2008). 
Previous experiments have shown that the mammary gland is an organ that is highly 
susceptible to foot-and-mouth disease virus (FMDV) replication, and FMDV can be 
detected in milk from experimentally infected animals before, during and after the 
appearance of clinical signs (Nardelli et al., 1968; Burrows et al., 1971; Blackwell and 
McKercher, 1982; Reid et al., 2006; Armson et al., 2018, see Chapter 2). Additionally, 
FMDV can be detected and typed by real-time reverse transcription polymerase chain 
reaction (rRT-PCR) assays in milk from naturally infected cattle in outbreak and 
endemic scenarios (Armson et al., 2018, 2019, see Chapters 2 and 3). Previous studies 
(Reid et al., 2006; Armson et al., 2018, see Chapter 2) have suggested that it could be 
possible to identify one acutely-infected milking cow in a typical-sized dairy herd 
(100–1000 individuals) using milk from bulk tanks or milk tankers, based on the 
detection of FMDV RNA in highly diluted milk samples from infected cattle. Simulation 
modelling using these data (Reid et al., 2006; Thurmond and Perez, 2006; Garner et al., 
2016) support the requirement for further research to assess the use of pooled milk as 
a useful tool to enhance FMD surveillance.  
Sampling of milk at the herd level could potentially offer a representative framework 
for FMD surveillance on large-scale dairy farms in endemic countries. Indeed, milk is 
routinely collected, and has several advantages over vesicular material or serum by 
being non-invasive and potentially less susceptible to selection bias in targeted (risk-
based) surveillance. For example, the use of milk does not rely on disease reporting by 
farmers or veterinary professionals, and may detect sub-clinically circulating viruses 
(Armson et al., 2019, seee Chapter 3) which may be under-represented, particularly in 
vaccinated populations (Knight-Jones et al., 2016).  
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These results motivated further studies using pooled milk from different production 
systems in endemic settings. Saudi Arabia is an FMD-endemic country in which a range 
of production systems exist, including nomadic and small-scale herds containing small 
ruminants and cattle, and large-scale dairy production systems (Asghar et al., 2016). 
Large-scale dairy farms can house up to 20,000 cattle, and often keep detailed records 
of individual cattle health, movements, milk yields and vaccination status (Hutber et 
al., 1999; Lyons et al., 2017; Gomaa Hemida et al., 2018). Recently, Saudi Arabia has 
experienced outbreaks due to viral lineages that are not normally present in this 
region, including the A/ASIA/G-VII and O/ME-SA/Ind-2001 lineages (Knowles et al., 
2015; Bachanek-Bankowska et al., 2018). These FMD outbreaks also affected large-
scale dairy farms, despite regular vaccination and strict biosecurity practices (Lyons et 
al., 2017; Gomaa Hemida et al., 2018). 
The aim of this study was therefore to validate the use of pooled milk for the 
surveillance of FMD in these large-scale production systems. The goal was to provide a 
representative model for cost-effective and efficient surveillance to rapidly detect 
infected herds during outbreaks in endemic countries. Similarities that exist in the 
production systems of FMD-free countries mean that this approach could support 
targeted/risk-based surveillance in response to an outbreak in a disease-free country. 
The specific objectives were to (i) validate the use of pooled milk collected from a large 
scale dairy farm in Saudi Arabia for the detection and characterisation of FMDV by real-
time rRT-PCR; (ii) compare the results obtained by FMDV rRT-PCR with clinical 
incidence; (iii) model the predicted CT values of pooled milk samples based on detailed 
epidemiological data available from the farm; (iv) estimate the sensitivity and 
specificity of this surveillance approach to assess the usefulness of pooled milk as a 
cost-effective, non-invasive surveillance tool. 
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6.3  Materials and Methods 
6.3.1 Study site and population 
The study site was a large-scale dairy farm located in central Saudi Arabia. The farm 
housed approximately 4,000 Holstein Friesian cattle and was organised into 
management houses (H) with lactating groups of up to 240 cows that were milked four 
times a day. The farm had a fenced outer perimeter and there were no other FMD 
susceptible livestock or wildlife present on the farm. The study population comprised 
all cattle on the farm that were in lactating groups during the study period 
(10/09/2015 to 25/02/2016). The farm had electronic recording systems for 
monitoring individual animal health and movements. Lactating cattle were vaccinated 
approximately every three months with a high potency (≥6.0 PD50), killed, aqueous 
adjuvanted (aluminium hydroxide and saponin), non-structural protein (NSP) purified 
FMD vaccine (containing O Manisa, O-3039, O-PanAsia2, A Iran-05, A Saudi-95, Asia-1 
Shamir and SAT-2 virus strains) (Aftovaxpur, Merial Animal Health) (Lyons et al., 
2017). 
In September 2015, the farm had clinical cases of FMD due to the then emerging 
A/ASIA/G-VII viral lineage (Bachanek-Bankowska et al., 2018). In February 2016, 
three months after the last clinical case (on 12/11/2015), new clinical cases were 
observed and confirmed as serotype O (ME-SA/Ind-2001d lineage), with the last 
recorded clinical case on 07/03/2016. All recording of clinical cases was done by farm 
staff supervised by veterinary surgeons employed by the farms. The resulting data 
were entered into an electronic farm recording system. FMD cases were defined by 
observation of increased salivation and any of the following additional clinical signs: 
mouth lesions, feet lesions, teat lesions, fever, reduced feed intake and lameness. The 
farm policy was to isolate new cases of FMD in a dedicated isolation facility. If the 
isolation facility was full or the number of observed cases in the group exceeded 
approximately 5%, cases remained within groups. Animals were moved from isolation 
back to the main herd either after complete recovery or when sufficiently recovered, 
depending on available space in the isolation facility. 
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6.3.2 Pooled milk sampling 
As part of routine herd health surveillance, milk samples were collected twice weekly 
using a proportional in-line milk sampler (Figure 6.1), designed to pull a representative 
sample from each house, and delivered to the farm laboratory. Throughout the study 
period (10/09/2015 to 25/02/2016), milk samples (n=732) were collected twice 
weekly (between 10/09/2015 - 03/12/2015), weekly (between 10/12/2015 – 
25/02/2016), or on an ad-hoc basis. Milk samples were collected from each 
management house containing lactating cows (n=17) and on an ad-hoc basis from two 
houses containing cows separated due to various diseases (a “sick-cow pen”). All milk 
samples were labelled with the date and house identification number and were stored 
in a freezer at -20°C until they were shipped to The Pirbright Institute (TPI, UK) for 
FMDV detection.  
 
 
Figure 6.1 Milk sample being collected by the proportional in-line sampler. Photo 
courtesy of Nick Lyons. 
 
6.3.3 Laboratory testing of pooled milk samples 
6.3.3.1 Viral isolates 
FMDV cell culture isolates (isolated once in primary bovine thyroid [BTY] cells) were 
obtained from archival stocks held in the OIE/FAO World Reference Laboratory for 
foot-and-mouth disease (WRLFMD) repository. O/SAU/1/2016 was diluted 10-2 in 
unpasteurised whole milk and used as a positive control for the pan-serotypic rRT-PCR 
assay and the serotype specific O (ME-SA/Ind-2001d lineage) rRT-PCR assay. For the 
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serotype specific A (ASIA/G-VII lineage) rRT-PCR assay, A/SAU/6/2015 was diluted 
10-4 in unpasteurised whole milk and used as a positive control. 
 
6.3.3.2 FMDV detection assays 
RNA extraction and the pan-serotypic rRT-PCR were carried out as previously 
described using an optimised method (Armson et al., 2018, see Chapter 2). Briefly, RNA 
extractions were carried out using the MagMAX™ Pathogen RNA/DNA Kit (Applied 
Biosystems®) using a sample input of 200 µL on a MagMAX™ Express 96 Extraction 
Robot (Applied Biosystems®) according to manufacturer’s instructions. VetMAX™ 
Xeno™ Internal Positive Control RNA (Applied Biosystems®) was added prior to 
extraction. Negative extraction controls consisted of unpasteurised whole milk added 
to lysis buffer. 
The pan-serotypic rRT-PCR assay was performed using the reagents, parameters and 
thermal cycling conditions previously reported (Shaw et al., 2007) with primers and 
probes described by Callahan et al. (Callahan et al., 2002). One µL per reaction of 
VetMAX™ Xeno™ Internal Positive Control LIZ™ Assay (Applied Biosystems®) was also 
included in the reaction mix. All rRT-PCR assays were performed in duplicate using an 
Applied Biosystems® 7500 Fast Real-time PCR System. Any milk sample with a CT 
value of ≤ 50 was considered positive, and was also tested in duplicate on both lineage-
specific rRT-PCR assays for A/ASIA/G-VII (Saduakassova et al., 2017) and O/ME-
SA/Ind-2001d (Knowles et al., 2015), using the reagents, parameters and thermal 
cycling conditions previously reported. Additionally, samples with amplification below 
the 0.2 fluorescence threshold (which therefore were not considered positive) by the 
pan-serotypic rRT-PCR assay (termed ‘inconclusive’ for this study) were also tested 
using the lineage specific rRT-PCR assays. The reason for this was that lower CT values 
have previously been obtained by A/ASIA/G-VII rRT-PCR assay when compared with 
values on the same samples using the pan-serotypic rRT-PCR assay (Saduakassova et 
al., 2017). 
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6.3.4 Development of a model to predict FMD virus concentrations (CT 
values) in pooled milk samples 
The CT values of pooled milk samples were predicted using information supplied by the 
farm and from the literature. These ‘predicted’ CT values were then compared with the 
‘observed’ CT values obtained by the pan-serotypic rRT-PCR assays. The values used 
for each parameter are described below. 
 
A) Equating CT value with the number of virus ‘units’  
The limit of detection of FMDV RNA in milk using the pan-serotypic rRT-PCR assay was 
based on a previous cattle challenge study (Armson et al., 2018, see Chapter 2), as this 
was the only study in the literature based on the same rRT-PCR methodology. In the 
previous study, ten-fold serial dilutions of a whole milk sample from an infected animal 
gave a limit of detection of 10-6 (Armson et al., 2018, see Chapter 2). For this study, a 
virus unit value of 1 was assigned to this last dilution at which FMDV RNA could be 
detected (i.e. 10-6) and subsequent virus unit values were assigned to each ten-fold 
dilution on a log scale (Figure 6.2). Linear regression was applied so that a CT value 
could be predicted from the fit when the total virus unit value (V) in the pooled milk 
was known.  
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Figure 6.2 Linear regression used to predict CT values from total virus unit values. Data 
is taken from limit of detection studies performed in Chapter 2 (Armson et al., 2018). 
 
B) Estimating the number of virus units excreted per cow at each stage of infection (Ui) 
Using data from the cattle challenge study performed in the same study (Armson et al., 
2018), FMDV RNA could be detected in milk by the pan-serotypic rRT-PCR assay 
between 3 to 28 days post infection (DPI), while clinical signs were first observed at 4 
DPI. As the day of infection for each cow on the large-scale farm in Saudi Arabia was 
unknown, the model assumed that the day clinical signs were first recorded was day 
[D] 0. Consequently, an excretion profile was created using the mean CT values based 
on data collected from two in-contact animals from the challenge study (Armson et al., 
2018, see Chapter 2) between D-1 to D24, subsequently referred to as the ‘stage of 
infection’ (i) (Figure 6.3). Missing values were interpolated, by retrieving values from 
the fitted line between the two nearest values. From these CT values, the virus unit 
value (U) was predicted for each stage of infection (i) using the linear regression model 
fitted in Figure 6.2. 
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Figure 6.3 Virus unit values (U) assigned to each stage of infection (i) between days -
1 and day 24, based on mean CT values of two animals in the challenge study performed 
in Chapter 2 (Armson et al., 2018).   = virus units for ‘1’ (no vaccination),  = ‘1/10’ 
virus units, and   = ‘1/100’ virus units. 
 
Previous studies have described a reduced level of virus excretion in nasal fluid, saliva, 
and oesophageal–pharyngeal fluid sample types in vaccinated versus non-vaccinated 
animals (Orsel et al., 2007; Parthiban et al., 2015; Thwiny, 2016). As the effect of 
vaccination on the duration of excretion or quantity of FMD virus in milk is unknown, 
additional factors were included to account for this possibility, as milk samples in this 
study were collected from regularly vaccinated cattle. Data from previous studies were 
therefore used to inform the model (Orsel et al., 2007; Parthiban et al., 2015; Stenfeldt 
et al., 2016; Thwiny, 2016), where significantly lower levels of viral excretion (by over 
102 copies/ml) were observed in vaccinated animals compared with unvaccinated 
animals. Consequently, in the model prediction for this study three ‘levels’ of viral 
excretion were adopted: ‘1’ as described above (no vaccination), and then tenfold 
reductions of ‘1/10’ and ‘1/100’ (Figure 6.3). In the model prediction, each (‘1’, ‘1/10’ 
and ‘1/100’) virus unit value for each stage of infection (i) was used separately to 
determine the effect this change had on the resulting CT value in the pooled milk 
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sample. Additionally, the reduction was assumed to remain constant throughout the 
course of infection (D-1 to D24). 
 
C) Determining the number of cattle at each stage of infection (Ni) per sampling date 
(t) 
Using records of the onset of clinical signs for each cow and individual movement data 
available from the farm, the number of cows at each stage of infection (Ni) per sampling 
date (t) per house was calculated. 
 
D) Determining the reduction in milk yield for infected cattle 
The only milk yield data available from the farm was the average milk yield per house 
for each sampling date. To enable simplification of the model, it was assumed that in 
each house all lactating cows produced equal volumes of milk (Mu). This was 
considered a reasonable assumption as cattle were placed into houses on the basis of 
stage of lactation.  
Due to limited studies quantifying the reduction in milk yield during FMDV infection in 
highly vaccinated cattle, original milk yield data from a large-scale Holstein-Friesian 
dairy farm in Kenya that reported a FMD outbreak in August 2012 (Lyons et al., 2015a; 
Lyons et al., 2015b) were used to inform this study. The mean milk yield from 189 cattle 
was calculated for each 5-day period during infection (D0 to D4, D5 to D9, D10 to D14, 
D15 to D19, D20 to D24) as a percentage of the mean yield before infection (‘normal 
yield’: D-10 to D-1). ANOVA and Welch two sample T-tests demonstrated a significant 
difference between D5 to D9 and normal yield (p = 0.001). Therefore, a value of 87% 
of the normal yield (Mi) was employed for each cow at stage D5-D9 of infection when 
determining the final number of virus units in a pooled milk sample.  
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E) Determining the final number of virus units in a pooled milk sample per sampling 
date (F(t)) 
Using the input parameters calculated in (A) to (D), the final number of virus units in a 
pooled milk sample per sampling date (F(t)) for each house can be calculated using the 
following equation:  
𝐹(𝑡) =
∑ 𝑀𝑖𝑈𝑖𝑁𝑖(𝑡)
24
𝑖=−1
∑ 𝑀𝑖𝑁𝑖(𝑡)
24
𝑖=−1 +𝑀𝑈(𝐻 − ∑ 𝑁𝑖(𝑡)
24
𝑖=−1 )
 
Where: 
 Ni is the number of cows at infection stage i 
 Ui is the number of virus units excreted per cow at infection stage i 
 Mi is the amount of milk produced by a cow in infection stage i 
 MU is the amount of milk produced by a healthy cow 
 H is the total number of cows contributing to the milk pool 
 
F) Predicting CT values for each sampling date (t) 
Using the value of F(t) for each house the CT value was predicted from the linear 
regression model fitted in (A) (Figure 6.2). 
 
6.3.5 Statistical analysis 
All data analyses were performed using R 3.5.3 (R Core Team, 2019) within RStudio 
IDE (RStudio Team, 2019). In order to compare the ‘observed’ CT values obtained from 
pooled milk samples with ‘predicted’ CT values, values were plotted for visual 
comparison. For each sampling date (t), ‘predicted’ and ‘observed’ CT values were 
assigned a 0 or 1 for a negative (CT of >50) or positive (CT of ≤50) result, respectively. 
Additional diagnostic cut-off CT values of 45 and 40 were also investigated. 
Contingency tables were constructed for each house, and for all houses combined using 
each virus unit value level (i.e. ‘1’, ‘1/10’ and ‘1/100’), for which sensitivity, specificity, 
and the Cohen’s Kappa statistic (κ) (Landis and Koch, 1977) were calculated.  
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6.4 Results 
6.4.1 Epidemiology of the FMD outbreak 
Throughout the study period, the mean number of lactating cows in each house was 
227 (median 237, range 44-240). Details of the farm and clinical incidence for the two 
FMD outbreaks are shown in Table 6.1. Based on the total number of cattle present on 
the farm, the overall incidence risk was 2.8% and 0.87% for the two separate outbreaks 
beginning on 02/09/2015 and 15/02/2016, respectively. The epidemic curves with 
corresponding sampling periods are shown in Figure 6.4c. Based on movement 
records, cows affected with suspected FMD were moved into a quarantine house at the 
start of the outbreak where they continued to be milked (if possible) until they had 
recovered sufficiently to move back to the same or an alternative lactating house. When 
quarantine houses reached maximum occupancy or the house level incidence exceeded 
5%, this practice was discontinued.   
 
Table 6.1. Summary of outbreak data on the large-scale dairy farm in Saudi Arabia. 
Variable  
Total number of lactating cattle during study 
period (approx.) 
4,000 
Number of lactating houses 17 
Number of lactating animals per housea 
(mean, median, range) 
227 (237, 44-240) 
Number of lactating houses affected (%) 10 (58.8)b 4 (23.5)c 
Number of clinical cases of FMDd 107b 33c 
Overall incidence risk (number of cases/total 
livestock on farm) (%) 
2.8b 0.87c 
Date of index case 02/09/2015b 15/02/2016c 
a Calculated on milk sampling days throughout the study period. b A/ASIA/GVII outbreak.                         
c O/ME-SA/Ind-2001 outbreak. Outbreaks were determined according to reports by WRLFMD.  
d Case definition used by the farm for FMD was any animal seen salivating with any of the 
following additional clinical signs: mouth lesions, feet lesions, teat lesions, fever, reduced feed 
intake and lameness. 
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Figure 6.4 (A) CT values from the pan-serotypic rRT-PCR assay ( ) for pooled milk 
samples collected from 19 lactating houses in the large-scale dairy farm in Saudi Arabia 
throughout the study period (n=732). (B) CT values for each lineage-specific rRT-PCR 
assay for samples that tested positive (CT ≤ 50), or where very low amplification (below 
the threshold) was observed, in the pan-serotypic rRT-PCR assay. : A/ASIA/G-VII. 
: O/ME-SA/Ind-2001d. : Sample could not be typed. (C) Epidemic curves of FMD 
outbreaks on the farm. Stars represent dates where clinical samples (vesicular 
epithelium/fluid) were collected and submitted to the World Reference Laboratory for 
Foot-and-mouth Disease (WRLFMD), and reported as : A/ASIA/G-VII, : O/ME-
SA/Ind-2001d. 
 
6.4.2 Pooled milk 
During the study period 732 milk samples were collected of which 42 (5.7%) were 
positive using the pan-serotypic rRT-PCR (Table 6.2, Figure 6.4A). Of the 42 positive 
samples and those considered ‘inconclusive’ due to amplification below the 0.2 
fluorescence threshold (n=22), 32.8% were positive by the A/ASIA/G-VII rRT-PCR 
assay, and 9.4% were positive by the O/ME-SA/Ind-2001d rRT-PCR assay (Figure 6.4B). 
Additionally, 3.1% of the samples tested on the lineage-specific assays were positive 
for both lineages. Of the samples that were positive on the pan-serotypic rRT-PCR 
assay, 19/42 (45.2%) could not be typed. Of the samples that were inconclusive on the 
pan-serotypic assay, 3/22 (13.6%) were positive for A/ASIA/G-VII and 1/22 (4.5%) 
was positive for O/ME-SA/Ind-2001d.  
 
Table 6.2. Summary of milk sample results for all rRT-PCR assays for the large-scale 
dairy farm in Saudi Arabia. 
Variable Value 
Duration of milk sampling (weeks) 25 
Number of houses milk samples were collected from 19 
Number of pooled milk samples tested 732 
Number positivea by pan-serotypic rRT-PCR assay (%) 42 (5.7%) 
Number positivea by A/ASIA/G-VII rRT-PCR assay (%) 21/64b (32.8%) 
Number positivea by O/ME-SA/Ind-2001d rRT-PCR assay (%) 6/64b (9.4%) 
a Positive results are those with at least one well giving a CT of ≤50. b 22 samples were 
considered ‘inconclusive’ (amplification was observed below the fluorescence threshold of 0.2) 
and were therefore also tested by the lineage-specific rRT-PCR assays. 
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6.4.3 Correlation between epidemiological data and FMDV RNA in pooled 
milk 
Laboratory results from the pooled milk samples were directly compared against 
clinical data collected during the FMD outbreaks. The first period of clinical disease was 
seen in lactating cows between 02/09/2015 and 24/09/2015 (n=99), with two 
recurrences of clinical disease in a smaller number of cows in mid-October (n=1) and 
the first half of November 2015 (n=7) (Figure 6.4C). Clinical samples (vesicular 
epithelium/fluid) were collected from clinically affected animals (n=3) in September 
and October 2015, and were characterised as belonging to the A/ASIA/G-VII lineage. 
Further clinical disease was recorded at the beginning of February 2016 (n=33) and a 
clinical sample identified the strain as from the O/ME-SA/Ind-2001d lineage. Visual 
comparison of the epidemic curve and temporal representations of rRT-PCR results 
indicates some clustering of positive pooled milk samples around the occurrence of 
new clinical cases but with a wider distribution (Figure 6.4). Clustering of lineage 
A/ASIA/G-VII positive results can also be seen from the commencement of sampling to 
the end of November, concurrent with reports of this lineage from clinical samples. The 
clinical incidence in lactating cows over the whole study period was 3.6% (Table 6.1), 
while FMDV genome was detected in 5.7% of pooled milk samples (Table 6.2). A 
contingency table was constructed to determine the sensitivity (Se) and specificity (Sp) 
of the pan-serotypic rRT-PCR, using the number of new clinical cases observed on milk 
sample collection days for all houses sampled as the gold standard: Se = 42.9% (95% 
confidence interval (CI): 21.4% - 67.4%), Sp = 95.0% (95% CI: 93.1% - 96.4%) 
(Appendix IV, Figure 8.6).   
FMDV genome was detected in pooled milk in 17 out of the 19 (89.5%) sampled houses 
compared to 14/19 (73.7%) houses that reported clinical cases. Of the latter, 13 were 
PCR positive at some point during the outbreaks (Figure 6.5). Furthermore, four 
houses were positive by rRT-PCR with no recorded clinical cases at any time during the 
outbreaks. There were also eight samples taken where the rRT-PCR result was negative 
but there were new clinical cases observed on that day.  
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6.4.4 Predicting CT values in pooled milk  
Predicted CT values were obtained for each house and compared with the observed CT 
values from the pan-serotypic rRT-PCR (Figure 6.5). The potential effect of reduced 
virus excretion that may occur due to vaccination was also investigated, where CT 
values were predicted for the different levels of virus excretion to accommodate the 
possible impact of FMDV vaccination (‘1’, ‘1/10’ and ‘1/100’) (Figure 6.5). Predicted CT 
values were not calculated for some houses due to a lack of available epidemiological 
data required for the analysis, or because the house was used as a quarantine pen to 
isolate new cases of FMD at the start of the outbreak, and therefore regular milk 
samples were not collected (Houses 17 and 18). Additionally, House 12 is not included 
in figure 6.5 as both the observed and predicted results were all negative. 
Visual comparison of observed versus predicted CT values revealed instances where (i) 
positive results were obtained for both observed and predicted values, and CT values 
were generally comparable, (ii) positive results were obtained for predicted values 
only, and (iii) positive results were obtained for the observed results only, although 
this was less frequent than when comparing observed CT values with new clinical cases 
(Figure 6.5). 
The lowest predicted CT values (i.e. the highest viral RNA concentration) obtained for 
‘1’, ‘1/10’, and ‘1/100’ were 30.4, 34.5 and 38.7, respectively, compared with 31.6 for 
the observed results. A reduction in viral excretion increased the predicted CT values 
and in some instances decreased the duration for which milk samples from a house 
would remain positive (CT≤50). Additionally, applying a diagnostic cut-off value of 45 
or 40 decreased the likelihood and duration of predicted positive CT values. 
Contingency tables for all houses combined indicated that a virus excretion level of 
‘1/10’ with a diagnostic cut-off CT value of 40 generated results closest to those of the 
observed rRT-PCR results (Se = 34.6% [95% CI: 19.4% - 53.8%], Sp = 97.2% [95% CI: 
95.7% - 98.2%], Aobs = 0.95, K = 0.31) (Appendix IV, Figure 8.7). A reduction in 
sensitivity and increase in specificity was observed when these values were compared 
with estimates of sensitivity and specificity using records of new clinical cases as the 
‘gold standard’.  
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Figure 6.5 ‘Observed’ CT values for the rRT-PCR of pooled milk samples ( ) vs 
‘Predicted’ CT values at ‘1’ viral excretion ( ), ‘1/10’ ( ) and 1’100 ( ), for each 
management house [1-16, and 20]. Houses 12 and 17 are not shown because they were 
not included in this analysis due to the absence of clinical cases and rRT-PCR positive 
results in milk. House 18 was an isolation pen and not enough epidemiological data 
were available for analysis. 
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6.5 Discussion 
This study aimed to expand on previous work to determine the utility of testing pooled 
milk by rRT-PCR as an alternative approach for FMD surveillance in vaccinated dairy 
herds. During the six-month study period, 732 pooled milk samples were collected 
from a large-scale dairy farm housing approximately 4,000 cattle during an FMD 
outbreak.  
The first objective of this study was to determine whether detection and 
characterisation of FMDV by rRT-PCR was possible from pooled milk samples, and 
compare these results with epidemiological data recorded during the outbreaks. This 
is the first study we are aware of showing that FMDV genome can be detected in pooled 
milk samples from regularly vaccinated cattle collected using a proportional in-line 
milk sampler on a large-scale dairy farm. The mean CT values obtained in the pan-
serotypic rRT-PCR assay were high (>31), most likely due to the dilution of milk from 
a relatively small number of infected animals in groups of lactating cattle numbering 
up to 240 and collectively producing in excess of 10,000 litres per day. These results 
confirm the hypotheses from previous laboratory and modelling studies that suggested 
FMDV genome could be detected at these dilutions during outbreaks in field settings 
(Reid et al., 2006; Thurmond and Perez, 2006; Armson et al., 2018, see Chapter 2).  
Lineage-specific rRT-PCR assays (Knowles et al., 2015; Saduakassova et al., 2017) 
confirmed the presence of the A/ASIA/G-VII and O/ME-SA/Ind-2001d lineages in the 
pooled milk samples, and this was supported by reports from samples collected from 
clinical cases that were sent separately for laboratory testing. Reports for these 
samples demonstrated that the two outbreaks were caused by different FMD viral 
lineages, the first due to the A/ASIA/G-VII lineage, and the second the O/ME-SA/Ind-
2001d lineage, both are which are thought to have emerged recently from the Indian 
sub-continent (Knowles et al., 2015; Bachanek-Bankowska et al., 2018). The rRT-PCR 
results from the pooled milk samples suggest that there was a period of co-circulation 
or even co-infection with FMD viruses from these lineages. Co-infection in clinical 
samples from individual cattle in Saudi Arabia has been reported previously 
(Woodbury et al., 1994), although this possibility cannot be confirmed in the present  
study given that samples were taken and tested from only three clinical cases. Indeed 
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the collection of a variety of sample types from numerous individual animals during 
this study (e.g. vesicular lesion material, blood, nasal/oral swabs and milk) may have 
allowed for the detection of co-infection, and may have also enabled a more thorough 
validation of the pooled milk surveillance approach.     
Although the farm routinely vaccinates with a high-potency, polyvalent FMD vaccine, 
both potency tests (Fishbourne et al., 2017; Waters et al., 2018) and field studies 
(Lyons et al., 2017) suggest that the vaccine does not confer complete protection 
against the A/ASIA/G-VII lineage or the O/ME-SA/Ind-2001d lineage. This may explain 
why clinical cases still occurred during the study period, albeit with a low overall 
incidence risk. This is especially the case for, the A/ASIA/G-VII lineage, which was 
detected in more pooled milk samples compared to O/ME-SA/Ind-2001d, consistent 
with expected vaccine performance from respective in vitro vaccine-matching data and 
experimental studies (Fishbourne et al., 2017; Waters et al., 2018, A. Ludi, personal 
communication). The detection of a greater number of milk samples positive for the 
A/ASIA/G-VII lineage could also be due to the relative performance of the typing rRT-
PCR assays. In previous validation studies, lower CT values for the A/ASIA/G-VII 
lineage typing assay have been demonstrated compared to the pan-serotypic rRT-PCR 
assay (indicating an increased sensitivity) (Saduakassova et al., 2017). In contrast, the 
O/ME-SA/Ind-2001d typing assay has been shown to generate CT values comparable 
to the pan-serotypic rRT-PCR (Knowles et al., 2015).  
In order to validate the use of pooled milk for the surveillance of FMDV on this large-
scale farm, pan-serotypic rRT-PCR results from the pooled milk samples were 
compared to the clinical incidence of FMD during the study period. At the farm level 
there were four temporal clusters of clinical cases with gaps of at least 15 days between 
them. Visual appraisal of the data indicated that FMDV rRT-PCR results were generally 
correlated to these clusters, although they showed a wider distribution around and in 
between the clusters of clinical cases. Comparison of the onset of individual clinical 
cases with assay results on milk sampling days at the house level revealed only 6 
occasions when milk samples were positive and a new clinical case was recorded on 
the same day. There were also occasions when either (i) positive milk samples were 
obtained when there were no new clinical cases on that day, or (ii) there were new 
clinical cases occurring but a positive result was not observed in the milk. This resulted 
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in a low sensitivity and moderate specificity for the pooled milk rRT-PCR assay (42.9% 
and 95.0% respectively). However, this approach is limited by only comparing the 
assay results with the onset of new clinical cases on the sampling day which does not 
account for FMDV genome shedding in pre-clinical, convalescent, or subclinically 
affected animals.  
In order to attempt to account for these limitations, ‘observed’ CT values obtained by 
the pan-serotypic rRT-PCR assays were compared with ‘predicted’ CT values for each 
house based on detailed epidemiological and cattle movement data from the farm, and 
data from recent literature. Although these results were similar, compared with the 
onset of clinical cases there was a reduction in sensitivity and an increase in specificity. 
It is likely that this may be due to the reduced number of sampling points available for 
the predictive analysis as a result of a lack of epidemiological data available from two 
of the houses. It is possible that this reduced sensitivity (i.e. instances where there were 
positive ‘predicted’ but negative ‘observed’ rRT-PCR results of the pooled milk) was 
due to a lower quantity and shorter duration of viral excretion in the milk of these 
vaccinated infected cattle than was assumed in the model. This theory supports 
findings by  Leeuw et al. (1978) who were unable to detect infectious FMD virus in the 
milk of vaccinated cattle after challenge. However, this previous study used a 
homologous vaccine to the challenge strain and focussed on the detection of live virus 
instead of FMDV RNA genome. As there are no other studies known to have considered 
viral excretion into the milk of vaccinated cattle, data used to inform the model was 
based on more recent studies that measured viral excretion from vaccinated and non-
vaccinated animals in alternative samples such as nasal fluid, saliva, and oesophageal–
pharyngeal fluid (Orsel et al., 2007; Parthiban et al., 2015; Thwiny, 2016). The authors 
acknowledge the limitation of this approach, particularly since the quantity and 
duration of viral excretion seemed to have a substantial impact on the likelihood of 
predicting a positive result in the milk. Consequently, further investigation into the 
effect of vaccination on viral excretion in milk is required and would enhance the 
predictive ability of the model. 
Management practices on the farm may also have contributed to the low sensitivity of 
the pooled milk rRT-PCR assay. These include the inconsistent removal of clinical cases 
and milking practices during the study period in response to the outbreak, with the 
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potential for increased sensitisation of farmers to disease as the outbreak progressed, 
resulting in a decreased chance of milk from an infected cow contributing to the milk 
pool. Additionally, the proportional in-line sampling method may not be truly 
representative of all cattle in the group, as reported previously (Clarke et al., 1997). 
Although the in-line sampler is designed to represent the whole milking, it has been 
demonstrated that this method may terminate sampling early (Clarke et al., 1997) and 
milk from infected cattle may be excluded from the sample tested leading to false 
negative results. This may explain the low sensitivity obtained for this FMDV detection 
system compared with what was predicted in the model. Other methods, for example 
collecting a sample from the bulk tank after thorough agitation, may be more 
representative (Barnard, 1977) and could be considered for future studies.  
During the study period there were also instances when positive rRT-PCR results 
observed in milk samples did not correspond to new clinical cases observed, or indeed 
‘infected’ (D-1 to D24) cows present in the house that would excrete virus into the milk 
pool. The possibility that these ‘false positives’ were due to laboratory contamination 
cannot be excluded. However, the laboratory methodology used in this study has been 
shown to be highly specific (see Chapter 4), and as there were a high number of 
‘negative’ samples it is unlikely that these results are due to either laboratory 
contamination or non-specific amplification. An alternative explanation for this 
observation include spill-over of virus between houses as cattle were being milked (i.e. 
virus from an infected animal in one house may have been carried over to the milk from 
the subsequent house, generating false-positive results for an otherwise negative 
house) as there was no milk line disinfection between houses. There is also the 
possibility of delays in clinical case detection, sub-clinical infections or mild clinical 
cases that may not have been noticed by farm workers. Subclinical infections in 
vaccinated animals have been reported previously (Bertram et al., 2018; Farooq et al., 
2018; Stenfeldt et al., 2018) and this is a possible explanation for the prolonged period 
between cases (up to 27 days), although it is unknown whether the outbreaks on this 
farm were due to prolonged circulation or new virus introductions.  
This is the first study to evaluate the use of pooled milk as a surveillance sample for the 
detection of FMDV on large-scale dairy farms in endemic regions. This study 
demonstrates that rRT-PCR testing of pooled milk may be utilised for FMD surveillance 
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and reveal underlying sub-clinical FMD infection. More representative sampling 
methods should be investigated that may increase the sensitivity of this approach 
including an exploration of how the dairy value chain may be exploited for FMD 
surveillance. Subsequently, this methodology could be integrated into FMD 
surveillance programmes providing significant benefits over conventional surveillance 
strategies. The similarities in the farming system evaluated in this study and dairy 
farms in FMD-free countries highlights the potential of this surveillance approach for 
use in disease-free regions in the event of an incursion of FMDV, to allow rapid 
identification of infected herds, tracing the source and spread of infection and to screen 
infected premises to assess disease freedom. 
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Discussion and future recommendations 
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7.1 Thesis summary 
Effective disease surveillance enables stakeholders to confidently determine the health 
status of animals, and allows the necessary control methods to be implemented in 
order to reduce disease impact. Additionally, surveillance output data may help to 
assess the effectiveness of intervention strategies such as vaccination programmes 
(Drewe et al., 2011; Falzon et al., 2019). Currently, several limitations exist for foot-
and-mouth disease (FMD) surveillance in endemic regions which have been described 
in more detail earlier in this thesis (see Chapter 1, section 1.5), and include the 
dependence on disease recognition and reporting by farmers, and the labour and costs 
involved in collecting and testing invasive clinical samples. Consequently, it is likely 
that much of the FMD circulation estimated to occur goes undetected (Sumption, 
Rweyemamu and Wint, 2008; Knight-Jones and Rushton, 2013).  
Milk has been utilised for the detection of several pathogens and their specific 
antibodies, including Coxiella burnetti (Kim et al., 2005) and bovine viral diarrhoea 
virus (Drew et al., 1999; Renshaw et al., 2000b), among others. Additionally, pooled 
milk systems for herd-level surveillance are in place for diseases such as brucellosis 
(DEFRA, 2015a) (see Chapter 1, section 1.6). Previous studies have demonstrated 
FMDV detection from milk samples in experimental and field scenarios (Burrows, 
1968; Reid et al., 2006; Ranjan et al., 2016; Ahmed et al., 2017). Additionally, the 
potential use of pooled milk samples for cost-effective FMD surveillance has also been 
highlighted (Reid et al., 2006; Thurmond and Perez, 2006).  
The principal aim of this thesis was to expand on previous studies to determine the 
utility of milk for FMDV detection and surveillance. The objectives were to (i) optimise 
a high-throughput molecular FMDV detection system to be employed throughout the 
project; (ii) determine the utility of milk samples compared to conventional sample 
types for FMDV diagnosis from individual experimentally and naturally infected 
animals; (iii) evaluate the stability of FMDV RNA in milk samples during 
transportation; (iv) determine the effects of pooling; and (v) assess the use of pooled 
milk surveillance approaches in different farming systems. By addressing these 
research gaps, this thesis demonstrates that milk can be used as a non-invasive, simple 
sample type for FMD surveillance.  
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7.1.1 The advantages of using milk for FMD surveillance 
7.1.1.1 FMDV detection in milk samples  
Since it was first demonstrated that FMDV was excreted in the milk of FMD infected 
animals by Lebailly (1920), many studies have evaluated methodologies for the 
detection of both FMD virus and antibodies in milk samples. These techniques are 
summarised in Figure 7.1, and include antibody detection assays, the detection of live 
virus by isolation onto susceptible cell lines, and various molecular detection methods.  
 
 
Figure 7.1 Techniques for the detection of FMDV/antibody in milk samples: (a) FMDV 
antibody assays (Stone and DeLay, 1960; Armstrong, 1997); (b) live virus on 
susceptible cell-lines (Burrows, 1968; Hedger and Dawson, 1970; Blackwell and 
McKercher, 1982; Reid et al., 2006; Armson et al., 2018)(Chapter 2); (c) the detection 
and typing of FMDV RNA genome by real-time rRT-PCR (Reid et al., 2006; Ranjan et al., 
2016; Ahmed et al., 2017; Armson et al., 2018, 2019)(Chapters 2 and 3); (d) VP1 
sequence data generation (Armson et al., 2019)(Chapter 3); and (e) the detection of 
FMDV RNA genome by point of care technology such as the Enigma® Mini Laboratory 
(Goller et al., 2018). 
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This thesis has expanded on these studies, focussing primarily on the application of 
molecular methods for the detection of FMDV RNA genome. A highly sensitive and 
specific real-time rRT-PCR using a high-throughput RNA extraction protocol was 
optimised and utilised for FMDV RNA genome identification throughout the project 
(Armson et al., 2018)(Chapter 2). Absolute quantification of the virus stocks used 
throughout this thesis was not performed and consequently the true analytical 
sensitivity could not be determined, and compared with previous studies such as that 
performed by Reid et al. (2006). However, milk samples collected in the experimental 
study (Chapter 2, Armson et al., 2019) were also tested using the method detailed in 
Reid et al. (2006) at the time of sample collection. The CT values observed were higher 
(weaker) than those observed when using ‘Method B’ after five years of sample storage. 
Therefore, the optimised method used throughout this thesis likely has a greater 
sensitivity than that used by Reid et al. (2006).  
Results from the testing of milk from experimentally and naturally infected cattle 
demonstrated that the FMDV serotype or lineage could be identified using previously 
developed type-specific or lineage-specific rRT-PCR assays, and VP1 sequence data 
could also be obtained (Armson et al., 2019)(Chapter 3). Additionally, RNA genome 
detection, and typing and sequence data obtained from milk samples was generally 
consistent with that of vesicular epithelium, fluid or serum samples commonly used for 
FMD diagnosis (Armson et al., 2018, 2019)(Chapters 2 and 3). Further studies should 
perform more thorough comparisons of these sample types with milk and include 
additional sample types such as nasal and oral swabs, and OP fluid. Consequently, these 
findings provide confidence that milk is a sample type from which a range of 
information may be obtained for FMDV diagnostic and epidemiological purposes.  
 
7.1.1.2 Increasing the window of detection compared to established sampling methods 
Utilising an optimised high-throughput screening method, Chapter 2 demonstrated the 
increased window of FMDV detection by rRT-PCR in milk samples compared to serum 
samples and as previously described, vesicular epithelium or fluid (Alexandersen et al., 
2003; King et al., 2012) (Figure 7.2). Evidence from this thesis supports previous 
observations that FMDV RNA genome can be detected before and during the 
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appearance of FMD clinical signs. Further evidence for the detection of FMDV in 
convalescing cows is also described in Chapter 2 (Armson et al., 2018), which supports 
previous observations by Reid et al., (2006). However, the termination of the cattle 
experiment while FMDV RNA genome was still being detected in the milk indicates 
further work is necessary to determine the true duration of virus excretion in the milk 
of naïve-infected animals. Additionally, comparison of the predictive modelling results 
with ‘observed’ rRT-PCR results (Chapter 6) suggested that the window of virus 
detection may have been different in these regularly vaccinated cows to that of the 
naïve cattle during the experimental study. Indeed it is unfortunate that milk was not 
collected from selected individual cattle during this study period (Chapter 6), so that 
the window of virus detection may have been defined in the milk of these regularly 
vaccinated animals. Future studies should therefore aim to elucidate viral excretion 
patterns in the milk of cattle of different breeds, and those vaccinated/infected with 
various serotypes/topotypes.  
 
 
Figure 7.2 Approximate clinical window of FMD virus detection from different sample 
types: oral swab (A), OP fluid (B), blood (C), vesicular epithelium (D) and milk (E). Day 
0 indicates the day vesicular lesions are first noticed. Based on data from Alexandersen 
et al., 2003; King et al., 2012; Stenfeldt, Lohse and Belsham, 2013; and Armson et al., 
2018, Chapter 2. Photographs courtesy of Bryony Armson and Emma Howson, 2016. 
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7.1.1.3 The detection of subclinical infection 
Several studies have identified FMDV infection in animals with no obvious signs of 
disease (Bertram et al., 2018; Hayer et al., 2018) (see Chapter 1, section 1.5). It is 
reasonable to assume that FMDV RNA genome may also be excreted in the milk of sub-
clinically infected animals. Multiple data sets in this thesis demonstrate the detection 
of FMDV RNA genome in milk samples in the absence of clinical disease (Chapters 3, 5 
and 6)(Armson et al., 2019), with subclinical infection as a possible explanation in 
some of these instances. These data support observations by Ahmed et al., (2017) 
where FMDV RNA genome was detected in the milk of apparently healthy vaccinated 
water buffaloes (Bubalis bubalis). It is unknown whether vaccination may increase the 
likelihood of sub-clinical infection. Investigating FMD viral excretion patterns in the 
milk of vaccinated versus non-vaccinated cattle is recommended as a research priority 
if milk is to be utilised as a sample type for FMD surveillance where regular vaccination 
is practised. For example, viral excretion in the milk of vaccinated animals could be 
measured as part of FMD vaccine field trials using dairy cattle. Further data from these 
types of studies may enhance the ability of predictive models and may be used to better 
inform milk surveillance programs. 
 
7.1.1.4 The detection of FMDV in pooled milk  
This thesis aimed to expand on previous studies to investigate whether FMDV RNA 
genome could be detected in pooled milk samples from outbreak or endemic settings 
which has not been demonstrated previously.  
Initially (A) the ability to detect FMDV from the milk of individual cattle was assessed 
(discussed above in section 7.1.1.1) (Figure 7.3A), and these data were used to inform 
pooling studies.  
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Figure 7.3 Summary of collection of milk from the field. (A) Milk samples from 
individual cattle in northern Tanzania. (B) Pooled milk samples representing dairy 
cattle on small-holder farms in Nakuru County, Kenya. (C) Pooled milk samples 
representing dairy cattle on a large-scale farm in Saudi Arabia. Photographs courtesy 
of Bryony Armson and Nick Lyons. 
 
Subsequently, proof-of-concept pilot studies were carried out which demonstrated the 
ability of the rRT-PCR assay to detect FMDV in pooled milk samples collected from two 
different farming systems: (B) small-holder farmers supplying local milk pooling 
facilities in Kenya (Figure 7.3B) (Chapter 5); and (C) individual management groups of 
a large-scale dairy farm in Saudi Arabia (Figure 7.3C)(Chapter 6).  
Results demonstrated that FMDV could be detected from milk pools of up to 5,000 
litres and 10,000 litres for studies (B) and (C) respectively, even when there were low 
numbers of clinical cases of FMD. Due to the methodology used for sampling pooled 
milk for study (B), the number of cows represented by each sample was not known but 
could be estimated from data obtained from small-holder farmer surveys, suggesting 
the contribution of milk by over 1000 cattle. For study (C) although the volume of milk 
per management group was greater, it was supplied by a relatively smaller number of 
high-yielding cattle, approximately 240 cattle per house. These data support 
laboratory findings from limit of detection studies using the optimised high-
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throughput FMDV rRT-PCR method carried out in Chapter 2 (Armson et al., 2018) and 
in a previous study that employed a different detection system (Reid et al., 2006), that 
suggested the assay would be sensitive enough to detect FMDV in pooled milk from 
large herds, even in the unlikely case that only one animal was infected. Data obtained 
in this thesis also support previous modelling studies which suggested that it would be 
possible to detect FMDV from a milk pool supplied by over 1000 cattle (Thurmond and 
Perez, 2006; Garner et al., 2016; Kompas et al., 2017). However, the milk pool volumes 
suggested in these studies (up to 20,000 litres) are larger than those tested in this 
thesis (up to 10,000 litres). Indeed, based on the weak CT values observed from pooled 
milk samples throughout this thesis (CT value > 30), it is unknown whether FMDV could 
be detected in pooled milk samples collected from larger herds (>1000), or samples 
collected higher up in the dairy value chain. Although it is assumed possible by limit of 
detection and modelling studies (Reid et al., 2006; Armson et al., 2018), these methods 
may not represent the realities of the field, and consequently field studies are required 
in order to determine the absolute limit of the FMDV detection system for pooled milk 
samples. 
 
7.1.2  The limitations of utilising milk for FMD surveillance 
7.1.2.1 Potential for contamination of the rRT-PCR assay 
The high-throughput RNA extraction and real-time rRT-PCR optimised and utilised for 
FMDV RNA genome identification throughout this project was shown to be highly 
sensitive, able to detect FMDV RNA genome in large milk pools of up to 10,000 litres 
(Armson et al., 2018)(see Chapters 2, 5 and 6). The FMDV detection method used 
throughout this project was also shown to be highly specific (99.66%) when testing a 
negative cohort of milk samples from UK dairy herds. However amplification was 
observed in several wells of the rRT-PCR plates during the testing of this negative 
cohort. Additionally, there were several occasions (see Chapters 5 and 6) where high 
(weak) CT values were observed where there were no clinical cases, or where there 
were no obvious alternative explanations for example viral excretion during 
convalescence or environmental contamination (such as contamination of the milk line 
from a previous ‘positive’ house [see Chapter 6]). 
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Due to the number of negative milk samples observed from Kenya and Saudi Arabia, it 
is unlikely that non-specific amplification of other template present in the milk (e.g. 
from other organisms) occurred, as it would be expected that more/all samples would 
have been positive. Additionally, the molecular detection method used throughout this 
thesis was based on the well-established and validated 3D pan-serotypic rRT-PCR 
assay utilised in reference laboratories that has been shown to be highly specific in a 
wide variety of sample types collected across the world (Callahan et al., 2002; Goris et 
al., 2009; Reid et al., 2009). However, as the negative cohort performed in chapter 4 
was only collected from select breeds in the UK, to fully validate the specificity of the 
rRT-PCR assay, further cohorts of known negative milk samples should be tested from 
various cattle breeds and locations, and from those that may contain organisms exotic 
to the UK,  
It is more likely that inter/intra-assay contamination of the rRT-PCR assay was 
responsible for the ‘false positive’ samples observed in the negative cohort of milk 
samples from the UK (see Chapter 4). The rRT-PCR assay performed throughout this 
thesis did not employ a cut-off value for positivity because the viral RNA in large milk 
pools may be highly dilute. A ‘positive’ result was therefore defined as the observation 
of amplification above the cycle threshold (CT) combined with a ‘healthy’ looking 
amplification curve, until the end of the run (50 cycles). Indeed, some of the CT values 
observed for the milk samples collected from Kenya and Saudi Arabia were higher than 
those observed for limit of detection experiments (see Chapters 2 and 4), and therefore 
contamination is a possible explanation. Consequently it is possible that at least some 
of the high CT values observed throughout this thesis may have been ‘false’ positive 
results.  
Due to the sensitive nature of the rRT-PCR assay, it is often impossible to differentiate 
between a true and a false positive result.  Interpretation of the amplification curve 
may help to identify non-specific amplification, however amplification due to 
contamination of the sample during collection or during assay set-up cannot be 
identified in this way. Future work should aim to incorporate the use of negative 
controls throughout the whole sampling process i.e. from sample collection to testing. 
Additionally, to define cut-off values for positivity using analytical and epidemiologic 
approaches (Caraguel et al., 2011), bearing in mind the increased likelihood of higher 
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CT values due to potentially highly diluted viral RNA. Additionally, absolute 
quantification of different serotypes of virus to more accurately determine the 
analytical sensitivity of the rRT-PCR assay may assist in the definition of these cut-off 
values. This would improve confidence in the results so that the milk sampling 
approach may be incorporated into active surveillance plans for FMD-free countries. 
To mitigate the risk of contamination in the field, stringent biosecurity measures must 
be applied, including the use of personal protective equipment where necessary and 
appropriate disinfection of equipment. Additionally in the laboratory, sample tubes 
should not be opened unnecessarily and samples from different regions and dates 
should be processed separately, which was the method used for testing milk samples 
throughout this thesis. Chapter 4 also highlighted the importance of performing 
multiple replicates of samples during assay set-up, where resources allow, so that true 
positive results may more easily be determined.   
 
7.1.2.2 Milk sampling methods  
Results presented in this thesis identified several limitations of the milk sample 
collection methods used in these studies, and have been discussed in more detail in the 
respective chapters. For example, in Kenya (see Chapter 5), three of the milk pooling 
facilities did not own, or were not using their bulk milk tank, and therefore an 
alternative sampling method taking a small amount of milk from all 50 litre cans was 
employed, resulting in a more labour-intensive sampling process. However, samples 
collected in this way were assumed to be as representative as collection from a bulk 
tank, and excluding facilities using this method may bias the surveillance as this 
appeared to be a common practice.  An optimal system could be designed for each of 
the various levels of pooling that occurs, including those further up the milk production 
chain (see section 7.2.2). Results from the large-scale dairy farm in Saudi Arabia (see 
Chapter 6) suggested that the proportional in-line milk sampler may not have always 
generated a representative sample from the herd, potentially resulting in ‘false 
negative’ results, especially if the sample container became full before the last cows of 
the group had been milked. Additionally, potential virus contamination of the milk line 
between different management groups may have resulted in ‘false positive’ results. 
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Consequently, it may be more suitable to collect milk samples directly from the bulk 
tank after mixing, that would be supplied by all/more lactating cows on the farm. This 
may have an additional cost-benefit of capturing more animals in fewer samples, 
although it is important to ensure that the FMDV detection method is indeed sensitive 
enough to still enable the detection of virus from one infected animal in this higher 
dilution of milk.  
 
7.1.2.3 Estimation of FMD clinical incidence 
The methods used for the pilot studies performed in this thesis (see Chapters 5 and 6) 
were appropriate, given that FMD surveillance using pooled milk has not previously 
been investigated, and therefore there were limited resources available. However, as 
discussed in more detail in these chapters, the estimation of disease incidence in the 
respective study populations may not have been truly accurate. For example, although 
it has been reported that farmers in Kenya had good knowledge of FMD (Nyaguthii et 
al., 2019), mild clinical signs, subclinical infection or indeed an unwillingness to report 
disease are likely to have resulted in low incidence estimates (Vosloo et al., 2002; 
Knight-Jones et al., 2014). Also, although farm staff on the large-scale dairy farm in 
Saudi Arabia were reported to be familiar with performing individual FMD case 
detection of individual cattle, it is possible that clinical signs may have been mild in this 
vaccinated population, and therefore cases may have gone undetected. Additionally, 
the study performed in Kenya was underpowered, due to the limited resources 
available for performing cross-sectional surveys of small-holder farmers. Future 
studies should therefore aim to more precisely estimate the level of FMD clinical 
incidence so that the milk sampling approach can be more robustly assessed. For 
example studies performed on large farms could integrate the collection of multiple 
sample types and milk from individual animals in addition to pooled milk samples. 
Additionally, those studies investigating small-holder farming systems could employ 
serological NSP testing of selected farms (discussed further in section 7.2.3).  
 
 
Chapter 7 
 
154 
 
7.1.2.4 Reduction in milk yield during FMDV infection 
Reservations exist as to the ability of FMDV detection in pooled milk due to the many 
reports of reduced milk yield during FMDV infection (James and Rushton, 2002; 
Knight-Jones and Rushton, 2013; Ferrari et al., 2014; Jemberu et al., 2014; Bastola, 
2015; Ansari-Lari et al., 2017; Casey-Bryars et al., 2018). Indeed, animals that are sick 
and/or experience a cessation or reduction in milk production may not contribute to 
the milk pool, and therefore a pooled milk sample may not be representative of FMD 
virus circulation in the whole herd. Additionally, the milk of uninfected cows may dilute 
the virus contained in the small amounts of milk produced by infected cattle so that the 
final virus concentration is beyond the analytical sensitivity of the rRT-PCR assay.  
Despite these reservations, data presented in this thesis demonstrated that FMDV RNA 
genome could still be detected from a pooled milk sample when the FMD incidence 
rates over each of the study periods were low (Chapters 5 and 6). For the study in Saudi 
Arabia (Chapter 6), sick or diseased animals were isolated from their management 
house, although this process was not consistent when isolation pens became full. Virus-
laden milk from these animals was therefore not included in the sampled milk pool, yet 
FMDV RNA could still be detected. It is possible that the regular vaccination of these 
animals resulted in less severe/no clinical signs in some animals, and consequently a 
reduced impact on milk yield. For the study performed in Kenya (Chapter 5), farm-level 
data was not available and therefore it is unknown how many infected animals did not 
contribute their milk. Although this information is not necessary when performing 
surveillance of the study population, it would be useful to determine the true 
sensitivity of the FMDV detection system, and to inform future modelling studies.  
 
7.1.2.5 Sampling bias 
Milk samples can only be collected from lactating female animals. Therefore, if 
surveillance approaches focus exclusively on dairy cattle; males, young stock, breeds 
designed for meat, and other species such as sheep, goats and pigs may not be 
represented. It is therefore anticipated that the milk sampling surveillance approach 
could act as a supplement to current surveillance systems that may be limited to the 
detection of acute disease. Therefore, it is important that data obtained from the milk 
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sample collected is representative of the FMDV circulation in the susceptible 
population. 
In FMD endemic regions such as East Africa and the Middle East, there are many 
nomadic and small-holder farmers that keep small ruminants together with their dairy 
cattle, and a small number of large-scale dairy farms (Nthiwa et al., 2019; Nyaguthii et 
al., 2019). It has been suggested that sheep and goats may play a significant role in the 
transmission of FMDV, and therefore the close proximity likely results in high levels of 
viral circulation between species (Kitching and Hughes, 2002; Asghar et al., 2016). In 
FMD-free countries such as Western Europe, dairy farms are also generally widespread 
(Department of Environment Food and Rural Affairs, 2010). It is likely that dairy cattle 
may act as sentinels for the surrounding susceptible FMD population, and 
consequently surveillance systems that focus on dairy cattle are likely to be highly 
representative of disease circulation in these settings. This was supported by 
simulation models performed by Garner et al. (2016) who suggested that bulk milk 
testing could enhance early detection in areas where there are many dairy cattle, even 
when the outbreak starts outside of a dairy area.  
In contrast, a milk sampling surveillance approach may not be appropriate for endemic 
countries such as Hong Kong SAR, China and Thailand that have large populations of 
pigs, and less market for dairy products resulting in a lower number of dairy cattle (see 
Figure 7.4) (Sumption et al., 2008; Robinson et al., 2014).  
 
Figure 7.4 The global distribution of cattle. Adapted from Robinson et al. (2014). 
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7.2 Recommendations for future studies 
Data presented in this thesis have demonstrated the benefits and limitations of milk as 
a sample type for FMDV detection and surveillance, with the potential of 
implementation into regional surveillance plans alongside existing surveillance 
schemes. Before integrating pooled milk into FMD surveillance systems, there are 
several considerations that require further investigation. 
 
7.2.1 Technologies for improved molecular data collection  
Although results from Chapter 4 demonstrated that FMDV RNA detection by rRT-PCR 
was not significantly affected during the long-term storage and simulated transport of 
milk samples, the use of point of care (POC) technologies would allow for rapid result 
reporting at source, reducing the need for expensive and logistically challenging 
transport of samples to national or international FMD laboratories. The detection of 
FMDV RNA from milk samples using a fully automated cartridge-based real-time RT-
PCR diagnostic system (the Enigma® Mini Laboratory) has been described (Goller et 
al., 2018), and although this system is no longer commercially available, similar 
systems could be designed that are suitable for use in mobile and local laboratories 
with limited resources, or on large-scale dairy farms where samples may be tested on-
site. It is possible that existing POC technologies that do not include an RNA extraction 
step may not be suitable for the detection of FMDV RNA from milk samples due to PCR 
inhibitors such as the proteins and lipids found in milk. Therefore, future work could 
aim to optimise these or alternative technologies in combination with effective simple 
sample preparation methods such as those described by Howson et al. (2018).  
Furthermore, as results obtained in Chapter 3 highlighted the ability to obtain VP1 
sequence data from milk samples, the potential for next-generation sequencing (NGS) 
should also be investigated. This genomic data could then be used to better understand 
the epidemiology of FMDV in a region, for example by investigating the viral diversity 
of pooled milk samples to determine the burden of infection in a region (Walker et al., 
2013; King et al., 2016). With the rapid advancement of technology, the potential exists 
for the application of POC NGS technology such as the MinION nanopore sequencer 
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(Oxford Nanopore Technologies, Oxford, UK) for real-time, portable genome 
sequencing of FMDV in milk samples (Hansen et al., 2019). However, it is possible that 
the low concentrations of viral RNA in a pooled milk sample may be too low to obtain 
quality sequence data, and milk may not be suitable for rapid field sequencing as prior 
processing may be required (Logan et al., 2014). 
 
7.2.2 Exploring the milk production chain for representative pooled milk 
sampling 
Pooling studies performed for this thesis have highlighted the importance of simple, 
representative sampling methods to ensure confidence in the test result. Further work 
is required to examine the pooling systems employed by different geographical regions 
or farming settings, and how they may be targeted for effective surveillance. For 
example, assessment of the ability to detect FMDV at different stages of the milk 
production chain, from the individual animal, to the farm-level and up to processing 
centres should be performed (Figure 7.5). Sampling milk at higher levels would capture 
the contribution of milk by a greater proportion of the dairy cattle population in a 
region. However, the stage at which pasteurisation occurs should be carefully 
considered, as it has been demonstrated that FMDV is less likely to be detected 
following this process (Reid et al., 2006; Aly and Gaber, 2007; Tomasula et al., 2007). 
Garner et al. (2016) modelled FMDV detection from a transport tanker containing 
20,000 litres of milk collected from up to five large-scale dairy farms, and it is 
important to externally validate these findings based on field data particularly if they 
are used to inform surveillance policy. Information should also be obtained concerning 
the cost implications for sampling at each stage, and how representative the sample is 
of the region of interest, i.e. what percentage of susceptible animals are contributing to 
the sample. Additionally, FMDV has been previously identified in the milk of sheep and 
goats (Aly and Gaber, 2007), and therefore it could be investigated whether this 
approach could be useful for FMD surveillance, as has been demonstrated for the 
detection of Brucella spp. (Hamdy and Amin, 2002).  
The adulteration of milk by farmers for financial gain has been reported, especially in 
underdeveloped countries (Azad and Ahmed, 2016). Substances added to milk may 
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include milk powder, water or chemicals such as hydrogen peroxide, formalin and 
salicylic acid. Although pooling facilities often perform tests for these substances, there 
remains the potential for milk contamination, and it is unknown how these substances 
may affect any FMD virus contained within the milk. Therefore, experiments should be 
performed to determine how the presence of these substances in milk samples may 
affect the ability of the rRT-PCR to detect FMDV RNA genome. Alternatively, milk 
samples could only be taken for testing once the appropriate quality assessments have 
been performed. 
 
 
Figure 7.5 Targeting different stages of the milk production chain for cost-effective 
pooled milk sampling. Yellow stars indicate sampling levels already investigated in this 
thesis. Red arrows indicate potential sampling levels for future research. Adapted from 
Recheis (2019) 
 
7.2.3 Improving sensitivity estimates of the pooled milk surveillance 
system 
Proof-of-concept pilot studies performed for this thesis demonstrated the ability to 
detect FMDV RNA genome from large milk pools. However, the methods used to 
estimate sensitivity involved comparing pooled milk sample results against reports of 
clinical disease by farmers. Although this method was appropriate for the pilot studies 
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performed for this thesis and with the resources available, it may not have provided an 
accurate representation of the true burden of disease in the population, as described 
earlier (section 7.1.2.3). 
Further studies are therefore required, in order achieve improved estimates of clinical 
incidence in a region, so that the sensitivity of the pooled milk surveillance system can 
be more precisely estimated. For example, testing frequently collected serum samples 
for non-structural protein (NSP) and structural protein (SP) antibodies, and for FMDV 
RNA genome alongside reports of clinical cases would provide evidence for FMD 
infection and may identify cases of subclinical infection in small-holder farming 
systems. Farmer surveys should also be powered to estimate the true incidence of 
disease if possible, instead of the detection of a specific threshold of FMD incidence, 
which was employed for this thesis. Additionally, studies performed on large farms 
could integrate the collection of multiple sample types e.g. vesicular epithelium, serum, 
nasal/oral swabs, or oesophageal-pharyngeal fluid from suspected infected animals 
and milk from individual animals throughout the period of infection. This would 
confirm suspected cases of FMD, provide further information on the window of 
detection of virus excretion in the milk of these cows, potentially identify/confirm 
cases of co-infection and consequently would assist in more robustly assessing the 
pooled milk sample surveillance approach. 
 
7.2.4 FMDV antibody testing 
Antibodies to FMDV have been detected in milk, and a significant correlation found 
with the levels of antibodies found in serum (Armstrong, 1997; Armstrong and 
Mathew, 2001; Fayed et al., 2013). Consequently, the detection of FMDV antibodies in 
milk samples could be integrated into surveillance schemes to identify infected 
cattle/herds, or could be a useful alternative sample type to blood for post-vaccination 
monitoring (Fayed et al., 2013). Although several assays for the detection of FMDV 
antibody from milk samples have been developed (Stone and DeLay, 1960; Armstrong, 
1997; Armstrong et al., 2000), newer methods may need to be optimised and validated, 
based on current commercially available tests for serum. Indeed, it is possible that 
virus-specific antibody testing of milk samples collected for work performed in this 
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thesis could provide additional information, for example to support suggestions of sub-
clinical infection, or provide support for results that could be interpreted as ‘false 
positives’.    
 
7.3 Potential applications of the pooled milk 
surveillance system 
Once further validation of the pooled milk surveillance system has been performed, it 
is anticipated that it may be valuable for targeted/risk-based surveillance alongside 
existing surveillance systems to facilitate improved knowledge of FMD epidemiology, 
or for use in FMD contingency plans.  
 
7.3.1 FMD endemic regions 
Data presented in this thesis have demonstrated the potential use of milk to improve 
knowledge on FMD epidemiology in endemic regions. It is anticipated that this 
approach could be utilised to answer specific research questions, such as: 
(i) Estimation of FMD incidence and circulating serotypes/lineages. The burden of 
infection could be predicted based on CT value, or through sequence diversity data; 
(ii) Estimation of the level of subclinical infection, for example in vaccinated vs. non-
vaccinated populations; 
(iii) Assessment of control strategies, such as the effectiveness of vaccination 
programmes. 
Although further research is required to fully validate the use of milk for FMD 
surveillance in different scenarios, it is possible that a simple, risk-based surveillance 
approach could be employed in the near future, especially to answer some of the 
questions that require less precise estimates of disease incidence, such as which 
serotypes/lineages are circulating in a region. Improved knowledge of the FMD 
epidemiology in a region may facilitate the progress of a country through the 
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Progressive Control Pathway for Foot and Mouth Disease (PCP-FMD) (Food and 
Agriculture Organization of the United Nations (FAO), 2011).  
 
7.3.2 FMD free countries 
Farm-level bulk milk sampling has been demonstrated to be effective for FMDV 
detection (see Chapter 6). Therefore, one speculates whether a similar milk sampling 
approach to that utilised for brucellosis in the United Kingdom (DEFRA, 2015a, 2015b) 
could be applied as an early warning indicator of disease, where milk samples are 
routinely submitted to testing laboratories (see Chapter 1, section 1.6). However, due 
to the short window of FMDV excretion in milk (<28 days), much shorter testing 
intervals (e.g. weekly) would be required. Consequently, the cost of pooled milk 
sampling at this frequency would likely outweigh the benefit of detection only a few 
days earlier than with passive surveillance methods, as suggested by modelling studies 
performed by Kompas et al. (2017) based on dairy herds in the Victoria state of 
Australia. There are however, several applications of the pooled milk surveillance 
system that could be cost-effective for use in FMD free countries and have been 
considered potentially valuable for use in the United States (Kompas et al., 2017; 
Lombard et al., 2017): 
(i) Testing of dairy premises in response to the threat of an outbreak in a 
neighbouring country or region for early preclinical diagnosis; 
(ii) Confirmation of a suspect case in a herd of dairy cattle; 
(iii) Testing of unpasteurised milk to be moved to a disease-free region; 
(iv) Screening of dairy herds after the cessation of clinical signs to signify disease 
freedom on a farm/region. 
A surveillance system designed for these purposes must be highly specific and sensitive 
to ensure a high degree of confidence in the test results. False results may have costly 
implications including the unnecessary culling of animals or onward viral transmission 
(Caporale et al., 2012; Lewerin et al., 2018). Therefore, in order for the milk sampling 
surveillance system to be implemented for these purposes, further research is required 
to obtain precise estimates of sensitivity and specificity, from studies performed in 
settings similar to those of FMD free countries. In the event of a future FMD outbreak 
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in a normally-free country, bulk milk sampling could be exploited in order for example, 
to determine the optimal frequency of milk sampling, which has only so far been 
hypothesised using simulation modelling  (Thurmond and Perez, 2006; Garner et al., 
2016; Kompas et al., 2017).  
 
7.4 Concluding remarks 
In conclusion, this thesis has demonstrated the utility of milk as a diagnostic sample 
for FMDV detection, and based on the proof-of-concept pilot studies performed, has 
highlighted the benefits and limitations of its application for FMD surveillance in both 
FMD endemic and free regions.  
Further research and investment are required to inform recommendations on how this 
simple, cost-effective, risk-based targeted surveillance system that is otherwise 
expensive and logistically challenging, could be used to contribute to FMD surveillance 
activities around the globe.  
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Appendices 
Appendix I 
Determination of the optimal high-throughput 
screening method for the detection of FMDV in milk 
samples 
 
 
Figure 8.1 Comparison of Methods A and B for the detection of FMDV from whole milk 
from each cow. CT values are the mean of two replicates.  : Method A, : Method B. 
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Appendix II  
FMD detection in milk samples from individual cattle 
Table 8.1 List of samples and virus isolates from northern Tanzania used throughout 
the study. The mean CT values for the pan-serotypic (3D) rRT-PCR and East Africa (O, 
A, SAT 1, SAT 2) rRT-PCR typing assays are reported. 
Animal ID/     
WRLFMD 
Reference 
Collection 
date 
Sample 
type 
Location 3D O A 
SAT 
1 
SAT 
2 
8177 26/05/2012 M Nyamburi No CT NP NP NP NP 
8146 30/07/2012 M Nyamburi No CT NP NP NP NP 
8233 17/08/2012 M Nyamburi No CT NP NP NP NP 
8233 17/08/2012 M Nyamburi No CT NP NP NP NP 
8401 18/08/2012 M Nyamsingisi 24.93 No CT 24.10 No CT No CT 
8266 17/10/2012 M Nyamburi No CT NP NP NP NP 
8233 18/10/2012 M Nyamburi 36.46 No CT No CT No CT No CT 
8259 18/10/2012 M Nyamburi No CT NP NP NP NP 
8269 18/10/2012 M Nyamburi No CT NP NP NP NP 
8401 10/11/2012 M Nyamsingisi No CT NP NP NP NP 
8403 10/11/2012 M Nyamsingisi No CT NP NP NP NP 
8406 10/11/2012 M Nyamsingisi No CT NP NP NP NP 
8427 13/11/2012 M Nyichoka No CT NP NP NP NP 
8438 13/11/2012 M Nyichoka No CT NP NP NP NP 
8445 13/11/2012 M Nyichoka No CT NP NP NP NP 
8457 13/11/2012 M Nyichoka No CT NP NP NP NP 
7470 23/11/2012 M Rwamchanga No CT NP NP NP NP 
7476 23/11/2012 M Rwamchanga No CT NP NP NP NP 
7689 23/11/2012 M N/A No CT NP NP NP NP 
7652 24/11/2012 M Rwamchanga No CT NP NP NP NP 
7653 24/11/2012 M Rwamchanga No CT NP NP NP NP 
7655 24/11/2012 M Rwamchanga No CT NP NP NP NP 
7910 20/12/2012 M Tamau No CT NP NP NP NP 
7913 20/12/2012 M Tamau No CT NP NP NP NP 
7930 18/01/2013 M Mbilikili 31.33 No CT 32.73 No CT No CT 
7941 18/01/2013 M Mbilikili No CT NP NP NP NP 
7945 18/01/2013 M Mbilikili 35.07 No CT 35.56 No CT No CT 
7950 18/01/2013 M Mbilikili 34.60 No CT No CT No CT No CT 
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7951 18/01/2013 M Mbilikili 26.99 No CT 27.17 No CT No CT 
7963 18/01/2013 M Mbilikili 29.58 No CT 28.75 No CT No CT 
7964 18/01/2013 M Mbilikili 25.93 No CT 26.76 No CT No CT 
8110 04/02/2013 M Natambiso No CT NP NP NP NP 
8225 14/02/2013 M Motukeri No CT NP NP NP NP 
8404 15/02/2013 M Nyamsingisi No CT NP NP NP NP 
8406 15/02/2013 M Nyamsingisi No CT NP NP NP NP 
6605 11/11/2013 M Nygoti No CT NP NP NP NP 
9151 11/11/2013 M Nygoti No CT NP NP NP NP 
9152 11/11/2013 M Nygoti No CT NP NP NP NP 
6778 16/11/2013 M Nyamburi No CT NP NP NP NP 
8261 16/11/2013 M Nyamburi No CT NP NP NP NP 
8562 16/11/2013 M Nyamburi 36.57 No CT No CT 48.00 No CT 
8806 16/11/2013 M Nyamburi No CT NP NP NP NP 
8808 16/11/2013 M N/A No CT NP NP NP NP 
8809 16/11/2013 M N/A 36.72 No CT No CT No CT No CT 
8811 16/11/2013 M N/A No CT NP NP NP NP 
8149 18/11/2013 M Nyamburi 32.39 41.40 No CT 34.26 No CT 
8413 18/11/2013 M Nyamburi No CT NP NP NP NP 
8194 22/11/2013 M Motukeri No CT NP NP NP NP 
8193 25/11/2013 M Motukeri 37.96 No CT No CT No CT No CT 
8530 25/11/2013 M Mbilikili No CT NP NP NP NP 
9202 19/01/2014 M N/A 33.53 No CT No CT No CT No CT 
7024 26/01/2014 M Nyichoka No CT NP NP NP NP 
9232 29/01/2014 M N/A 33.67 No CT No CT No CT No CT 
6532 05/02/2014 M Tamau No CT NP NP NP NP 
6537 05/02/2014 M Tamau No CT NP NP NP NP 
7700 05/02/2014 M Tamau No CT NP NP NP NP 
8850 05/02/2014 M N/A No CT NP NP NP NP 
6545 06/02/2014 M Tamau No CT NP NP NP NP 
6551 06/02/2014 M Tamau No CT NP NP NP NP 
6582 06/02/2014 M Tamau No CT NP NP NP NP 
7908 06/02/2014 M Tamau No CT NP NP NP NP 
7909 06/02/2014 M Tamau 35.48 No CT No CT No CT No CT 
7913 06/02/2014 M Tamau 32.41 38.05 No CT 35.65 No CT 
7914 06/02/2014 M Tamau No CT NP NP NP NP 
7545 10/02/2014 M Mbilikili No CT NP NP NP NP 
8544 10/02/2014 M Mbilikili 31.97 34.16 No CT 36.25 No CT 
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8687 10/02/2014 M N/A 36.97 No CT No CT 40.75 No CT 
7950 12/02/2014 M Mbilikili 37.04 No CT No CT 38.85 No CT 
7955 12/02/2014 M Mbilikili 36.18 No CT No CT 36.86 No CT 
7956 12/02/2014 M Mbilikili No CT NP NP NP NP 
7961 12/02/2014 M Mbilikili 35.44 No CT No CT 40.69 No CT 
7963 12/02/2014 M Mbilikili No CT NP NP NP NP 
8682 12/02/2014 M N/A No CT NP NP NP NP 
8884 12/02/2014 M N/A No CT NP NP NP NP 
8889 12/02/2014 M N/A No CT NP NP NP NP 
8897 12/02/2014 M N/A No CT NP NP NP NP 
8110 18/02/2014 M Natambiso 36.83 No CT No CT No CT No CT 
8300 19/02/2014 M Nyamsingisi No CT NP NP NP NP 
8401 19/02/2014 M Nyamsingisi No CT NP NP NP NP 
8403 19/02/2014 M Nyamsingisi No CT NP NP NP NP 
8533 19/02/2014 M Nyamsingisi 39.66 No CT No CT No CT No CT 
8534 19/02/2014 M Nyamsingisi No CT NP NP NP NP 
9200 19/02/2014 M N/A 34.66 38.01 No CT 37.20 No CT 
9201 19/02/2014 M N/A 35.38 No CT No CT 36.38 No CT 
9203 19/02/2014 M N/A No CT NP NP NP NP 
9204 19/02/2014 M N/A No CT NP NP NP NP 
9205 19/02/2014 M N/A No CT NP NP NP NP 
9206 19/02/2014 M N/A No CT NP NP NP NP 
7459 22/02/2014 M Rwamchanga 37.69 No CT No CT No CT No CT 
7461 22/02/2014 M Rwamchanga 35.68 No CT No CT No CT No CT 
7472 22/02/2014 M Rwamchanga 33.69 No CT No CT No CT No CT 
7476 22/02/2014 M Rwamchanga No CT NP NP NP NP 
7479 22/02/2014 M Rwamchanga No CT NP NP NP NP 
7485 22/02/2014 M Rwamchanga No CT NP NP NP NP 
7487 22/02/2014 M Rwamchanga No CT NP NP NP NP 
7494 22/02/2014 M Rwamchanga No CT NP NP NP NP 
7652 22/02/2014 M Rwamchanga No CT NP NP NP NP 
7653 22/02/2014 M Rwamchanga No CT NP NP NP NP 
7665 22/02/2014 M Rwamchanga No CT NP NP NP NP 
7670 22/02/2014 M Rwamchanga No CT NP NP NP NP 
8694 22/02/2014 M Tamau No CT NP NP NP NP 
8698 22/02/2014 M Rwamchanga No CT NP NP NP NP 
7050 24/02/2014 M Nyichoka No CT NP NP NP NP 
9310 24/02/2014 M N/A No CT NP NP NP NP 
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9311 24/02/2014 M Nyichoka No CT NP NP NP NP 
9312 24/02/2014 M N/A 37.41 No CT No CT No CT No CT 
9313 24/02/2014 M N/A No CT NP NP NP NP 
9315 24/02/2014 M N/A No CT NP NP NP NP 
7028 26/02/2014 M Nyichoka No CT NP NP NP NP 
7030 26/02/2014 M Nyichoka 35.61 40.80 No CT No CT No CT 
7033 26/02/2014 M Nyichoka 35.58 No CT No CT No CT No CT 
7040 26/02/2014 M Nyichoka 37.18 40.35 No CT No CT No CT 
7043 26/02/2014 M Nyichoka No CT NP NP NP NP 
7048 26/02/2014 M Nyichoka No CT NP NP NP NP 
6625 28/03/2014 M Natambiso No CT NP NP NP NP 
6644 28/03/2014 M Natambiso No CT NP NP NP NP 
6657 28/03/2014 M Natambiso No CT NP NP NP NP 
6585 14/04/2014 M Nygoti No CT NP NP NP NP 
6599 14/04/2014 M Nygoti 35.06 No CT No CT 39.79 No CT 
6605 14/04/2014 M Nygoti No CT NP NP NP NP 
9151 14/04/2014 M Nygoti 36.80 37.36 No CT 35.96 No CT 
9152 14/04/2014 M Nygoti 36.71 No CT No CT No CT No CT 
6675 19/05/2014 M Nygoti No CT NP NP NP NP 
6700 19/05/2014 M Nygoti 36.64 No CT No CT 39.71 No CT 
9243 20/05/2014 M N/A 38.58 No CT No CT No CT No CT 
9247 20/05/2014 M N/A No CT NP NP NP NP 
9248 20/05/2014 M N/A No CT NP NP NP NP 
8257 23/05/2014 M Nyamburi No CT NP NP NP NP 
8565 23/05/2014 M Nyamburi 35.48 No CT No CT No CT No CT 
8806 23/05/2014 M Nyamburi No CT NP NP NP NP 
8809 23/05/2014 M N/A 24.54 26.77 31.33 26.52 No CT 
8177 26/05/2014 M Nyamburi No CT NP NP NP NP 
8413 26/05/2014 M Nyamburi No CT NP NP NP NP 
8816 26/05/2014 M Nyamburi 37.09 No CT No CT No CT No CT 
8829 26/05/2014 
M 
N/A 
No 
CT 
NP NP NP NP 
8643 30/05/2014 M Nygoti 34.60 No CT No CT No CT No CT 
8646 30/05/2014 M Nygoti 35.53 No CT No CT 39.09 No CT 
9149 30/05/2014 M Nygoti No CT NP NP NP NP 
8225 18/08/2014 M Motukeri 32.90 37.00 No CT 37.01 No CT 
9111 18/08/2014 M Motukeri 36.38 37.25 No CT 48.18 No CT 
7736 03/09/2014 M Nyichoka 33.31 No CT No CT No CT No CT 
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7601 09/09/2014 M N/A 23.55 No CT No CT 23.79 No CT 
7602 09/09/2014 M N/A 31.01 No CT No CT 31.27 No CT 
7608 09/09/2014 M N/A 23.28 34.92 No CT 31.76 No CT 
7609 09/09/2014 M Nyichoka 30.79 33.11 37.07 32.43 No CT 
7716 29/09/2014 M N/A No CT NP NP NP NP 
7730 08/10/2014 M N/A No CT NP NP NP NP 
7743 08/10/2014 M N/A No CT NP NP NP NP 
7805 09/10/2014 M Bunchugu 27.39 No CT No CT 27.05 No CT 
7808 10/10/2014 M N/A No CT NP NP NP NP 
7815 16/10/2014 M Rwamchanga 26.30 No CT No CT 24.48 No CT 
7828 16/10/2014 M N/A 37.75 No CT No CT No CT No CT 
7832 16/10/2014 M N/A 35.66 No CT No CT No CT No CT 
7834 16/10/2014 M N/A No CT NP NP NP NP 
7848 16/10/2014 M N/A 32.76 37.76 No CT 40.70 No CT 
8011 07/11/2014 M N/A 29.62 No CT No CT 32.62 No CT 
8014 07/11/2014 M N/A No CT NP NP NP NP 
8021 07/11/2014 M N/A 33.81 No CT No CT No CT No CT 
8032 07/11/2014 M N/A 34.20 47.61 No CT 37.21 No CT 
8039 07/11/2014 M N/A No CT NP NP NP NP 
8040 07/11/2014 M N/A 33.70 37.24 No CT 36.48 No CT 
8044 07/11/2014 M N/A 35.13 No CT No CT No CT No CT 
8045 11/11/2014 M N/A No CT NP NP NP NP 
8227 25/11/2014 M Motukeri No CT NP NP NP NP 
7033 27/11/2014 M Nyichoka No CT NP NP NP NP 
9013 27/11/2014 M Nyichoka 39.58 No CT No CT No CT No CT 
7960 02/12/2014 M Mbilikili 31.62 35.85 No CT 33.34 No CT 
7961 02/12/2014 M Mbilikili 40.31 No CT No CT No CT No CT 
8840 02/12/2014 M Motukeri No CT NP NP NP NP 
8884 02/12/2014 M N/A 31.78 35.06 No CT 44.97 No CT 
8502 18/12/2014 M Mbilikili 37.69 No CT No CT No CT No CT 
8517 18/12/2014 M Mbilikili 35.43 No CT No CT No CT No CT 
9511 18/12/2014 M N/A 32.56 36.07 No CT 33.94 No CT 
8644 26/12/2014 M Nygoti No CT NP NP NP NP 
9205 09/01/2015 M N/A 36.99 No CT No CT No CT No CT 
9144 28/01/2015 M Nyichoka 30.14 34.54 37.05 37.40 No CT 
9150 28/01/2015 M Nygoti No CT NP NP NP NP 
9201 28/01/2015 M N/A 27.37 36.80 No CT 34.45 No CT 
9202 28/01/2015 M N/A 36.33 No CT No CT No CT No CT 
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6778 29/01/2015 M Nyamburi No CT NP NP NP NP 
6779 29/01/2015 M Nyamburi No CT NP NP NP NP 
8261 29/01/2015 M Nyamburi No CT NP NP NP NP 
8806 29/01/2015 M Nyamburi No CT NP NP NP NP 
8808 29/01/2015 M N/A No CT NP NP NP NP 
8811 29/01/2015 M N/A 34.58 No CT No CT No CT No CT 
9227 29/01/2015 M N/A No CT NP NP NP NP 
7605 13/03/2015 M N/A No CT NP NP NP NP 
7951 02/12/2015 M N/A 32.30 35.31 No CT No CT No CT 
6516 N/A M Tamau 32.27 No CT No CT 37.89 No CT 
8297 N/A M Nyamsingisi No CT NP NP NP NP 
TAN/19/2012 
(SAT 2) 
28/04/2012 C Simanjiro           
TAN/39/2012 
(O) 
31/05/2012 C 
Ngorongoro 
district  
     
TAN/6/2013 
(A) 
16/03/2013 C Nyamburi           
TAN/33/2014 
(SAT 1) 
16/10/2014 C Rwamchanga 
     
TAN/20/2014 03/09/2014 E Nyichoka           
TAN/22/2014 09/09/2014 E Nyichoka      
TAN/23/2014 09/09/2014 VF Nyichoka           
TAN/28/2014 09/10/2014 E Bunchugu      
TAN/29/2014 09/10/2014 VF Bunchugu           
TAN/34/2014 16/10/2014 E Rwamchanga      
N/A – information not available. NP – Not performed. M – Milk. CC – Cell culture isolate. E – Epithelium. 
VF – Vesicular fluid. No CT – No CT value observed (>50). 
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Appendix III  
FMD surveillance in Nakuru County, Kenya 
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Figure 8.2 Description of the study area and Survey 1 (Chapter 5) are described in the 
above research article, published in Veterinary Research. 
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Figure 8.3 The paper form of the questionnaire used when interviewing small-holder 
dairy farmers during surveys 2 and 3. 
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Figure 8.4 Graph showing the temporal trend of the total volume of milk supplied to 
each milk pooling facility on the sampling dates (week 1 –16/11/2016, week 45 – 
20/09/2017). 
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Figure 8.5 Graph showing the temporal trend of the total number of farmers supplying 
to each milk pooling facility on the sampling dates (week 1 – 16/11/2016, week 45 – 
20/09/2017). 
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Appendix IV  
FMD surveillance on a large scale dairy farm in Saudi 
Arabia 
 
 
New clinical cases observed 
   Positive Negative Total 
Pan-serotypic 
rRT-PCR 
Positive 6        36 42 
Negative 8 682 690 
Total 14 718 732 
Se = 42.9%, Sp = 95.0%, Aobs = 0.94, K = 0.19 
Figure 8.6 Comparison of pan-serotypic rRT-PCR assay results for pooled milk with 
the number of new clinical cases observed on the milk sample collection day for all 
houses.  
 
 
 
‘Predicted’ rRT-PCR 
   Positive Negative Total 
‘Observed’ 
rRT-PCR 
Positive 9 19 28 
Negative 17 657 674 
Total 26 676 702 
                          Se = 34.6%, Sp = 97.2%, Aobs = 0.95, K = 0.31 
*Houses 17 and 18 were not included in the analysis due to incomplete epidemiological data. 
Figure 8.7 Comparison of actual rRT-PCR assay results for pooled milk with the 
predicted results for all houses* for ‘1/10’ virus excretion with a cut-off CT value of 40. 
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